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Population Stratification is from the 
migration patterns of  haplotypes  
throughout human history 

By Kelly Servick
L
ast month, researchers at Boston 
Children’s Hospital published a study 
that closely examined the DNA of 
158 people with brain malformations 
who had been unable to identify the 
cause of their disorders through clini-
cal genetic testing. With highly sensitive 
sequencing, the group found eight disease-
causing mutations that occurred in only a 
small fraction of each person’s cells, mak-
ing them too subtle for conventional ge-
netic diagnostic tests.
Such genetic variation among cells, 
known as mosaicism, is present in all of us 
and has long been common knowledge. The 
phenomenon was a feature of “college dorm 
room conversations in the decades past,” 
says Chad Shaw, a statistician at Baylor Col-
lege of Medicine in Houston, Texas. “It was 
like, ‘Hey, this will blow your mind.’ ” 
But now that genetic technologies make 
it possible to hunt down specific mutations 
in small numbers of cells, researchers, cli-
nicians, genetic counselors, and funders 
are paying closer attention to mosaicism. 
Next month, the U.S. National Institutes of 
Health (NIH) will begin reviewing applica-
tions for grants to find genetic variation 
in brain tissue that may help explain neu-
ropsychiatric disorders. And as research-
ers find more cases of mosaicism, they’re 
wondering how many genetic causes of 
disease remain invisible to even the best 
clinical tests.
Traditionally, genetic disease research 
has focused on mutations inherited through 
the germ line—the legacy of parents who 
are carriers, or of genetic mistakes dur-
ing the formation of their eggs and sperm. 
These DNA mishaps end up in every cell of 
a child. But once an embryo starts devel-
oping, genetic errors can arise every time 
a cell divides. And because cells can then 
proliferate and spread their mutations, 
each body is “a kind of micro evolutionary 
experiment,” says Leslie Biesecker, a ge-
neticist at NIH’s National Human Genome 
Research Institute in Bethesda, Maryland. 
The number of cells with a given mutation 
depends on when and where the mutation 
arose and how it changes a cell’s function. 
Many such mutations are benign, but some 
cause disease. 
The systematic hunt for disease-causing 
mosaic mutations is only beginning. Some 
are obvious—cases where “nature is stick-
ing its finger in our eye,” Biesecker says. 
In conditions such as McCune-Albright 
syndrome, the abnormal cells can be seen 
as patches or patterns on a person’s skin. 
But any genetic disease could be mosaic. 
Cancers, which consist of genetically dis-
tinct cells, are a familiar example, and are 
a common focus of sequencing efforts. But 
other studies have shown that mosaic mu-
tations can underlie dozens of conditions, 
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other countries to push for access.
Meanwhile, camera networks continu-
ously monitor the night skies with fisheye 
lenses. Some, such as the European Fireball 
Network, are well established, but many rely 
on enthusiastic amateurs and outdated film 
cameras. Philip Bland, a researcher at Curtin 
University, Bentley, in Australia, has larger 
ambitions. By the end of this month, he and 
his colleagues will have finished installing 
some 30 camera stations in the Australian 
outback, covering an area the size of Alaska. 
Each AU$7000 station in the Desert Fire-
ball Network includes a high-resolution 
camera that takes 30-second time-lapse stills 
for calculating trajectories and brightnesses. 
It also has a video camera to determine the 
exact duration of the fireball, which can be 
translated into its speed. The solar-powered 
stations can collect data, unattended, for 
months on end. 
Bland expects to catch between five and 
10 fireballs a year. He also believes that re-
covering the meteorites will be easier than 
it is in places such as Europe—even though 
he often won’t be able to enlist radar to re-
fine his trajectories. This part of Australia 
largely lacks people and precipitation, and 
hence has few weather radars. But the dark 
meteorites should be easy to spot against the 
light-colored, largely barren desert. A camera-
equipped drone will aid the search. 
With such a wide net for trapping space 
rocks, Bland believes that he can start to 
determine the rate at which material from 
space hits the Earth—and not just extra-
terrestrial material. Humanmade space junk 
regularly falls to Earth and can be distin-
guished by its slower speed: Anything that 
strikes the atmosphere at less than 11 kilo-
meters per second can be assumed to have 
been lofted by humans.
All this technology could eventually make 
retrieving meteorite fragments routine and 
efficient. The old way—rare, momentous 
fireball sightings followed by frenzied yet 
agonizingly slow searches on foot—would be 
history. But for now, researchers still thrill to 
the chase. During the radar technique work-
shop, Josep Trigo-Rodríguez, a researcher 
at the Institute of Space Sciences in Barce-
lona, Spain, learned that a massive fireball, 
brighter than the full moon, had been seen 
over Catalonia early on 7 September. Trigo-
Rodríguez worked through the week to re-
fine the meteorite’s trajectory, based on data 
from five fireball network cameras and two 
pictures from eyewitnesses. 
He would not reveal its exact location; he 
sent out a search party last week and did not 
want to be scooped by local meteorite hunt-
ers. But he suspects that several kilograms 
of fresh meteorite are waiting for him some-
where in the northeast of Spain. ■
Harmful mutations can
fly under the radar
With more sensitive genetic tests, researchers are hunting 
the roots of disease in the human “mosaic”
CLINICAL TESTING
Zygote Genetic change Proliferation
Building a human mosaic
Depending on when and where in embryonic development a mutation 
occurs, a subset of adult cells will harbor the genetic change.
Mosaic mutation
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By Kelly Servick
L
ast month, researchers at Boston 
Children’s Hospital published a study 
that closely examined the DNA of 
158 people with brain malformations 
who had been unable to identify the 
cause of their disorders through clini-
cal genetic testing. With highly sensitive 
sequencing, the group found eight disease-
causing mutations that occurred in only a 
small fraction of each person’s cells, mak-
ing them too subtle for conventional ge-
netic diagnostic tests.
Such genetic variation among cells, 
known as mosaicism, is present in all of us 
and has long been common knowledge. The 
phenomenon was a feature of “college dorm 
room conversations in the decades past,” 
says Chad Shaw, a statistician at Baylor Col-
lege of Medicine in Houston, Texas. “It was 
like, ‘Hey, this will blow your mind.’ ” 
But now that genetic technologies make 
it possible to hunt down specific mutations 
in small numbers of cells, researchers, cli-
nicians, genetic counselors, and funders 
are paying closer attention to mosaicism. 
Next month, the U.S. National Institutes of 
Health (NIH) will begin reviewing applica-
tions for grants to find genetic variation 
in brain tissue that may help explain neu-
ropsychiatric disorders. And as research-
ers find more cases of mosaicism, they’re 
wondering how many ge e ic causes of 
disease remain invisible to even the best 
clinical tests.
Traditionally, genetic disease research 
has focused on mutations inherited through 
the germ line—the legacy of parents who 
are carriers, or of genetic mistakes dur-
ing the formation of their eggs and sperm. 
These DNA mishaps end up in every cell of 
a child. But once an embryo starts devel-
oping, genetic errors can arise every time 
a cell divides. And because cells can then 
proliferate and spread their mutations, 
each body is “a kind of micro evolutionary 
experiment,” says Leslie Biesecker, a ge-
neticist at NIH’s National Human Genome 
Research Institute in Bethesda, Maryland. 
The number of cells with a given mutation 
depends on when and where the mutation 
arose and how it changes a cell’s function. 
Many such mutations are benign, but some 
cause disease. 
The systematic hunt for disease-causing 
mosaic mutations is only beginning. Some 
are obvious—cases where “nature is stick-
ing its finger in our eye,” Biesecker says. 
In conditions such as McCune-Albright 
syndrome, the abnormal cells can be seen 
as patches or patterns on a person’s skin. 
But any genetic disease could be mosaic. 
Cancers, which consist of genetically dis-
tinct cells, are a familiar example, and are 
a common focus of sequencing efforts. But 
other studies have shown that mosaic mu-
tations can underlie dozens of conditions, 
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other countries to push for access.
Meanwhile, camera networks continu-
ously monitor the night skies with fisheye 
lenses. Some, such as the European Fireball 
Network, are well established, but many rely 
on enthusiastic amateurs and outdated film 
cameras. Philip Bland, a researcher at Curtin 
University, Bentley, in Australia, has larger 
ambitions. By the end of this month, he and 
his colleagues will have finished installing 
some 30 camera stations in the Australian 
outback, covering an area the size of Alaska. 
Each AU$7000 station in the Desert Fire-
ball Network includes a high-resolution 
camera that takes 30-second time-lapse stills 
for calculating trajectories and brightnesses. 
It also has a video camera to determine the 
exact duration of the fireball, which can be 
translated into its speed. The solar-powered 
stations can collect data, unattended, for 
months on end. 
Bland expects to catch between five and 
10 fireballs a year. He also believes that re-
covering the meteorites will be easier than 
it is in places such as Europe—even though 
he often won’t be able to enlist radar to re-
fine his trajectories. This part of Australia 
largely lacks people and precipitation, and 
hence has few weather radars. But the dark 
meteorites should be easy to spot against the 
light-colored, largely barren desert. A camera-
equipped drone will aid the search. 
With such a wide net for trapping space 
rocks, Bland believes that he can start to 
determine the rate at which material from 
space hits the Earth—and not just extra-
terrestrial material. Humanmade space junk 
regularly falls to Earth and can be distin-
guished by its slower speed: Anything that 
strikes the atmosphere at less than 11 kilo-
meters per second can be assumed to have 
been lofted by humans.
All this technology could eventually make 
retrieving meteorite fragments routine and 
efficient. The old way—rare, momentous 
fireball sightings followed by frenzied yet 
agonizingly slow searches on foot—would be 
history. But for now, researchers still thrill to 
the chase. During the radar technique work-
shop, Josep Trigo-Rodríguez, a researcher 
at the Institute of Space Sciences in Barce-
lona, Spain, learned that a massive fireball, 
brighter than the full moon, had been seen 
over Catalonia early on 7 September. Trigo-
Rodríguez worked through the week to re-
fine the meteorite’s trajectory, based on data 
from five fireball network cameras and two 
pictures from eyewitnesses. 
He would not reveal its exact location; he 
sent out a search party last week and did not 
want to be scooped by local meteorite hunt-
ers. But he suspects that several kilograms 
of fresh meteorite are waiting for him some-
where in the northeast of Spain. ■
Harmful mutations can
fly under the radar
With more sensitive genetic tests, researchers are hunting 
the roots of disease in the human “mosaic”
CLINICAL TESTING
Zygote Genetic change Proliferation
Building a human mosaic
Depending on when and where in embryonic development a mutation 
occurs, a subset of adult cells will harbor the genetic change.
Mosaic mutation
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Beyond	  our	  Kuhnian	  inheritance	  
A	  recent	  lecture	  by	  Prof	  Greg	  Radick	  ques)ons	  our	  scien)ﬁc	  inheritance,	  
through	  textbook	  histories	  of	  gene)cs	  and	  Thomas	  Kuhn's	  legacy	  
hXp://www.guardian.co.uk/science/the-­‐h-­‐word/2012/aug/28/thomas-­‐
kuhn	  
Walter	  Frank	  Raphael	  Weldon	  
Vs.	  	  
William	  Bateson	  
Forthcoming	  by	  Greg	  Radick.	  Scholarly	  edi)on	  of	  W.	  F.	  R.	  Weldon's	  Theory	  of	  
Inheritance	  (1904-­‐1905),	  coedited	  with	  Annie	  Jamieson.	  
Mendel’s laws of alternative inheritance in peas 29 
ESP FO U N D A T IO N S  SE R IE S  
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MENDEL’S LAWS  
OF  
ALTERNATIVE INHERITANCE IN PEAS. 
W. F.  R.  WELD O N 
 
 
 
 
 
 
 
 
 
Weldon, W. F. R. 1902. Mendel’s laws of alternative 
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•  “The	  fundamental	  mistake	  which	  vi4ates	  all	  work	  
based	  upon	  Mendel’s	  method	  is	  the	  neglect	  of	  ancestry,	  
and	  the	  a>empt	  to	  regard	  the	  whole	  eﬀect	  upon	  
oﬀspring,	  produced	  by	  a	  par4cular	  parent,	  as	  due	  to	  
the	  existence	  in	  the	  parent	  of	  par4cular	  structural	  
characters;	  while	  the	  contradictory	  results	  obtained	  by	  
those	  who	  have	  observed	  the	  oﬀspring	  of	  parents	  
apparently	  iden4cal	  in	  certain	  characters	  show	  clearly	  
enough	  that	  not	  only	  the	  parents	  themselves,	  but	  their	  
race,	  that	  is	  their	  ancestry,	  must	  be	  taken	  into	  account	  
before	  the	  result	  of	  pairing	  them	  can	  be	  predicted”	  –	  
Walter	  Frank	  Raphael	  Weldon	  (Weldon,	  1902).	  
	  

“Biological	  Indeterminacy”	  
•  Bateson	  became	  famous	  as	  the	  outspoken	  
Mendelian	  antagonist	  of	  Walter	  Raphael	  Weldon,	  
his	  former	  teacher,	  and	  Karl	  Pearson	  who	  led	  the	  
biometric	  school	  of	  thinking.	  This	  concerned	  the	  
debate	  over	  salta)onism	  versus	  gradualism	  
(Darwin	  had	  been	  a	  gradualist,	  but	  Bateson	  was	  a	  
salta)onist).	  Later,	  Ronald	  Fisher	  and	  
J.B.S.	  Haldane	  showed	  that	  discrete	  muta)ons	  
were	  compa)ble	  with	  gradual	  evolu)on:	  see	  the	  
modern	  evolu)onary	  synthesis.	  
Biological	  Indeterminacy.	  Greenspan	  RJ.	  Sci	  Eng	  
Ethics.	  2012	  Jul	  3	  
	  
Biological	  Robustness.	  
The	  canalisa)on	  metaphor	  suggests	  that	  phenotypes	  are	  very	  robust	  to	  small	  perturba)ons,	  
for	  which	  development	  does	  not	  exit	  the	  canal,	  and	  rapidly	  returns	  back	  down,	  with	  liXle	  
eﬀect	  on	  the	  ﬁnal	  outcome	  of	  development.	  But	  perturba)ons	  whose	  magnitude	  exceeds	  a	  
certain	  threshold	  will	  break	  out	  of	  the	  canal,	  moving	  the	  developmental	  process	  into	  
uncharted	  territory.	  Strong	  robustness	  up	  to	  a	  limit,	  with	  liXle	  robustness	  beyond,	  is	  a	  paXern	  
that	  could	  increase	  evolvability	  in	  a	  ﬂuctua)ng	  environment.	  
E.	  coli	  adap)ng	  to	  low	  glucose	  condi)ons,	  in	  the	  context	  of	  media	  containing	  citrate.	  
–	  Richard	  Lemski	  experiment	  	  
"Finally,	  novel	  func)ons	  ohen	  emerge	  in	  rudimentary	  forms	  that	  must	  be	  reﬁned	  to	  
exploit	  the	  ecological	  opportuni)es.	  This	  three-­‐step	  process	  —	  in	  which	  poten)a)on	  
makes	  a	  trait	  possible,	  actualiza)on	  makes	  the	  trait	  manifest,	  and	  reﬁnement	  makes	  
it	  eﬀec)ve	  —	  is	  probably	  typical	  of	  many	  new	  func)ons.”	  -­‐	  Lemski	  
	  
Genotype	  ≠	  Phenotype	  
Environment	  maXers!	  
Ancestry	  maXers!	  
Genomic	  background	  maXers!	  
Longitudinal	  course	  maXers!	  
	  
Categorical	  Thinking	  Misses	  Complexity	  
A	  conceptual	  model	  of	  genotype-­‐phenotype	  correla;ons.	  	  The	  y	  plane	  represents	  a	  
phenotypic	  spectrum,	  the	  x	  plane	  represents	  the	  canalized	  progression	  of	  development	  
through	  )me,	  and	  the	  z	  plane	  represents	  environmental	  ﬂuctua)ons.	  	  	  
Time	  
Environment	  
Phenotypic	  
Spectrum	  
Some	  Deﬁni)ons	  …	  
•  The	  words	  “penetrance”	  and	  “expressivity”,	  deﬁned	  
classically	  as:	  
•  Penetrance:	  whether	  someone	  has	  ANY	  symptoms	  of	  a	  
disease,	  i.e.	  all	  or	  none,	  0%	  or	  100%.	  Nothing	  in	  between.	  
•  Expressivity:	  how	  much	  disease	  (or	  how	  many	  symptoms)	  
someone	  with	  100%	  penetrance	  has.	  
•  This	  has	  led	  to	  endless	  confusion!	  	  
•  Some	  just	  use	  the	  word	  “penetrance”	  to	  mean	  the	  
expressivity	  of	  disease,	  i.e.	  incomplete	  penetrance,	  and	  
maybe	  we	  should	  combine	  the	  two	  terms	  into	  ONE	  word	  
with	  the	  full	  expression	  from	  0-­‐100%	  of	  phenotypic	  
spectrum.	  
Deﬁni;ons.	  It	  is	  unknown	  what	  
por)on	  of	  au)sm	  will	  be	  oligogenic	  vs.	  
polygenic	  
•  Oligogenic	  –	  mul)ple	  muta)ons	  together	  
contribu)ng	  to	  aggregate	  disease,	  BUT	  with	  only	  
1	  muta)on	  of	  ~	  >10%	  “eﬀect	  size	  in	  EACH	  person.	  
•  Polygenic	  –	  Dozens	  to	  hundreds	  of	  muta)ons	  in	  
diﬀerent	  genes	  in	  the	  SAME	  person,	  together	  
contribu)ng	  to	  the	  disease	  in	  the	  SAME	  person,	  
hence	  addi;ve	  and/or	  epista;c	  contribu)on	  with	  
~0.01-­‐1%	  penetrance	  for	  each	  muta)on.	  
	  “Of	  complex	  gene)c	  diseases,	  schizophrenia	  has	  perhaps	  
been	  the	  subject	  of	  the	  most	  specula)on	  and	  debate	  
rela)ng	  to	  its	  gene)c	  architecture4,5,	  and	  the	  rela)ve	  
importance	  of	  common	  causal	  variants	  remains	  
controversial6,7.”	  
Example	  of	  Polygenic	  Model	  
Visscher	  et	  al.	  2011	  
Expression	  Issues	  
•  We	  do	  not	  really	  know	  the	  expression	  of	  
preXy	  much	  ALL	  muta)ons	  in	  humans,	  as	  we	  
have	  not	  systema)cally	  sequenced	  or	  
karyotyped	  any	  gene)c	  altera)on	  in	  
Thousands	  to	  Millions	  of	  randomly	  selected	  
people,	  nor	  categorized	  into	  ethnic	  classes,	  i.e.	  
clans.	  
•  Complexity,	  or	  “The	  False	  Nega)ve	  Problem”	  
1857-­‐1936	  
Observed	  and	  deduced	  gene)c	  paXern	  for	  4	  human	  diseases:	  alkaptonuria,	  cys)nuria,	  
pentosuria,	  and	  albinism.	  
	  
Deﬁni)ve	  Biography:	  Archibald	  Garrod	  &	  the	  Individuality	  of	  Man,	  by	  Alexander	  Bearn.	  
Director,	  1866-­‐1944	  
Charles	  Davenport	  
Sta)on	  for	  Experimental	  Evolu)on	  –	  1904	  
(Carnegie	  Ins)tu)on	  of	  Washington)	  
	  
Davenport	  on	  Applying	  Human	  Gene)cs	  
Shall	  we	  not…take	  
the	  steps	  that	  
scien)ﬁc	  study	  
dictates	  as	  
necessary,	  to	  dry	  
up	  the	  springs	  that	  
feed	  the	  torrent	  of	  
defec)ve	  and	  
degenerate	  
protoplasm?	  
Cri)que	  of	  Davenport	  
•  “Most	  studies	  were	  performed	  by	  volunteers	  of	  
class	  I	  social	  standing,	  who	  were	  given	  a	  
summer’s	  training,	  then	  turned	  loose.”	  James	  
Neel’s	  book,	  p.	  15.	  
•  From	  Heron	  (quoted	  from	  Neel):	  “the	  material	  
has	  been	  collected	  in	  an	  unsa)sfactory	  manner,	  
the	  data	  have	  been	  tabled	  in	  a	  most	  slipshod	  
fashion,	  and	  the	  Mendelian	  conclusions	  drawn	  
have	  no	  jus)ﬁca)on	  whatever”.	  	  

Gene)cists	  Begin	  to	  Cri)cize	  the	  Eugenicists	  
A	  mingled	  mess	  of	  ill-­‐grounded	  and	  uncri)cal	  
sociology,	  economics,	  anthropology	  and	  
poli)cs,	  full	  of	  emo)onal	  appeals	  to	  class	  and	  
race	  prejudices,	  solemnly	  put	  forward	  as	  
science,	  and	  unfortunately	  accepted	  as	  such	  
by	  the	  general	  public.	  
R.	  Pearl,	  The	  Present	  State	  of	  Eugenics,	  1928	  
Gene)cists	  Begin	  to	  Cri)cize	  the	  Eugenicists	  
T.	  H.	  Morgan,	  Evolu4on	  &	  Gene4cs,	  1925	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Sickle Cell Anemia, a. Molecular Disease'
Linus Pauling, Harvey A. Itano,2 S. J. Singer, and Ibert C. Wells3
Gates and Crellin Laboratories of Chemistry,
California Institute of Technology, Pasadena, California4
T HE ERYTHROCYTES of certain individuals
possess the capacity to undergo reversible
changes in shape in response to changes in the
partial pressure of oxygen. When the oxygen
pressure is lowered, these cells change their forms from
the normal biconcave disk to crescent, holly wreath,
and other forms. This process is known as sickling.
About 8 percent of American Negroes possess this
characteristic; usually they exhibit no pathological
consequences ascribable to it. These people are said
to have sicklemia, or sickle cell trait. However, about
1 in 40 (4) of these individuals whose cells are capable
of sickling suffer from a severe chronic anemia re-
sulting from excessive destruction of their erythro-
cytes; the term sickle cell anemia is applied to their
condition.
The main observable difference between the erythro-
cytes of sickle cell trait and sickle cell anemia has been
that a considerably greater reduction in the partial
pressure of oxygen is required for a major fraction
of the trait cells to sickle than for the anemia cells
(11). Tests in vivo have demonstrated that between
30 and 60 percent of the erythrocytes in the venous
circulation of sickle cell anemic individuals, but less
than 1 percent of those in the venous circulation of
sicklemic individuals, are normally sickled. Experi-
ments in vitro indicate that under sufficiently low oxy-
gen pressure, however, all the cells of both types as-
sume the sickled form.
The evidence available at the time that our investi-
gation was begun indicated that the process of sick-
ling might be intimately associated with the state and
the nature of the hemoglobin within the erythrocyte.
Sickle cell erythrocytes in which the hemoglobin is
combined with oxygen or carbon monoxide have the
biconcave disk contour and are indistinguishable in
1 This research was carried out with the aid of a grant
from the United States Public Health Service. The authors
are grateful to Professor Ray D. Owen, of the Biology Di-
vision of this Institute, for his helpful suggestions. We are
indebted to Dr. Edward R. Evans, of Pasadena, Dr. Travis
Winsor, of Los Angeles, and Dr. G. E. Burch, of the Tulane
University School of Medicine, New Orleans, for their aid in
obtaining the blood used in these experiments.
2 U. S. Public Health Service postdoctoral fellow of the
National Institutes of Health.
3Postdoctoral fellow of the Division of Medical Sciences
of the National Research Council.
4Contribution No. 1333.
that form from normal erythrocytes. In this condi-
tion they are termed promeniscocytes. The hemo-
globin appears to be uniformly distributed and ran-
domly oriented within normal cells and promenisco-
cytes, and no birefringence is observed. Both types
of cells are very flexible. If the oxygen or carbon
monoxide is removed, however, transforming the hemo-
globin to the uncombined state, the promeniscocytes
undergo sickling. The hemoglobin within the sickled
cells appears to aggregate into one or more foci, and
the cell membranes collapse. The cells become bire-
fringent (11) and quite rigid. The addition of oxy-
gen or carbon monoxide to these cells reverses these
phenomena. Thus the physical effects just described
depend on the state of combination of the hemoglobin,
and only secondarily, if at all, on the cell membrane.
This conclusion is supported by the observation that
sickled cells when lysed with water produce discoidal,
rather than sickle-shaped, ghosts (10).
It was decided, therefore, to examine the physical
and chemical properties of the hemoglobins of indi-
viduals with sicklemia and sickle cell anemia, and to
compare them with the hemoglobin of normal indi-
viduals to determine whether any significant differ-
ences might be observed.
EXPERIMENTAL METHODS
The experimental work reported in this paper deals
largely with an electrophoretic study of these hemo-
globins. In the first phase of the investigation, which
concerned the comparison of normal and sickle cell
anemia hemoglobins, three types of experiments were
performed: 1) with carbonmonoxyhemoglobins; 2)
with uncombined ferrohemoglobins in the presence of
dithionite ion, to prevent oxidation to methemoglo-
bins; and 3) with carbonmonoxyhemoglobins in the
presence of dithionite ion. The experiments of type
3 were performed and compared with those of type 1
in order to ascertain whether the dithionite ion itself
causes any specific electrophoretic effect.
Samples of blood were obtained from sickle cell
anemic individuals who had not been transfused within
three months prior to the time of sampling. Stroma-
free concentrated solutions of human adult hemoglobin
were prepared by the method used by Drabkin (3).
These solutions were diluted just before use with the
November . SCIENCE r5&3
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The isoelectric points are listed in
sults prove that the electrophoretic
normal hemoglobin and sickle cell a
TABLE 1
ISOELECTRIC POINTS IN PHOSPHATE
Compound Normal Si(
a
Carbonmoinoxylhemoglobin 6.87
Ferrohemoglobin ...... 6.87
Table 1. These re- tion of 1 percent were performed with known mixtures
difference between of sickle cell anemia and normal carbonmonoxyhemo-
inemia hemoglobin globins in the caeodylate-sodium chloride buffer of 0.1
ionic strength and pH 6.52 described above. This
buffer was chosen in order to minimize the anomalous
I BUFFER~& 0 electrophoretic effects observed in phosphate buffers
ckle cell Diference (7). Since the two hemoglobins were incompletely
mnemia resolved after 15 hours of electrophoresis under a
7.09 0.22 potential gradient of 2.79 volts/cm, the method of
7.09 0.22 Tiselius and Kabat (16) was employed to allocate the
exists in both ferrohemoglobin and carbonmonoxy-
hemoglobin. We have also performed several experi-
ments in a buffer of 0.1 ionic strength and pH 6.52
containing 0.08 M NaCl, 0.02 M sodium cacodylate, and
0.0083 M cacodylic acid. In this buffer the average
mobility of sickle cell anemia carbonmonoxyhemo-
globin is 2.63 x 10-5, and that of normal carbonmon-
oxyhemoglobin is 2.23 x 10-5 cn/see per volt/cm.6
a) Norma
b)Sickle Cell Anemia
c) Sickle Cell Trait
d) 50-50 Mixture of a) and b)
FIG. 3. Longsworth scanning diagrams of carbonmon-
oxyhemoglobins in phosphate buffer of 0.1 ionic strength and
pH 6.90 taken after 20 hours' electrophoresis at a potential
gradient of 4.73 volts/cm.
These experiments with a buffer quite different from
phosphate buffer demonstrate that the difference be-
tween the hemoglobins is essentially independent of
the buffer ions.
Typical Longsworth scanning diagrams of experi-
men s wi h n r al, sickle cell anemia, and sicklemia
carbonmonoxyhemoglobins, and with a mixture of the
first two comp unds, all in phosphate buffer of pH
6.90 and ionic strength 0.1, are reproduced in Fig. 3.
It is apparent from this figure that the sicklemia mate-
rial contains less than 50 percent of the anemia com-
ponent. In order to determine this quantity accu-
rat ly some experiments at a total protein coneentra-
the absence of other ions. These results might be reconciled
by assuming that the ferrous iron of ferrohemoglobin forms
complexes with phosphate ions which cannot be formed when
the iron is combined with oxygen or carbon monoxide. We
propose to continue the study of this phenomenon.
6 The mobility data show that in 0.1 Ionic strength cacody-
late buffers the isoelectric points of the hemoglobins are
increased about 0.5 pH unit over their values in 0.1 Ionic
strength phosphate buffers. This effect is similar to that
observed by Longsworth in his study of ovalbumin (7).
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ACTUAL PERCENTAGE
SICKLE CELL ANEMIA CARBONMONOXYHEMOGLOBIN
FIG. 4. The determination of the percent of sickle cell
anemia carbonmonoxyhemoglobin in known mixtures of the
protein with normal carbonmonoxyhemoglobin by means of
electrophoretic analysis. The experiments were performed
in a cacodylate sodium chloride buffer described in the text.
areas under the peaks in the electrophoresis diagrams
to the two components. In Fig. 4 there is plotted the
percent of the anemia component calculated from the
areas so obtained against the percent of that comn-
ponent in the known mixtures. Similar experiments
were performed with a solution in which the hemo-
globins of 5 sicklemic individuals were pooled. The
relative concentrations of the two hemoglobins were
calculated from the electrophoresis diagrams, and the
actual proportions were then determined from the plot
of Fig. 4. A value of 39 percent for the amount of
the sickle cell anemia component in the sicklemia
hemoglobin was arrived at in this manner. From the
experiments we have performed thus far it appears
that this value does not vary greatly from one sick-
lemic individual to another, but a more extensive study
of this point is required.
Up to this stage we have assumed that one of the
two components of sicklemia hemoglobin is identical
with sickle cell anemia hemoglobin and the other is
identical with the normal compound. Aside from the
3. l. 110 SCIENCE
1901-­‐1994	  
544SCIENCE November 25, 1949, Vol. 110
appropriate buffer until the hemoglobin concentrations
were close to 0.5 grams per 100 mi er, and then
were dialyzed against large volumes of these buffers
for 12 to 24 hours at 40 C. The buffers for the ex-
periments of types 2 and 3 were prepared by adding
300 ml of 0.1 ionic strength sodium dithionite solu-
$gon to 3.5 liters of 0.1 ionic strength buffer. About
T00 ml of 0.1 molar NaOH was then added to bring
the pH of the buffer back to its original value. Fer-
rohemoglobin solutions were prepared by diluting the
0
5.0 6.0 7.0 8.0 9.0
pH
FIG. 1. Mobility(p)-pHI curves for carbonmonoxyhemo-
globins in phosphate buffers of 0.1 ionic strength. The black
circles and black squares denote the data for experiments
performed with butters containing dithionite ion. The open
square designated by the arrow represents an average value
of 10 experiments on the hemoglobin of different Individuals
with sickle cell anemia. The mobilities recorded in this
graph are averages of the mobilities in the ascending, and
descending limbs.
emie
~ ~A
pH
FtG. 2. Mobility (t) -pH curves for ferrohemoglobins in
phosphate buffers of 0.1 ionic strength containing dithionite
ion. The mobilities recorded in the graph are averages of
t* mobilities In the ascending and descending limbs.
concentrated solutions with this dithionite-containing
buffer and dialysing against it under a nitrogen atmos-
phere. The hemoglobin solutions for the experiments
of type 3 were made up similarly, except that they
were saturated with carbon monoxide after dilution
and were dialyzed under a carbon monoxide atmos-
phere. The dialysis bags were kept in continuous
motion in the buffers by means of a stirrer with a
mercury seal to prevent the escape of the nitrogen
and carbon monoxide gases.
The experiments were carried out in the modified
Tiselius electrophoresis apparatus described by Swingle
(14). Potential gradients of 4.8 to 8.4 volts per centi-
meter were employed, and the duration of the runs
v ried from 6 to 20 hour . T pH values of the
buffers were measured after dialysis o samples which
had come to room temperature.
RESULTS
The results indicate that a significant difference ex-
ists between the electrophoretic mobilities of hemo-
globin derived from erythrocyt s of normal individuals
and from those of sickle cell anemic individuals. The
two types of hemoglobin are particularly easily dis-
tinguished as the carbonmonoxy compounds at pH 6.9
in phosphate buffer of 0.1 ionic strength. In this
buffer the sickle cell anemia carbonmonoxyhemoglobin
moves as a positive ion, while the nor al compound
moves as a negative ion, and there is no detectable
amount of one type present in the other.4 The hemo-
globin derived from erythrocytes of individuals with
sicklemia, however, appears to be a mixture of the
normal hemoglobin nd sickle cell anemi hemoglobin
in roughly equal proportions. Up to the present time
the hemoglobins of 15 persons with sickle cell anemia,
8 persons with sicklemia, and 7 normal adults have
been examined. The hemoglobins of normal adult
white and negro individuals were found to be indis-
tinguishable.
The mobility data obtained in phosphate buffers of
0.1 ionic strength and various values of pH are sum-
marized in Figs. 1 and 2.5
4 Occasionally small amounts (less than 5 percent of the
total pro ein) of materi l with mobilities different from that
of either kind of hemoglobin were observed in these uncrys-
tallized hemoglobin preparations According to the observa-
tions of Stern, Reiner, and Silber (12) a small amount of a
component with a mobility smaller than that of oxyhemo-
globin is present in human e ythrocy e hemolyzates.
6 The results obtained with carbonmonoxyhemoglobins with
and without dithionite ion in the buffers indicate that the
dithionite ion plays no significant role in the electrophoretic
properties of the proteins. It is th refore of interest that
ferrohemoglob~n was found to have a lower isoelectric point
in phosphate buffer than carbonmonoxyhemoglobin. Titra-
tion studies have indicated (5, 6) that oxyhemoglobin (simi-
lar in electrophoretic properties to the carbonmonoxy com-
pound) has a lower isoelectric point than ferrohemoglobin in
November Vol. 1 1044 SCI NCE
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The Inheritance of Sickle Cell Anemial
James V. Neel
Heredity Clinic, Laboratory of Vertebrate Biology, University of Michigan, Ann Arbor
IF A DROP OF BLOOD is collected from each
member of a randomly assembled series of Amer-
ican Negroes and sealed under a cover slip with
vaseline, to be observed at intervals up to 72 hours,
in the case of about 8 percent of the individuals com-
posing the series a high proportion of the erythrocytes
will be observed to assume various bizarre oat, sickle,
or holly leaf shapes. This ability of the erythrocytes
to "sickle," as the phenomenon is commonly described,
appears to be attended by no pathological consequences
in the majority of these individuals, and they are
spoken of as having sicklemia, or the sickle cell trait.
However, a certain proportion of the individuals who
sickle are the vic4ims of a severe, chronic, hemolytic
type of anemia known as sickle cell anemia. This pro-
portion has been variously estimated at between 1: 1.4
(8) and 1: 40 (4). The essential difference between
sicklemia and sickle cell anemia appears at present
to depend at least in part upon the relative ease with
which sickling takes place. In sickle cell anemia the
erythrocytes may frequently sickle under the condi-
tions encountered in the circulating blood, whereas
in sicklemia sickling does not usually occur under
these conditions (12). This difference has been at-
tributed to a greater tendency of the erythrocytes of
sickle cell anemia to sickle when the 02-tension is
reduced, although recently this viewpoint has been
challenged (13). Perhaps because of this difference-
although there may be other factors involved, such as
the aniso- and poikilocytosis to be observed in some
individuals with the disease, and a greater resistance
to hemolysis of trait cells when sickled than sickle cell
anemia cells when sickled-the erythrocytes of a
patient with sickle cell anemia have a greatly short-
ened life span, both in the individuals with the disease
and in normal persons who have been transfused with
the cells of sickle cell anemia patients, whereas sick-
lemia erythrocytes have an normal life span (3, 14).
The ability of the red cells to sickle was observed
to have a genetic basis not long after sickle cell anemia
1 This investigation was supported in part by a grant from
the U. S. Public Health Service. The study has been pos-
sible only through the generous cooperation of the Anemia
Clinic of the Children's Hospital of Michigan, Detroit, Michi-
gan, The University Hospital of the University of Michigan,
Ann Arbor, Michigan, and the Wayne County General Hos-
pital and Infirmary, Eloise, Michigan; all three institutions
have made their case records of sickle cell anemia freely
available. It is a pleasure to acknowledge my indebtedness
to Mrs. Marion Weyrauch for technical assistance, and to
Mrs. Laura Williams for case work.
was recognized as a clinical entity (5). On the basis
of a study of one large family, Taliaferro and Huck
(15) postulated that the ability to sickle was due to
a single dominant gene. At that time the clinical dis-
tinction between sicklemia and sickle cell anemia had
not been clearly drawn, and the inference was that
this gene was more strongly expressed in some indi-
viduals (sickle cell anemia) than in others (sicklemia).
This has remained the accepted hypothesis up to the
present time. Several years ago the author, in a
review on the clinical detection of the genetic carriers
of inherited disease (9), was led to suggest an alterna-
tive hypothesis-namely, that there existed in Negro
populations a gene which in heterozygous condition
results in sicklemlia, and in homozygous condition in
sickle cell anemia. This hypothesis has a counterpart
in the relationship which has been demonstrated to
exist between thalassemia major and minor (10, 16).
Recently the opportunity has arisen to give this
hypothesis a thorough test.
There exist a number of arguments permitting a
critical decision between the two hypotheses. The
present preliminary note will consider only one of
these arguments. If the homozygous-heterozygotus
hypothesis is correct, then both the parents of any
patient with sickle cell anemia should always sickle
(barring the occasional role of mutation; see below).
If, on the other hand, the disease is due to a domi-
nant gene with variable expression, only one parent
need sickle, although occasionally, due to the chance
marriage of two sicklers, both parents may sickle.
In calculating the exact proportion of sicklemia to be
expected among the parents of individuals with sickle
cell anemia according to the dominant hypothesis, cer-
tain assumptions must be made. To the best of the
author's knowledge, the question of the phenotype of
the homozygote has never been raised by those who
have accepted the variable dominant hypothesis of
sickle cell anemia. For purposes of calculation we
shall assume that under the variable dominant hy-
pothesis all homozygotes have sickle cell anemia-
alternative assumptions, such as intra-uterine lethal-
ity, are possible. We shall further assume that one in
fifty heterozygotes also develops sickle cell anemia.
Finally, we shall assume on the basis of the clinical
data that the fertility of those with sickle cell anemnia
approximates 20 percent of normal, with the result
that only a few individuals with this disease-so few
SCIENCE July 15, 1949, Vol. 1 1064
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that they may be disregarded in so rough a calcula- for the sickling phenomenon are known to be variable;
tion-have one or both parents who are likewise it is felt that the experience quoted may be explained
affected. With these assumptions we may calculate, in terms of lack of familiarity with the techniques
as shown in Table 1, that the proportion of sickling necessary to elicit sickling.
TABLE 1
CALCULATION OF THE PROPORTION OF SICKLING TO BE EXPECTED AMONG THE PARENTS OF INDIVIDUALS WITH SICKLE
CELL ANEMIA ACCORDING TO THE VARIBLE DOMINANT HYPOTHESIS*
Frequency of offspring of Sickle cell anemia patients
the indicated genotype
Type of Frequency of
marriage marriage Proportion in Proportion among
Sk Sk Sk sk sk sk general total anemia
population patients
One sickler parent
(Sk sk x sk sk) 2 x 0.08 x 0.92 = 0.1472 ..... 0.0736 0.0736 0.02 x 0.0736 0.4693
= 0.001472
Two sickler parents
(Sk sk x Sk sk) 0.08 x 0.08 = 0.0064 0.0016 0.0032 0.0016 0.0016 + 0.5307
(0.02 x 0.0032)
= 0.001664
Total 0.003136 1.0000
* The assumption is made that all individuals homozygous for the sickling gene (Sk) develop sickle cell anemia, as do
1 in 50 persons heterozygous for the gene, and further that individuals with sickle cell anemia reproduce so infrequently
that no significant error is introduced by their omission.
Expected proportion of sickling parents= (proportion of patients having one parent sickler) x (proportion of sicklers
among these parents) + (proportion of patients having both parents sicklers) x (proportion of sicklers among these parents)
= 0.4693 x 1/2 + 0.5307 x 1 = 0.765.
among the parents of individuals with sickle cell
anemia should be 0.765. If one assumes that more
than one in fifty of the heterozygotes develop sickle
cell anemia, or that the homozygote is lethal, then the
proportion of sickling parents should be even lower.
Thus far we have tested 42 parents of 29 patients
with sickle cell nemia for the occurrence of sickling.
In 13 instances both parents were studied and in 16,
only one. Tests have been conducted in a variety of
ways; especial reliance has been placed on a com-
bination of the techniques described by Scriver and
Waugh (11) and Hansen-Pruss (7), whereby a tour-
niquet is applied to a finger for 3-5 minutes, and
then a drop of static blood from the finger is placed
on a slide to which a small amount of Janus green or
mnethylene blue has been added, and it is quickly cov-
ered with a cover slip which is s aled with vaseline.
Observations are made at intervals up to 72 hours.
Five p eparations have been made for each individual.
Every parent tested to date has sickled. This is the
result expected from the homozygous-heterozygous
hypothesis outlined above. On the other hand, the
probability of the occurrence of such a number of
p sitive parents under the variable dominant hypothe-
sis is (0.765 ) 42, or 0.000013.
There are to be found in the literature a number of
reports where one or both parents of a child with
sickle cell anemia have been tested and found not to
sickle (review in reference 9). The results of tests
The approximate frequency of the gene responsible
for sickling in the American Negro (p) may be deter-
mined from the equation 2p (1 - p) = 0.08. Solution
of this equation yields a p value of 0.042, from which
the incidence at birth of this chronic, disabling, and
fatal disease among American Negroes may be placed
at (0.042)2=1.8 per 1000.2 The ratio among Negro
births in the United States of those with sicklemia to
those who will develop sickle cell anemia should there-
fore be approximately 80: 1.8 = 44: 1; in the Negro
population as a whole the ratio of sicklemia: sickle
cell anemia is significantly higher because of the
greater mortality among those with sickle cell anemia.
In Africa, the incidence of sickling has been reported
to vary from approximately 12 percent in Northern
Rhodesia (1) to 17 percent in the Gold Coast Negroes
and 19 percent in natives of Nigeria and the Camar-
oons (6). This would correspond to a gene frequency
of approximately 0.064-0.106, and a frequency of the
homozygote of 4.1-11.2/1000. The complex and fasci-
nating problems in gene dynamics raised by frequen-
cies of this order will be dealt with in another paper.
In a genetic situation such as appears to obtain
here, where the heterozygote, who may be termed the
genetic carrier of the disease, may be readily distin-
2 The correct formula is y = a p + (1 - a)p2, where a the
mean coefficient of inbreeding. The value of a for the Ameri-
can Negro is unknown, but probably quite small, In the
neighborhood of 0.0005. For present purposes the value of
p2 is a sufficiently close approximation to p.
10 SCIENCE 65
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IF A DROP OF BLOOD is collected from each
member of a randomly assembled series of Amer-
ican Negroes and sealed under a cover slip with
vaseline, to be observed at intervals up to 72 hours,
in the case of about 8 percent of the individuals com-
posing the series a high proportion of the erythrocytes
will be observed to assume various bizarre oat, sickle,
or holly leaf shapes. This ability of the erythrocytes
to "sickle," as the phenomenon is commonly described,
appears to be attended by no pathological consequences
in the majority of these individuals, and they are
spoken of as having sicklemia, or the sickle cell trait.
However, a certain proportion of the individuals who
sickle are the vic4ims of a severe, chronic, hemolytic
type of anemia known as sickle cell anemia. This pro-
portion has been variously estimated at between 1: 1.4
(8) and 1: 40 (4). The essential difference between
sicklemia and sickle cell anemia appears at present
to depend at least in part upon the relative ease with
which sickling takes place. In sickle cell anemia the
erythrocytes may frequently sickle under the condi-
tions encountered in the circulating blood, whereas
in sicklemia sickling does not usually occur under
these conditions (12). This difference has been at-
tributed to a greater tendency of the erythrocytes of
sickle cell anemia to sickle when the 02-tension is
reduced, although recently this viewpoint has been
challenged (13). Perhaps because of this difference-
although there may be other factors involved, such as
the aniso- and poikilocytosis to be observed in some
individuals with the disease, and a greater resistance
to hemolysis of trait cells when sickled than sickle cell
anemia cells when sickled-the erythrocytes of a
patient with sickle cell anemia have a greatly short-
ened life span, both in the individuals with the disease
and in normal persons who have been transfused with
the cells of sickle cell anemia patients, whereas sick-
lemia erythrocytes have an normal life span (3, 14).
The ability of the red cells to sickle was observed
to have a genetic basis not long after sickle cell anemia
1 This investigation was supported in part by a grant from
the U. S. Public Health Service. The study has been pos-
sible only through the generous cooperation of the Anemia
Clinic of the Children's Hospital of Michigan, Detroit, Michi-
gan, The University Hospital of the University of Michigan,
Ann Arbor, Michigan, and the Wayne County General Hos-
pital and Infirmary, Eloise, Michigan; all three institutions
have made their case records of sickle cell anemia freely
available. It is a pleasure to acknowledge my indebtedness
to Mrs. Marion Weyrauch for technical assistance, and to
Mrs. Laura Williams for case work.
was r cognized as a clinical entity (5). On the basis
of a study of one large family, Taliaferro and Huck
(15) postulated that the ability to sickle was due to
a single dominant gene. At that time the clinical dis-
tinction between sicklemia and sickle cell anemia had
not been clearly drawn, and the inference was that
this gene was more strongly expressed in some indi-
vidu ls (sickle cell anemia) than i others (sicklemia).
This has remained the accepted hypothesis up to the
present time. Several years ago the author, in a
review on the clinical detection of the genetic carriers
of inherited disease (9), was led to suggest an alterna-
tive hypothesis-namely, that there existed in Negro
populations a gene which in heterozygous condition
results in sicklemlia, and in homozygous condition in
sick e cell nemia. T is hypothesis has a coun erpart
in the relationship which has been demonstrated to
exist between thalassemia major and minor (10, 16).
Recently the opportunity has arisen to give this
hypothesis a thorough test.
There exist a number of arguments permitting a
critical decision between the two hypotheses. The
present prel minary note will consider only one of
these arguments. If the homozygous-heter zygotus
hypothesis is correct, then both the parents of any
patient with sickle cell anemia should always sickle
(barring the occasional role of mutation; see below).
If, on the other hand, the disease is due to a domi-
nant gene with variabl expression, only one parent
need sickle, although occasionally, due to the chance
marriage of two sicklers, both parents may sickle.
In calculating the exact proportion of sicklemia to be
expected among the parents of individuals with sickle
cell anemia according to the dominant hypothesis, cer-
tain assumptions must be made. To the best of the
author's knowledge, the question of the phenotype of
the homozygote has never been raised by those who
have accepted the variable dominant hypothesis of
sickle cell anemia. For purposes of calculation we
shall assume that under the variable dominant hy-
pothesis all homozygotes have sickle cell anemia-
alternative assumptions, such as intra-uterine lethal-
ity, are possible. We shall further assume that one in
fifty heterozygotes also develops sickle cell anemia.
Finally, we shall assume on the basis of the clinical
data that the fertility of those with sickle cell anemnia
approximates 20 percent of normal, with the result
that only a few individuals with this disease-so few
SCIENCE July 15, 1949, Vol. 1 1064
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Cys)c	  Fibrosis	  	  
•  Gene	  cloned	  in	  1989	  	  
•  Finally,	  drugs	  screened	  in	  human	  cells,	  restoring	  CFTR	  
func)on,	  in	  par)cular	  mutated	  version,	  G551D.	  
•  Trials	  for	  one	  mutated	  version	  G551D,	  present	  in	  4%	  of	  
CF	  pa)ents.	  The	  drug	  worked.	  
•  FDA	  approval	  in	  record	  )me.	  
•  Cost	  of	  Drug?	  $294,000	  per	  year,	  to	  be	  taken	  for	  a	  
life)me.	  For	  60	  years,	  that	  is	  ~$18	  million	  per	  person.	  
•  4%	  of	  30,000	  people	  with	  CF	  in	  US	  =	  1200.	  
•  So,	  $21.6	  billion	  to	  treat	  1200	  people	  for	  60	  years	  
(assuming	  lower	  than	  average	  lifespan).	  
•  From	  2000-­‐2004,	  82	  children	  born	  with	  CF	  in	  Victoria,	  Australia.	  	  
•  5	  of	  these	  (6%)	  were	  from	  families	  with	  known	  history	  of	  CF.	  
•  Even	  when	  a	  family	  history	  is	  known,	  most	  rela)ves	  do	  not	  undertake	  
carrier	  tes)ng.	  In	  an	  audit	  of	  cascade	  carrier	  tes)ng	  aher	  a	  diagnosis	  of	  
CF	  through	  newborn	  screening,	  only	  11.8%	  of	  eligible	  (non-­‐parent)	  
(82/716)	  rela)ves	  were	  tested.	  
•  The	  other	  94%	  could	  have	  been	  prevented	  with	  carrier	  screening	  too.	  
	  	  


•  Pre-­‐sequencing	  era:	  not	  so	  
much	  data	  
–  1.	  High-­‐quality	  data	  
–  2.	  Well	  designed	  sohware	  tools	  
	  
•  Sequencing	  era:	  too	  much	  data	  
–  1.	  Noisy	  data	  
–  2.	  Massive	  quan)ty	  to	  handle	  
The Genomic Data Deluge 
A typical exome sequencing study 
What	  to	  do	  next?	  
3	  million	  SNPs	  
0.5	  million	  indels	  
1	  thousand	  structural	  variants	  
Which	  one	  causes	  the	  disease?	  
Which	  ones	  confer	  suscep)bility?	  
	  
We	  need	  func)onal	  
interpreta)on	  of	  
personal	  genomes!	  
Iden)fy	  cases	  
Sequencing…	  
Call	  variants	  
By Kelly Servick
L
ast month, researchers at Boston 
Children’s Hospital published a study 
that closely examined the DNA of 
158 people with brain malformations 
who had been unable to identify the 
cause of their disorders through clini-
cal genetic testing. With highly sensitive 
sequencing, the group found eight disease-
causing mutations that occurred in only a 
small fraction of each person’s cells, mak-
ing them too subtle for conventional ge-
netic diagnostic tests.
Such genetic variation among cells, 
known as mosaicism, is present in all of us 
and has long been common knowledge. The 
phenomenon was a feature of “college dorm 
room conversations in the decades past,” 
says Chad Shaw, a statistician at Baylor Col-
lege of Medicine in Houston, Texas. “It was 
like, ‘Hey, this will blow your mind.’ ” 
But now that genetic technologies make 
it possible to hunt down specific mutations 
in small numbers of cells, researchers, cli-
nicians, genetic counselors, and funders 
are paying closer attention to mosaicism. 
Next month, the U.S. National Institutes of 
Health (NIH) will begin reviewing applica-
tions for grants to find genetic variation 
in brain tissue that may help explain neu-
ropsychiatric disorders. And as research-
ers find more cases of mosaicism, they’re 
wondering how many genetic causes of 
disease remain invisible to even the best 
clinical tests.
Traditionally, genetic disease research 
has focused on mutations inherited through 
the germ line—the legacy of parents who 
are carriers, or of genetic mistakes dur-
ing the formation of their eggs and sperm. 
These DNA mishaps end up in every cell of 
a child. But once an embryo starts devel-
oping, genetic errors can arise every time 
a cell divides. And because cells can then 
proliferate and spread their mutations, 
each body is “a kind of micro evolutionary 
experiment,” says Leslie Biesecker, a ge-
neticist at NIH’s National Human Genome 
Research Institute in Bethesda, Maryland. 
The number of cells with a given mutation 
depends on when and where the mutation 
arose and how it changes a cell’s function. 
Many such mutations are benign, but some 
cause disease. 
The systematic hunt for disease-causing 
mosaic mutations is only beginning. Some 
are obvious—cases where “nature is stick-
ing its finger in our eye,” Biesecker says. 
In conditions such as McCune-Albright 
syndrome, the abnormal cells can be seen 
as patches or patterns on a person’s skin. 
But any genetic disease could be mosaic. 
Cancers, which consist of genetically dis-
tinct cells, are a familiar example, and are 
a common focus of sequencing efforts. But 
other studies have shown that mosaic mu-
tations can underlie dozens of conditions, 
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other countries to push for access.
Meanwhile, camera networks continu-
ously monitor the night skies with fisheye 
lenses. Some, such as the European Fireball 
Network, are well established, but many rely 
on enthusiastic amateurs and outdated film 
cameras. Philip Bland, a researcher at Curtin 
University, Bentley, in Australia, has larger 
ambitions. By the end of this month, he and 
his colleagues will have finished installing 
some 30 camera stations in the Australian 
outback, covering an area the size of Alaska. 
Each AU$7000 station in the Desert Fire-
ball Network includes a high-resolution 
camera that takes 30-second time-lapse stills 
for calculating trajectories and brightnesses. 
It also has a video camera to determine the 
exact duration of the fireball, which can be 
translated into its speed. The solar-powered 
stations can collect data, unattended, for 
months on end. 
Bland expects to catch between five and 
10 fireballs a year. He also believes that re-
covering the meteorites will be easier than 
it is in places such as Europe—even though 
he often won’t be able to enlist radar to re-
fine his trajectories. This part of Australia 
largely lacks people and precipitation, and 
hence has few weather radars. But the dark 
meteorites should be easy to spot against the 
light-colored, largely barren desert. A camera-
equipped drone will aid the search. 
With such a wide net for trapping space 
rocks, Bland believes that he can start to 
determine the rate at which material from 
space hits the Earth—and not just extra-
terrestrial material. Humanmade space junk 
regularly falls to Earth and can be distin-
guished by its slower speed: Anything that 
strikes the atmosphere at less than 11 kilo-
meters per second can be assumed to have 
been lofted by humans.
All this technology could eventually make 
retrieving meteorite fragments routine and 
efficient. The old way—rare, momentous 
fireball sightings followed by frenzied yet 
agonizingly slow searches on foot—would be 
history. But for now, researchers still thrill to 
the chase. During the radar technique work-
shop, Josep Trigo-Rodríguez, a researcher 
at the Institute of Space Sciences in Barce-
lona, Spain, learned that a massive fireball, 
brighter than the full moon, had been seen 
over Catalonia early on 7 September. Trigo-
Rodríguez worked through the week to re-
fine the meteorite’s trajectory, based on data 
from five fireball network cameras and two 
pictures from eyewitnesses. 
He would not reveal its exact location; he 
sent out a search party last week and did not 
want to be scooped by local meteorite hunt-
ers. But he suspects that several kilograms 
of fresh meteorite are waiting for him some-
where in the northeast of Spain. ■
Harmful mutations can
fly under the radar
With more sensitive genetic tests, researchers are hunting 
the roots of disease in the human “mosaic”
CLINICAL TESTING
Zygote Genetic change Proliferation
Building a human mosaic
Depending on when and where in embryonic development a mutation 
occurs, a subset of adult cells will harbor the genetic change.
Mosaic mutation
Published by AAAS
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By Kelly Servick
L
ast month, researchers at Boston 
Children’s Hospital published a study 
that closely examined the DNA of 
158 people with brain malformations 
who had been unable to identify the 
cause of their disorders through clini-
cal genetic testing. With highly sensitive 
sequencing, the group found eight disease-
causing mutations that occurred in only a 
small fraction of each person’s cells, mak-
ing them too subtle for conventional ge-
netic diagnostic tests.
Such genetic variation among cells, 
known as mosaicism, is present in all of us 
and has long been common knowledge. The 
phenomenon was a feature of “college dorm 
room conversations in the decades past,” 
says Chad Shaw, a statistician at Baylor Col-
lege of Medicine in Houston, Texas. “It was 
like, ‘Hey, this will blow your mind.’ ” 
But now that genetic technologies make 
it possible to hunt down specific mutations 
in small numbers of cells, researchers, cli-
nicians, genetic counselors, and funders 
are paying closer attention to mosaicism. 
Next month, the U.S. National Institutes of 
Health (NIH) will begin reviewing applica-
tions for grants to find genetic variation 
in brain tissue that may help explain neu-
ropsychiatric disorders. And as research-
ers find more cases of mosaicism, they’re 
wondering how many ge e ic causes of 
disease remain invisible to even the best 
clinical tests.
Traditionally, genetic disease research 
has focused on mutations inherited through 
the germ line—the legacy of parents who 
are carriers, or of genetic mistakes dur-
ing the formation of their eggs and sperm. 
These DNA mishaps end up in every cell of 
a child. But once an embryo starts devel-
oping, genetic errors can arise every time 
a cell divides. And because cells can then 
proliferate and spread their mutations, 
each body is “a kind of micro evolutionary 
experiment,” says Leslie Biesecker, a ge-
neticist at NIH’s National Human Genome 
Research Institute in Bethesda, Maryland. 
The number of cells with a given mutation 
depends on when and where the mutation 
arose and how it changes a cell’s function. 
Many such mutations are benign, but some 
cause disease. 
The systematic hunt for disease-causing 
mosaic mutations is only beginning. Some 
are obvious—cases where “nature is stick-
ing its finger in our eye,” Biesecker says. 
In conditions such as McCune-Albright 
syndrome, the abnormal cells can be seen 
as patches or patterns on a person’s skin. 
But any genetic disease could be mosaic. 
Cancers, which consist of genetically dis-
tinct cells, are a familiar example, and are 
a common focus of sequencing efforts. But 
other studies have shown that mosaic mu-
tations can underlie dozens of conditions, 
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other countries to push for access.
Meanwhile, camera networks continu-
ously monitor the night skies with fisheye 
lenses. Some, such as the European Fireball 
Network, are well established, but many rely 
on enthusiastic amateurs and outdated film 
cameras. Philip Bland, a researcher at Curtin 
University, Bentley, in Australia, has larger 
ambitions. By the end of this month, he and 
his colleagues will have finished installing 
some 30 camera stations in the Australian 
outback, covering an area the size of Alaska. 
Each AU$7000 station in the Desert Fire-
ball Network includes a high-resolution 
camera that takes 30-second time-lapse stills 
for calculating trajectories and brightnesses. 
It also has a video camera to determine the 
exact duration of the fireball, which can be 
translated into its speed. The solar-powered 
stations can collect data, unattended, for 
months on end. 
Bland expects to catch between five and 
10 fireballs a year. He also believes that re-
covering the meteorites will be easier than 
it is in places such as Europe—even though 
he often won’t be able to enlist radar to re-
fine his trajectories. This part of Australia 
largely lacks people and precipitation, and 
hence has few weather radars. But the dark 
meteorites should be easy to spot against the 
light-colored, largely barren desert. A camera-
equipped drone will aid the search. 
With such a wide net for trapping space 
rocks, Bland believes that he can start to 
determine the rate at which material from 
space hits the Earth—and not just extra-
terrestrial material. Humanmade space junk 
regularly falls to Earth and can be distin-
guished by its slower speed: Anything that 
strikes the atmosphere at less than 11 kilo-
meters per second can be assumed to have 
been lofted by humans.
All this technology could eventually make 
retrieving meteorite fragments routine and 
efficient. The old way—rare, momentous 
fireball sightings followed by frenzied yet 
agonizingly slow searches on foot—would be 
history. But for now, researchers still thrill to 
the chase. During the radar technique work-
shop, Josep Trigo-Rodríguez, a researcher 
at the Institute of Space Sciences in Barce-
lona, Spain, learned that a massive fireball, 
brighter than the full moon, had been seen 
over Catalonia early on 7 September. Trigo-
Rodríguez worked through the week to re-
fine the meteorite’s trajectory, based on data 
from five fireball network cameras and two 
pictures from eyewitnesses. 
He would not reveal its exact location; he 
sent out a search party last week and did not 
want to be scooped by local meteorite hunt-
ers. But he suspects that several kilograms 
of fresh meteorite are waiting for him some-
where in the northeast of Spain. ■
Harmful mutations can
fly under the radar
With more sensitive genetic tests, researchers are hunting 
the roots of disease in the human “mosaic”
CLINICAL TESTING
Zygote Genetic change Proliferation
Building a human mosaic
Depending on when and where in embryonic development a mutation 
occurs, a subset of adult cells will harbor the genetic change.
Mosaic mutation
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Cre;nism	  –	  lack	  of	  iodine	  in	  the	  diet,	  leading	  to	  
thyroid	  hormone	  deﬁciency.	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•  Seguin	  E.	  1866,	  -­‐	  	  “our	  incomplete	  studies	  do	  
not	  permit	  actual	  classiﬁca)on;	  but	  it	  is	  beXer	  
to	  leave	  things	  by	  themselves	  rather	  than	  to	  
force	  them	  into	  classes	  which	  have	  their	  
founda)on	  only	  on	  paper”-­‐	  from	  Idiocy	  and	  its	  
treatment	  by	  the	  physiological	  method.	  
•  Walter	  Frank	  Raphael	  Weldon	  1902	  –	  “the	  
accumula)on	  of	  records,	  in	  which	  results	  are	  
massed	  together	  in	  ill-­‐deﬁned	  categories	  of	  
variable	  and	  uncertain	  extent,	  can	  only	  result	  
in	  harm”.	  
OBSERVATIONS ON AN ETHNIC CLASSIFICATION OF IDIOTS *
J. LANGDON H. DOWN M.D., London
THOSE who have given any attention to congenital mental lesions, must have
been frequently puzzled how to arrange, in any satisfactory way, the different
classes of this defect which may have come under their observation. Nor
will the difficulty be lessened by an appeal to what has been written on the
subject. The systems of classification are generally so vague and artificial,
that, not only do they assist but feebly, in any mental arrangement of the
phenomena which are presented, but they completely fail in exerting anypractical influence on the subject.
The medical practitioner who may be consulted in any given case, has,
perhaps in a very early condition of the child's life, to give an opinion on
points of vital importance as to the present condition and probable future of
the little one. Moreover, he may be pressed as to the question, whether the
supposed defect dates from any cause subsequent to the birth or not. Has
the nurse dosed the child with opium? Has the little one met with any
accident? Has the instrumental interference which maternal safety de-
manded, been the cause of what seems to the anxious parents, a vacant future?
Can it be that when away from the family attendant the calomel powders
were judiciously prescribed? Can, in fact, the strange anomalies which the
child presents, be attributed to the numerous causes which maternal solici-
tude conjures to the imagination, in order to account for a condition, for
which any cause is sought, rather than hereditary taint or parental influence.
Will the systems of classification, either all together, or any one of them,
assist the medical adviser in the opinion he is to present, or the suggestions
which he is to tender to the anxious parent? I think that they will entirely
fail him in the matter, and that he will have in many cases to make a guarded
diagnosis and prognosis, so guarded, in fact, as to be almost valueless, or to
venture an authoritative assertion which the future may perhaps confirm.
I have for sometime had my attention directed to the possibility of
making a classification of the feeble minded by arranging them around
various ethnic standards—in other words, framing a natural system to
supplement the information to be derived by an inquiry into the history of
the case.
I have been able to find among the large number of idiots and imbeciles
which come under my observation, both at Earlswood and the out-patient
department of the Hospital, that a considerable portion can be fairly re-
ferred to one of the great divisions of the human family other than the class
from which they have sprung. Of course, there are numerous representatives
of the great Caucasian family. Several well-marked examples of the Ethi-
opian variety have come under my notice, presenting the characteristic
malar bones, the prominent eyes, the puffy lips, and retreating chin. The
* This paper from the London Hospital Clinical Report 3, 259-262 (i866) is republishedon account of its historical interest (see page 698). The editors are indebted to Dr J. H.
Edwards, The Medical School, University of Birmingham who proposed republication and
provided the copy.
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The life expectancy, however, is far below the average, and the tendency is
to the tuberculosis, which I believe to be the hereditary origin of the
degeneracy.Apart from the practical bearing of this attempt at an ethnic classification,
considerable philosophical interest attaches to it. The tendency in the
present day is to reject the opinion that the various races are merely varieties
of the human family having a common origin, and to insist that climatic,
or other influences, are insufficient to account for the different types of man.
Here, however, we have examples of retrogression, or at all events, of de-
parture from one type and the assumption of the characteristics of another.
If these great racial divisions are fixed and definite, how comes it that disease
is able to break down the barrier, and to simulate so closely the features os
the members of another division. I cannot but think that the observations
which I have recorded are indications that the differences in the races are not
specific but variable.
These examples of the result of degeneracy among mankind, appear to me
to furnish some arguments in favour of the unity of the human species.
London Hospital Cli ical Lecture Report. 3, 259-262, i866.
2Y
“Those	  who	  hav 	  given	  any	  aX n) n	  to	  congenital	  mental	  
lesions,	  must	  have	  been	  frequently	  puzzled	  how	  to	  arrange,	  in	  
any	  sa)sfactory	  way,	  the	  diﬀerent	  classes	  of	  this	  defect	  which	  
may	   ave	  come	  under	  their	  observa)on.	  Nor	  will	  the	  diﬃculty	  be	  
lessened	  by	  an	  appeal	  to	  what	  has	  been	  wriXen	  on	  the	  subject.	  
The	  systems	  of	  classiﬁca)on	  are	  generally	  so	  vague	  and	  ar)ﬁcial,	  
that,	  not	  only	  do	  they	  assist	  but	  feebly,	  in	  any	  mental	  
arra gement	  of	  the	  phenomena	  represented,	  but	  they	  
completely	  fail	  in	  exer)ng	  a y	  prac)cal	  inﬂuenc 	  on	  the	  subject.”	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Down	  Syndrome	  
Down	  Syndrome	  
Christopher	  Joseph	  "Chris"	  Burke	  (born	  August	  
26,	  1965)	  is	  an	  American	  actor	  and	  folk	  singer,	  
who	  lives	  with	  Down	  syndrome,	  who	  has	  
become	  best	  known	  for	  his	  character	  Charles	  
"Corky"	  Thacher	  on	  the	  television	  series	  Life	  
Goes	  On.	  
	  
And	  there	  are	  people	  with	  Mosaic	  Down	  
Syndrome,	  who	  are	  much	  less	  aﬀected.	  
Velocardiofacial	  (22q11.2)	  Syndrome	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Understanding the spectrum of allelic variation in human genes and 
revealing the demographic and evolutionary forces that shape this varia-
tion within and among populations is a major aim of human genetics 
research. Such information is critical for defining the architecture of 
common diseases, identifying functionally important variation, and ulti-
mately facilitating the interpretation of personalized disease risk profiles 
(1–3). To date, surveys of human variation have been dominated by 
studies of single nucleotide polymorphisms (SNPs) genotyped using 
high-density arrays composed of common variants (4–6). While these 
projects have substantially improved our knowledge of common allelic 
variation and enabled genome-wide association studies (GWAS), they 
have been generally uninformative about the population genetics charac-
teristics of rare variants, defined here as a minor allele frequency (MAF) 
of less than 0.5%. 
Rare genetic variants are predicted to vastly outnumber common 
variants in the human genome (7, 8). By capturing and sequencing all 
protein-coding exons (i.e., the exome, which comprises ~1-2% of the 
human genome), exome sequencing is a powerful approach for discover-
ing rare variation and has facilitated 
the genetic dissection of unsolved 
Mendelian disorders and studying 
human evolutionary history (9–14). 
Rare and low frequency (MAF be-
tween 0.5%-1%) variants have been 
hypothesized to explain a substantial 
fraction of the heritability of common, 
complex diseases (15). Since common 
variants explain only a modest fraction 
of the heritability of most traits (16, 
17), NHLBI recently sponsored the 
multicenter Exome Sequencing Project 
(ESP), to identify novel genes and 
molecular mechanisms underlying 
complex heart, lung, and blood disor-
ders by sequencing the exomes of a 
large number of individuals measured 
for phenotypic traits of substantial 
public health significance (e.g., early-
onset myocardial infarction, stroke, 
body mass index). 
Data generation and variant dis-
covery. A total of 63.4 terabases of 
DNA sequence was generated at two 
centers with three complimentary defi-
nitions of the exome target and two 
different capture technologies (18). We 
sequenced samples from 14 different 
cohorts in the ESP to an average medi-
an depth of 111x (range 23x – 474x). 
We found no evidence of cohort- 
and/or phenotype specific effects, or 
other systematic biases, in the analysis 
of the filtered SNV data (18; Figs. S1-
S7). Exomes from related individuals 
were excluded from further analysis 
(18; Fig. S8) resulting in a dataset of 
2,440 exomes. We inferred genetic 
ancestry using a clustering approach 
(18), and focused the remaining anal-
yses on the inferred 1,351 EA and 
1,088 AA individuals. We subjected 
the 563,698 variants in the intersection 
of all three capture targets to standard 
quality control filters (18) resulting in a final data set of 503,481 single 
nucleotide variants (SNVs) identified in 15,585 genes and 22.38 Mb of 
targeted sequence per individual. We assessed data quality and error 
rates using complementary strategies (18). Approximately 98% 
(941/961) of all variant sites that were experimentally tested were con-
firmed, including 98% (234/238) of singletons, 98% (678/693) of non-
singleton SNV sites with a MAF < 10%, and 97% (29/30) of SNV sites 
ZLWKD0$) 
The vast majority of coding variation is rare and novel. We ob-
served a total of 503,481 SNVs and 117 fixed, non-reference sites, of 
which 325,843 and 268,903 were found in AA and EA, respectively (18; 
Fig. S9A). Excluding singletons, ~58% of SNVs were population-
specific (93,278 and 32,552 variants were uniquely observed in AA, or 
EA, respectively), and the vast majority of these variants were rare (18; 
Fig. S9B). Most SNVs (292,125 or 58%) were nonsynonymous includ-
ing 285,960 missense variants and 6,165 nonsense variants (18; Fig. 
S9C). Synonymous variants accounted for 38% (188,975) of the total 
SNVs (18; Fig. S9C), with the remaining 4% of SNVs (22,381) located 
Evolution and Functional Impact of 
Rare Coding Variation from Deep 
Sequencing of Human Exomes 
Jacob A. Tennessen,1* Abigail W. Bigham,2*† Timothy D. O’Connor,1* Wenqing 
Fu,1 Eimear E. Kenny,3 Simon Gravel,3 Sean McGee,1 Ron Do,4,5 Xiaoming Liu,6 
Goo Jun,7 Hyun Min Kang,7 Daniel Jordan,8 Suzanne M. Leal,9 Stacey Gabriel,4 
Mark J. Rieder,1 Goncalo Abecasis,7 David Altshuler,4 Deborah A. Nickerson,1 
Eric Boerwinkle,6,10 Shamil Sunyaev,4,8 Carlos D. Bustamante,3 Michael J. 
Bamshad,1,2‡ Joshua M. Akey,1‡ Broad GO, Seattle GO, on behalf of the NHLBI 
Exome Sequencing Project 
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USA. 6Human Genetics Center, University of Texas Health Sciences Center at Houston, Houston, Texas, 
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As a first step toward understanding how rare variants contribute to risk for 
complex diseases, we sequenced 15,585 human protein-coding genes to an average 
median depth of 111x in 2,440 individuals of European (n=1,351) and African 
(n=1,088) ancestry. We identified >500,000 single nucleotide variants (SNVs), the 
majority of which were rare (86% with a minor allele frequency < 0.5%), novel (82%), 
and population-specific (82%). On average, 2.3% of the 13,595 SNVs each person 
carries were predicted to impact protein function of ~313 genes per genome, and 
~95.7% of SNVs predicted to be functionally important were rare. This excess of rare 
functional variants is due to the combined effects of explosive, recent accelerated 
population growth and weak purifying selection. Furthermore, we show that large 
sample sizes will be required to associate rare variants with complex traits. 
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Crohn’s disease and ulcerative colitis are classified as chronic, idi-
opathic inflammatory bowel diseases (IBDs) of the gastrointestinal 
tract with unknown etiology (MIM266600). Crohn’s disease occurs 
in about 100–150 per 100,000 individuals of European a cestry1. 
Generally, the disease affects the ileum and colon, but it can affect any 
region of the gut. Ulcerative colitis has similar population prevalence, 
and although it has some similarities to Crohn’s disease in clinical 
manifestation, the location of inflammation is limited to the colonic 
mucosa. Strong familial aggregation has been observed in twin studies 
of Crohn’s disease and ulcerative colitis2,3. Recent population-based 
sibling risk is 26-fold greater for Crohn’s diseas  and 9-fold greater for 
ulcerative colitis2, and overall Crohn’s disease and ulcerative colitis 
concordance rates in nonselected twin studies are 30% and 15%, 
respectively, among monozygotic twins compared with 4% for 
Crohn’s disease or ulcerative colitis among dizygotic twins3. Like most 
complex diseases, Crohn’s disease and lcerative colitis result from 
a combination of genetic and nongenetic risk factors, and each 
individual factor probably has a modest effect on disease risk4.
Deep resequencing of GWAS loci identifies independent 
rare variants associated with inflammatory bowel disease
Manuel A Rivas1–3, Mélissa Beaudoin4,23, Agnes Gardet5,23, Christine Stevens2,23, Yashoda Sharma6,  
Clarence K Zhang6, Gabrielle Boucher4, Stephan Ripke1,2, David Ellinghaus7, Noel Burtt2, Tim Fennell2,  
Andrew Kirby1,2, Anna Latiano8, Philippe Goyette4, Todd Green2, Jonas Halfvarson9, Talin Haritunians10,  
Joshua M Korn2, Finny Kuruvilla2,11, Caroline Lagacé4, Benjamin Neale1,2, Ken Sin Lo4, Phil Schumm12,  
Leif Törkvist13, National Institute of Diabetes and Digestive Kidney Diseases Inflammatory Bowel Disease 
Genetics Consortium (NIDDK IBDGC)14, United Kingdom Inflammatory Bowel Disease Genetics Consortium14, 
International Inflammatory Bowel Disease Genetics Consortium14, Marla C Dubinsky15, Steven R Brant16,17, 
Mark S Silverberg18, Richard H Duerr19,20, David Altshuler1,2, Stacey Gabriel2, Guillaume Lettre4, Andre Franke7, 
Mauro D’Amato21, Dermot P B McGovern10,22, Judy H Cho6, John D Rioux4, Ramnik J Xavier1,2,5 & Mark J Daly1,2
More than 1,000 susceptibility loci have been identified through genome-wide association studies (GWAS) of common variants; 
however, the specific genes and full allelic spectrum of causal variants underlying these findings have not yet been defined. Here 
we used pooled next-generation sequencing to study 56 genes from regions associated with Crohn’s disease in 350 cases and 350 
controls. Through follow-up genotyping of 70 rare and low-frequency protein-altering variants in nine independent case-control 
series (16,054 Crohn’s disease cases, 12,153 ulcerative colitis cases and 17,575 healthy controls), we identified four additional 
independent risk factors in NOD2, two additional protective variants in IL23R, a highly significant associa i n with a protective 
splice varia t in CARD9 (P < 1 × 10−16, odds ratio y 0.29) and additional associations with coding variants in IL18RAP, CUL2, 
C1orf106, PTPN22 and MUC19. We extend the results of successful GWAS by identifying new, rare and probably functional 
variants that could aid functional experiments and predictive models.
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Hospital Inflammatory Bowel Disease Group, University of Toronto, Toronto, Ontario, Canada. 19Division of Gastroenterology, Hepatology and Nutrition, Department 
of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 20Department of Human Genetics, Graduate School of Public Health, 
University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 21Karolinska Institutet, Department of Bioscience  and Nutrition, Stockholm, Sweden. 22Inflammatory  
Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. 23These authors contributed equally to this work. 
Correspondence should be addressed to M.J.D. (mjdaly@atgu.mgh.harvard.edu) or M.A.R. (rivas@broadinstitute.org).
Received 5 January; accepted 31 August; published online 9 October 2011; doi:10.1038/ng.952
Neuron
Article
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SUMMARY
While it is known that rare copy-number variants
(CNVs) contribute to risk for some neuropsyc iatric
disorders, the role of CNVs in bipolar disorder is
unclear. Here, we reasoned that a contribution of
CNVs to mood disorders might be most evident for
de novo mutations. We performed a genome-wide
an lysis of de novo CNVs in a cohort of 788 rios.
Diagnoses of offspring included bipolar disorder
(n = 185), schizophre ia ( = 177), and healthy
controls (n = 426). Frequencies of de novo CNVs
were significantly higher in bipolar disorder as com-
pared with controls (OR = 4.8 [1.4,16.0], p = 0.009).
De novo CNVs were particularly enriched among
cases with an age at onset younger than 18 (OR =
6.3 [1.7,22.6], p = 0.006). We also confirmed a signifi-
cant enrichment of de novo CNVs in schizophrenia
(OR = 5.0 [1.5,16.8], p = 0.007). Our results suggest
that rare spontaneous mutations are an important
contributor to risk for bipolar diso der and other
major neurop ychiatric diseases.
INTRODUCTION
Bipolar disorder (BD, also known s a ic-depressive illness) is
a severe ood disord r onsisti g of episodes of mania and
epression. The lifetime prevalence of bipolar disorder in the
gen ral population is !1% and the illness i associated with
consid rable morbidity and a high lif time isk of suicide (Meri-
kangas et al., 2011).
Genes play an important r le in risk for BD. Th rate of concor-
dance formonozygotic twins is 40%, comparedwith a 5% rate in
dizygotic twins (Kendler et al., 1995; Kieseppa¨ et al., 2004;
McGuffin et al., 2003), and risk among the first-degree relatives
of individuals with BD is ten-fold greater than risk among the
general population (Barnett and Smoller, 2009). However, as
with other psychiatric disorders, the genetics of BD is complex,
Neuron 72, 951–963, December 22, 2011 ª2011 Elsevier Inc. 951
Rare	  Variants	  –	  CNVs,	  SNVs,	  indels,	  etc…	  in	  Rare	  AND	  Common	  diseases	  
“Superpower”	  muta)ons???	  
LRP5	  muta)on	  
D111Y,	  G171R,	  A214T,	  A214V,	  A242T,	  and	  
T253I	  	  	  
Myosta)n	  muta)on	  	  
	  Exon	  2	  allele	  	  P198A	  
**Thanks	  to	  George	  Church	  for	  discussions	  on	  this.	  
Another	  example:	  Liam	  Hoekstra,	  known	  as	  the	  world's	  strongest	  
toddler	  at	  age	  3,	  has	  a	  condi)on	  called	  myosta)n-­‐related	  muscle	  
hypertrophy	  which	  results	  in	  increased	  muscle	  mass	  and	  reduced	  body	  
fat.	  Myosta)n-­‐related	  muscle	  hypertrophy,	  or	  muscle	  enlargement,	  is	  
an	  extremely	  rare	  gene)c	  condi)on.	  –	  How	  rare???	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hours after birth, and the infant was admitted to
the neonatal ward for assessment. He appeared ex-
traordinarily muscular, with protruding muscles
in his thighs (Fig. 1A) and upper arms. With the
exception of increased tendon reflexes, the physi-
cal examination was normal. Hypoglycemia and
increased levels of testosterone and insulin-like
growth factor I were excluded. Muscular hypertro-
phy was verified by ultrasonography when the in-
fant was six days of age (Fig. 1B and 1C). Doppler
echocardiography and electrocardiography per-
formed soon after birth and every six months there-
after were consistently normal. At 4.3 years of age
(body-surface area, 0.78 m
 
2
 
), the child had a pulse
rate of 95 beats per minute, a left ventricular ejection
fraction of 70 percent, fractional shortening at the
midwall of 56 percent, and a cardiac output of 2.81
liters per minute, with a left ventricular measure-
ment of 3.42 cm during diastole (50th percentile)
and 1.99 cm (25th percentile) during systole and
respective septal measurements of 0.59 cm (75th
percentile) and 0.81 cm (75th percentile).
The stimulus-induced myoclonus gradually sub-
sided after two months. The child’s motor and
mental development has been normal. Now, at 4.5
years of age, he continues to have increased muscle
bulk and strength, and he is able to hold two 3-kg
dumbbells in horizontal suspension with his arms
extended.
Several family members (Fig. 1D) have been re-
ported to be unusually strong. Family member II-3
was a construction worker who was able to unload
curbstones by hand. The 24-year-old mother of the
child (III-5) appeared muscular, though not to the
extent observed in her son; she did not report any
health problems. No family members aside from
the mother were available to provide samples for
genetic analysis.
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Figure 1. Photographs of the Child at the Ages of Six Days 
and Seven Months (Panel A), Ultrasonograms (Panel B) 
and Morphometric Analysis (Panel C) of the Muscles 
of the Patient and a Control Infant, and the Patient’s 
Pedigree (Panel D).
 
The arrowheads in Panel A indicate the protruding mus-
cles of the patient’s thigh and calf. In Panel B, an ultra-
sonographic transverse section (linear transducer, 10 
MHz) through the middle portion of the thigh reveals 
differences between the patient and a control infant of 
the same age, sex, and weight. VL denotes vastus latera-
lis, VI vastus intermedius, VM vastus medialis, RF rectus 
femoris, and F femur. In Panel C, retracings of the mus-
cle outlines and results of the morphometric analysis of 
the muscle cross-sectional planes of the two infants also 
reveal marked differences. Panel D shows the patient’s 
pedigree. Solid symbols denote family members who are 
exceptionally strong, according to information in their 
clinical history. Square symbols denote male family 
members, and circles female family members.
The New England Jour al of Medicine 
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exception of increased tendon reflexes, the physi-
cal examination was normal. Hypoglycemia and
increased levels of testosterone and insulin-like
growth factor I were excluded. Muscular hypertro-
phy was verified by ultrasonography when the in-
fant was six days of age (Fig. 1B and 1C). Doppler
echocardiography and electrocardiography per-
formed soon after birth and every six months there-
after were consistently normal. At 4.3 years of age
(body-surface area, 0.78 m
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), the child had a pulse
rate of 95 beats per minute, a left ventricular ejection
fraction of 70 percent, fractional shortening at the
midwall of 56 percent, and a cardiac output of 2.81
liters per minute, with a left ventricular measure-
ment of 3.42 cm during diastole (50th percentile)
and 1.99 cm (25th percentile) during systole and
respective septal measurements of 0.59 cm (75th
percentile) and 0.81 cm (75th percentile).
The stimulus-induced myoclonus gradually sub-
sided after two months. The child’s motor and
mental development has been normal. Now, at 4.5
years of age, he continues to have increased muscle
bulk and strength, and he is able to hold two 3-kg
dumbbells in horizontal suspension with his arms
extended.
Several family members (Fig. 1D) have been re-
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Figure 1. Photographs of the Child at the Ages of Six Days 
and Seven Months (Panel A), Ultrasonograms (Panel B) 
and Morphometric Analysis (Panel C) of the Muscles 
of the Patient and a Control Infant, and the Patient’s 
Pedigree (Panel D).
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in-
 
herited and acquired disorders and include the muscular dystrophies,
cachexia, and ag -related wasting. Since there is no generally accepted
treatment to i prove muscle bulk and strength, these conditions pose a substantial
burden to patients as well as to public health. Consequently, there has been consider-
able interest in a recently described inhibitor of muscle growth, myostatin, or growth/
differentiation factor 8 (GDF-8), which belongs to the transforming growth factor 
 
b
 
superfamily of secreted proteins that control the growth and differentiation of tissues
throughout the body. The myostatin gene is expressed almost exclusively in cells of
skeletal-muscle lineage throughout embryonic development as well as in adult ani-
mals and functions as a negative regulator of muscle growth.
 
1,2
 
 Targeted disruption of
the myostatin gene in mice doubles skeletal-muscle mass.
 
1
 
 Conversely, systemic over-
expression of the myostatin gene leads to a wasting syndrome characterized by ex-
tensive muscle loss.
 
3
 
 In adult animals, myostatin appears to inhibit the activation of
satellite cells, which are stem cells resident in skeletal muscle.
 
4,5
 
The potential relevance of myostatin to the treatment of disease in humans has been
suggested by studies involving 
 
mdx
 
 mi e, which carry a mutation in the dystrophin gene
and therefore serve as a genetic model of Duchenne’s and Becker’s muscular dystro-
phy.
 
6
 
 For example
 
, mdx
 
 mice that lacke  myost tin were foun  not only to be stronger
and more muscular than their
 
mdx
 
 counterparts with normal myostatin, but also to have
reduced fibrosis and fatty remodeling, suggesting mproved regeneration of us-
cle.
 
7
 
 Furthermore, injection of neutralizing monoclonal antibodies directed against
myostatin into either wild-type or 
 
mdx
 
 mice increases mus le mass and specific force,
suggesting that myostatin plays an important role in regulating muscle growth in adult
animals.
 
8,9
 
The function of myostatin appears to be conserved across species, since mutations
in the myostatin gene have been shown to be responsible for the “double-muscling”
phenotype in cattle.
 
10-13 
 
The phenotypes of mice and cattle lacking myostatin and the
high degree of sequence conservation of the predicted myostatin protein in many mam-
malian species have raised the possibility that myostatin may help regulate muscle
growth in humans. We report the identification of a myostatin mutation in a child with
muscle hypertrophy, thereby providing strong evidence that myostatin does play an im-
portant role in regulating muscle mass in humans.
A healthy woman who was a former professional athlete gave birth to a son after a nor-
mal pregnancy. The identity of the child’s father was not revealed. The child’s birth
weight was in the 75th percentile. Stimulus-induced myoclonus developed several
m
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Double muscling is a trait previously described in several mammalian species including cattle and sheep and is caused
by mutations in the myostatin (MSTN) gene (previously referred to as GDF8). Here we describe a new mutation inMSTN
found in the whippet dog breed that results in a double-muscled phenotype known as the ‘‘bully’’ whippet. Individuals
with this phenotype carry two copies of a two-base-pair deletion in the third exon ofMSTN leading to a premature stop
codon at amino acid 313. Individuals carrying only one copy of the mutation are, on average, more muscular than wild-
type individuals (p ¼ 7.43 3 10"6; Kruskal-Wallis Test) and are significantly faster than individuals carrying the wild-
type genotype in competitive racing events (Kendall’s nonparametric measure, s¼ 0.3619; p ’ 0.00028). These results
highlight the utility of performance-enhancing polymorphisms, marking the first time a mutation in MSTN has been
quantitatively linked to increased athletic performance.
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Introduction
The wide variety of behaviors and morphological types
exhibited among dog breeds and the overall low genetic
diversity within each breed make the dog an excellent genetic
system for mapping traits of interest [1,2]. Recently, owners of
whippets, an established racing-dog breed, have reported a
phenotype of heavy muscling occurring within the breed
(http://www.k9community.co.uk/forums/index.php). The typi-
cal whippet is similar in conformation to the greyhound, a
medium-sized sighthound, weighing about 9 kg and charac-
terized by a slim build, long neck, small head, and pointed
snout (Figure 1A) [3]. Heavily muscled dogs, termed ‘‘bully’’
whippets by breeders, have broad chests and unusually well-
developed leg and neck musculature (Figure 1C). ‘‘Bully’’
whippets are easily distinguished from their normal litter-
mates based on physical appearance alone (compare Figure
1A and 1C). Owners report that ‘‘bully’’ whippets do not have
any health abnormalities other than muscle cramping in the
shoulder and thigh. However, the dogs are often euthanized
at an early age as they do not conform to the American
Kennel Club breed standard. In addition, about 50% of
‘‘bully’’ whippets have a distinctive overbite.
The ‘‘bully’’ whippet phenotype is reminiscent of the
double muscling phenotype seen in other species that is
caused by mutations in the myostatin (MSTN) gene. Such
variants have been observed in mice [4], cattle [5,6], sheep [7],
and human, the latter described once in a German boy [8].
The myostatin protein has been shown to affect both the
amount and composition of muscle fibers. For instance, the
muscle mass of Mstn knockout mice is two to three times
greater than that of wild-type mice [9]. Furthermore, the
sequence of the MSTN gene is relatively conserved across
species [9]. Therefore, we chose to interrogate theMSTN gene
for possible mutations resulting in the ‘‘bully’’ whippet
phenotype.
Results
MSTN Genotypes in the Whippet
We sequenced the three exons and the majority of introns
of the MSTN gene in an initial set of 22 whippets. A 2-bp
deletion was discovered in the third exon of the MSTN gene
(Figure 2). This deletion removes nucleotides 939 and 940
within exon three and leads to a premature stop codon at
amino acid 313 instead of the normal cysteine, removing 63
aa from the predicted 375-aa protein. The lost cysteine is one
of several highly conserved cysteines known to form disulfide
dimers required for protein function [9].
Of the 22 whippets sequenced, all ‘‘bully’’ whippets tested
(n ¼ 4) were homozygous for the deletion (mh/mh) while all
dogs that sired or whelped a ‘‘bully’’ whippet (n ¼ 5) were
heterozygous for the deletion (mh/þ). None of the initial set of
13 normal-appearing whippets that lacked a family history of
the ‘‘bully’’ phenotype carried the deletion; these dogs were
designated wild type (þ/þ). An additional set of DNA samples
from 146 whippets (both racers and nonracers) were collected
at racing events and through the mail without regard to the
dogs’ family histories of the ‘‘bully’’ phenotype. These were
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Recent advances in sequencing technology are making possible the application of large-scale genomic anal-
yses to individualized care, both in wellness and disease. However, a number of obstacles remain before ge-
nomic sequencing can become a routine part of clinical practice. One of the more signiﬁcant and
underappreciated is the lack of consensus regarding the proper environment and regulatory structure
under which clinical genome sequencing and interpretation should be performed. The continued reliance
on pure research vs. pure clinical models leads to problems for both research participants and patients in
an era in which the lines between research and clinical practice are becoming increasingly blurred. Here,
we discuss some of the ethical, regulatory and practical considerations that are emerging in the ﬁeld of geno-
mic medicine. We also propose that many of the cost and safety issues we are facing can be mitigated through
expanded reliance on existing clinical regulatory frameworks and the implementation of distributive
work-sharing strategies designed to leverage the strengths of our genomics centers and clinical interpretive
teams.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
We are entering a fascinating and uncertain period of medical his-
tory, as today's DNA sequencing technology has the potential to help
each of us direct our care and predict our future based on knowledge
of our own individual inherited and acquired genetics. However,
from a global and local economic perspective, these are lean years,
and this adds a signiﬁcant degree of uncertainty to the immediate fu-
ture of this enterprise. It is therefore incumbent upon us to show that
the personalized medical application of large-scale genomic analysis
will not just be a luxury or a burdensome cost center, but that it
truly has the potential to save both lives and health care expenses
via data-driven management, early disease detection/screening and
more efﬁcacious pharmaceutical delivery. To this end, we need to de-
termine how to move forward towards expanded clinical use of this
technology in a manner both rapid and economical, while ensuring
the integrity of the process and the safety and well-being of patients
and research participants. This will require careful thought and con-
sideration regarding the proper environment and regulatory structure
surrounding genomics, as well as the development of consensus re-
gardingwhat exactly constitutes a genetic test in the age of large-scale
genomics and informatics.
2. Paving the way for the broad implementation of clinical
genomic medicine
A report published in 2011 by the National Research Council for
the National Academy of Sciences elegantly described the major divi-
sions between the clinical and research worlds, including in regards
to large-scale genomic analyses, such as whole genome (WGS) se-
quencing. The report went on to offer suggestions for how to help
merge these two worlds, including articulating the need for a “Knowl-
edge Network” and “New Taxonomy”, with the recommendation that
pilot studies along such lines should be conducted (Anon., 2011).
However, the report did not address a critical issue related to genetic
testing, namely the rules that should govern genomic research and
clinical care as we move into the coming era of individualized medi-
cine. The United States federal government mandates that any labora-
tory performing tests on human specimens “for the purpose of
providing information for the diagnosis, prevention, or treatment of
any disease”must satisfy the conditions set forth in the Clinical Labo-
ratory Improvement Amendments (CLIA) of 1988 (Group®, 2012).
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Medical genetics typically entails the detailed characterization of a patient’s phenotypes followed
by genotyping to discover the responsible gene or mutation. Here, we propose that the systematic
discovery of genetic variants associatedwith complex diseases such as autism are progressing to a
point where a reverse strategy may be fruitful in assigning the pathogenic effects of many different
genes and in determining whether particular genotypes manifest as clinically recognizable pheno-
types. This ‘‘genotype-first’’ approach for complex disease necessitates the development of large,
highly integrated networks of researchers, clinicians, and patient families, with the promise of
improved therapies for subsets of patients.
The genetic study of complex disease has
historically been difficult, meeting with
limited success and often even fewer
therapeutic advances in patient care. Un-
like Mendelian disorders, complex dis-
ease is defined as a phenotype that is
not caused by a single gene mutation
but, rather, by many individual gene
events, with a significant contribution
from environmental factors. The nature
of complex genetic diseasemakes patient
care difficult, as a clinician may never see
two individuals with the same gene muta-
tion and, therefore, the same underlying
genetic etiology. Classical approaches
to the study of complex disease have
identified patientswith similar phenotypes
and have attempted to identify the com-
mon causative mutation for this pheno-
type using association studies. Though
there have been numerous loci reported
over the last 10 years, in most cases,
much of the heritability of complex dis-
ease remains unresolved (Manolio et al.,
2009). The number of success stories
for complex neurocognitive and neuro-
behavioral disease are even fewer, with
enormous numbers of patients (>30,000)
being required to discover a small fraction
of the genetic risk using genome-wide
association study (GWAS) approaches
(McCarroll and Hyman, 2013). Complex
neurodevelopmental disorders, such as
autism, schizophrenia, bipolar disorder,
intellectual disability (ID), and devel-
opmental delay (DD), require better
approaches to link genotype to pheno-
type. In this Essay, we focus on autism
spectrum disorder (ASD)—a highly com-
plex neurodevelopmental disease with a
range of phenotypes and a large patient
base—and propose a gene-centric meth-
odology to model a streamlined approach
for subtyping autism starting with the
genotype (Schulze and McMahon, 2004).
The explosion of data from recent
exome studies (Iossifov et al., 2012; Neale
et al., 2012; O’Roak et al., 2012b; Sanders
et al., 2012) and earlier work on large copy
number variants (CNVs) (de Vries et al.,
2005; Sebat et al., 2007; Sharp et al.,
2006) have emphasized the importance
of sporadic truncating mutations in ASD,
revealing a surprising level of genetic het-
erogeneity among patients. From these
data, it has been estimated that >500
distinct loci may be related to disease
etiology in ASD, assuming a model of
sporadic protein-encoding mutations.
Interestingly, more than two decades
ago, Percy postulated that a ‘‘very wide
variety of autistic syndromes depending
on underlying etiology’’ may exist based
on his observation that a significant frac-
tion of individuals with fragile X, Rett,
and tuberous sclerosis syndromes could
be classified as having autistic features
(Percy et al., 1990). Whereas traditional
genetics approaches were entirely under-
powered to detect small subpopulations
of autism with a common mutant gene,
the advent of next-generation sequencing
technology has made it possible to begin
to systematically classify genetic sub-
types of ASD and, further, to ask whether
these define specific clinical subtypes of
ASD. For the purpose of this Essay, we
will define a ‘‘genetic subtype’’ as a gene
in which recurrent mutations show an
excess of burden in patients versus con-
trols. This is distinguished from a ‘‘molec-
ular subtype’’ that constitutes a group of
genetic subtypes that are linked together
in a common pathway (coexpression,
protein-protein interaction network, etc.)
(O’Roak et al., 2012b).
The extreme genetic heterogeneity
exemplified by autism, we believe, re-
quires a shift in the approach to studying
the genetics of complex neurological
disease. Instead of comprehensive and
exhaustive phenotyping as the first step
to reducing genetic heterogeneity, we
propose to leverage technology to genet-
ically classify subtypes of disease among
patients in whom clinical recontact is
possible. We outline three logical steps
in characterizing genetic subtypes from
the perspective of autism: (1) candidate
discovery and determination of pathoge-
nicity, (2) comprehensive clinical pheno-
typing, and (3) resolution of genetic
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random mutation modeling40 to calculate the likelihood that observed 
(de novo) mutations have a damaging effect. Similar prioritizations 
are provided by tools that score individual mutation severity (SIFT, 
PolyPhen2, MutationTaster, MutPred, CONDEL, etc.), some of which 
can be adapted to a gene-based prioritization score from genome-wide 
data41. These population data provide a powerful unbiased approach 
to home in on genes that are likely to be among the most penetrant 
because of the complete absence of disruptive variation in the general 
population (for example, CHD8 or DYRK1A). A critical aspect of such 
analyses is the reliability of a particular gene model. Most human 
genes show evidence of alternative splice forms, many of which have 
no known function. Apparent hotspots of mutation for a particular 
exon (often exon-intron boundaries) in both cases and controls may 
suggest misannotation, the presence of a processed pseudogene or an 
alternative, nonfunctional splice form.
Pathway enrichment and links to cancer biology
Another popular approach to discern the most important gene 
candidates for further disease association and characterization has 
been to identify specific biological networks of genes enriched in 
cases as compared to controls. Although this approach cannot be used 
unequivocally to define causality, membership of a specific gene in a 
particular protein-protein interaction (PPI) or coexpression network 
may increase the likelihood of its association with disease. Numerous 
studies have reported significant enrichment of both de novo 
CNV and single-nucleotide variant (SNV) mutations in particular 
pathways3,4,42,43. O’Roak et al.3, for example, reported a significant 
enrichment of de novo disruptive autism mutations among proteins 
associated with chromatin remodeling and B-catenin and WNT 
signaling—a finding that was replicated in a follow-up resequencing 
study of more than 2,400 probands. One recent instance, in which 
membership of a new candidate gene in a PPI network led to the 
discovery of an autism-associated gene, is ADNP. A single ADNP 
LoF mutation was initially observed in exome sequencing studies. 
Although the observed mutation frequency in this gene did not reach 
statistical significance when cases and controls were compared20, 
it was strongly implicated in the PPI network originally defined 
by O’Roak et al.3 Targeted resequencing experiments combined 
with clinical exome sequencing identified several more cases with 
de novo mutations and remarkably similar phenotypes represent-
ing a new SWI-SNF–related autism syndrome (Fig. 3)44. Notably, 
many of the genes implicated in the B-catenin pathway have also been 
described as mutated in patients with ID1 but not in patients with 
SCZ. Similarly, an enrichment of genes interacting with FMR1 (also 
known as FMRP)—the gene responsible for fragile X syndrome—has 
been reported with de novo mutations in ASD5, epilepsy11 and, most 
recently, SCZ10,45. Whether this observation is due to the relative high 
incidence of cases that also presented with comorbid ID remains to 
be determined.
In addition to PPI networks, studies of coexpression have shown 
enrichment for specific spatio-temporal patterns of expression. 
A study of coexpressed genes affected by de novo mutations reported 
an enrichment in fetal prefrontal cortical network in SCZ8, which is 
in line with the finding by Xu et al.9 that genes with higher expression 
Table 4 Recurrent identical de novo mutations in 6 genes identified in 11 exome studies with different neurodevelopmental phenotypes
Gene Coding effect Mutation (genomic DNA level) Mutation (cDNA level)
Mutation  
(protein level) Study Disorder
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser de Ligt et al.1 ID
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser Allen et al.11 EE
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser Allen et al.11 EE
KCNQ3 Missense Chr8(GRCh37):g.133192493G>A NM_001204824.1:c.328C>T p.Arg110Cys Rauch et al.2 ID
KCNQ3 Missense Chr8(GRCh37):g.133192493G>A NM_001204824.1:c.328C>T p.Arg110Cys Allen et al.11 EE
SCN1A Splice donor LRG_8:g.24003G>A NM_006920.4:c.602+1G>A p.? Allen et al.11 EE
SCN1A Splice donor LRG_8:g.24003G>A NM_006920.4:c.602+1G>A p.? Allen et al.11 EE
CUX2 Missense Chr12(GRCh37):g.111748354G>A NM_015267.3:c.1768G>A p.Glu590Lys Rauch et al.2 ID
CUX2 Missense Chr12(GRCh37):g.111748354G>A NM_015267.3:c.1768G>A p.Glu590Lys Allen et al.11 EE
SCN2A Missense Chr2(GRCh37):g.166198975G>A NM_021007.2:c.2558G>A p.Arg853Gln Allen et al.11 EE
SCN2A Missense Chr2(GRCh37):g.166198975G>A NM_021007.2:c.2558G>A p.Arg853Gln Allen et al.11 EE
DUSP15 Missense Chr20(GRCh37):g.30450489G>A NM_080611.2:c.320C>T p.Thr107Met Neale et al.7 ASD
DUSP15 Missense Chr20(GRCh37):g.30450489G>A NM_080611.2:c.320C>T p.Thr107Met Fromer et al.10 SCZ
EE, epileptic encephalopathies; ASD, autism spectrum disorder; ID, intellectual disability; SCZ, schizophrenia.
Figure 1 Genes with recurrent de novo mutations in four 
neurodevelopmental disorders. (a) We estimate the number of fully penetrant 
genes that can explain disease once mutated, based on a de novo model 
using the ‘unseen species problem’. We consider all recurrent missense or 
LoF de novo mutations pathogenic, as well as a defined fraction of mutations 
in genes observed just once (because it is unlikely that all de novo mutations 
are pathogenic). The ratio between genes mutated recurrently and the rate 
of singleton mutations suggests an estimate for the true number of genes 
pathogenic when mutated. Including more singleton mutations increases 
the fraction of each disorder explained by single de novo SNVs at the cost 
of including more genes as pathogenic. Initial exome sequencing studies of 
epilepsy and ID focused on specific pediatric subtypes or the most severe 
cases; thus, the number of generalized epilepsy- or ID-associated genes is 
likely to be much higher. EE, epileptic encephalopathies; ASD, autism spectrum disorder; ID, intellectual disability; SCZ, schizophrenia. (b) Expected  
hit rate (or sensitivity) of true positive genes discovered using trio sequencing studies (under a family-wise error rate of 5%; that is, each gene passes exome-
wide significance of 2.6 × 10−6). We estimate the power of trio sequencing to detect statistically significant associations for disease-associated genes,  
under the assumption that 10% or 20% of singleton mutations could be fully penetrant (vertical bars in a). We assume the distribution of these genes is 
uniform within each disorder and that they do not differ significantly from all genes in terms of length and mutability, although these are taken into account 
when determining significance.
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Recent exome (and genome) sequencing studies of families have aimed 
to comprehensively discover genetic variation to identify the most 
likely causal mutation in patients with disease. Sequencing studies of 
parent-proband trios for probands with intellectual disability (ID)1,2, 
autism spectrum disorder (ASD)3–7, schizophrenia (SCZ)8–10 and epi-
lepsy11 have all suggested that de novo point mutations are important 
in pediatric and adult disorders of brain development (Table 1). The 
relative contribution of de novo mutations to each disorder remains to 
be determined but appears to correlate well with the degree of reduced 
fitness or fecundity of the given condition12. However, not only 
de novo events but also rare inherited copy number variants (CNVs) 
can have an effect on fecundity, though their overall effect on fecundity 
is still debated13. Biologically, 75–80% of de novo point mutations arise 
paternally3,14, likely as a result of the greater number of cell divisions 
in the male germline lineage than in the female lineage. These findings 
are consistent with some epidemiological data that find advancing 
paternal age to be a significant predictor of ASD, ID and SCZ15–17 and 
argue for the need to properly control for paternal age when comparing 
mutation rates between probands and siblings. The importance of 
de novo and private rare mutations is especially important clinically, 
as there are now reports of diagnostic yields ranging from 10–55%  
for select (usually the most severe) groups of patients with ID1,2 and 
epilepsy18, in addition to resolution of unsolved Mendelian disorders19. 
It is clear that next-generation sequencing approaches have provided 
powerful tools for identifying genes harboring potentially pathogenic 
mutations. Deciding which genes to pursue, however, is not always 
self-evident because follow-up research and diagnostic studies are 
critical to understanding the full contribution of a particular mutation 
to its respective phenotype.
In this Review, we will discuss the prioritization of candidate genes 
identified through sequencing studies, show emerging trends and 
highlight potential strategies for subsequent functional characteriza-
tion of these neurodevelopmental genes. We focus on lessons learned 
from 11 recent studies that report 2,368 de novo mutations from a 
total of 2,358 probands and 600 de novo mutations from 731 controls 
(Table 1). The bulk of the data originate from sequencing studies 
of parents and probands with ASD, ID and epileptic encephalopa-
thies, but more recent studies have also highlighted the importance of 
de novo mutations in SCZ. There is evidence that de novo mutations, 
particularly disruptive mutations, occur in the same genes despite the 
nosological distinction for these different diseases. For the purpose of 
this Review, we collectively term these diseases ‘neurodevelopmental 
disorders’ but recognize that some, especially adult-onset diseases 
such as SCZ, may have etiologic components that are not neurode-
velopmental in origin.
Recurrently mutated genes
One of the frequently used concepts in considering possible ‘new 
disease genes’ responsible for a given neurodevelopmental pheno-
type is the recurrence of de novo mutations in the same gene, along 
with the absence of such mutations in healthy controls. This rule 
follows the precedent established for the discovery of pathogenic 
de novo CNVs during the last decade, with the highest priority 
given to recurrent mutations that lead to a complete loss of func-
tion of one of the parental copies of the gene. Up to ten independ-
ent reports of de novo mutations in SCN2A and nine independent 
reports of de novo mutations in SCN1A and STXBP1 have been 
described (Tables 2 and 3). Strikingly, de novo mutations in those 
genes have so far been found exclusively in probands and never in 
controls. Simulation data suggest that at least two but certainly three 
or more recurrent de novo loss-of-function (LoF) events (that is, 
predicted nonsense, frameshift or canonical splice site mutations) 
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Prioritization of ne rodevelopmental disease 
genes by discovery of new mut tions
Alexande  Hoischen1, Niklas Krumm2 & Evan E Eichler2,3
Advances in genome sequencing technologies have begun to revolutionize neurogenetics, allowing the full spectrum of genetic 
variation to be better understood in relation to disease. Exome sequencing of hundreds to thousands of samples from patients 
with autism spectrum disorder, intellectual disability, epilepsy and schizophrenia provides strong evidence of the importance of 
de novo and gene-disruptive events. There are now several hundred new candidate genes and targeted resequencing technologies 
that allow screening of dozens f genes in tens of thousa ds of individuals with h gh specificity and sensitivity. The de ision 
of which genes to pursue depends on many factors, including recurrence, previous evidence of overlap with pathogenic copy 
number variants, the position of the mutation in the protein, the mutational burden among healthy individuals and membership 
of the candidate gene in disease-implicated protein networks. We discuss these emerging criteria for gene prioritization and the 
potential impact on the field of neuroscience.
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in early fetal life have substantial contribu-
tion to SCZ by de novo mutations. Similarly, 
Willsey et al.46 working with a few high- 
confidence sets of ASD-associated genes as 
seeds reported a convergence of the expres-
sion of these genes in deep-layer cortical 
projection neurons (layers 5 and 6) in mid-
fetal development. Another analysis using a 
larger set of ASD and ID risk genes suggested translational regulation 
by FMR1 and an enrichment in superficial cortical layers43. Implicit 
in these types of analyses is the notion that, while more than 1,000 
genes may be responsible for ASD or ID, in the end the genes will con-
verge on a few highly enriched networks of related genes. It is possible 
that molecular therapies targeted to the network at a specific stage of 
development, as opposed to the individual gene, may be beneficial to 
specific groups of patients.
Related to this, it is intriguing that several recurring genes and 
pathways that have been implicated in neurodevelopmental disease 
have also been associated with different forms of cancer (Fig. 4)47. 
While clear-cut examples such as the mutation of the tumor sup-
pressor genes PTEN (Cowden syndrome) or ARID1B (Coffin-Siris 
syndrome) in neurodevelopmental disease have been extensively 
reviewed48, more recent exome sequencing data from patients with 
neurodevelopmental disease suggest new links. The most striking 
observation here is the identical point mutations reported to cause 
cancer when mutated somatically and severe neurodevelopmental syn-
dromes when mutated in the germline. Examples include the identical 
mutations in SETBP1 (ref. 32), ASXL1 (ref. 49) and EZH2 (ref. 50), as 
well as several genes of the RAS–MAP kinase pathway associated with 
parental-age-effect Mendelian disorders51 (Supplementary Table 1). 
It is important to stress that this is an observation at an individual 
gene level and should not be translated to an epidemiological link: 
that is, this cannot be generalized to speculate that patients with neuro-
developmental disorders in these specific genes will all be at a higher 
risk for certain cancer types. Instead, it is likely that this convergence 
represents a selection of genes that are fundamental to cell biology 
(for example, cell proliferation and/or membership in multi-subunit 
complexes associated with chromatin remodeling). There is also the 
distinct possibility of pleiotropy; that is, the genes and pathways have 
completely unrelated functions, explaining developmental defects and 
cancer independently. Therefore, de novo mutations in those genes 
can result in different outcomes depending on timing, genetic back-
ground and cellular context. Nevertheless, there may be advantages 
to integrating sequence data from patients with neurodevelopmental 
disease and massive sequencing programs devoted to the discovery of 
somatic mutations in tumors—for example, the International Cancer 
Genome Project52. It is possible that these intersections will help to 
further prioritize genes important in both cellular development and 
neurodevelopment.
Phenotypic similarity of recurrent de novo mutations
Although essential, statistical support of recurrent mutations is 
not the sole arbiter in determining pathogenicity of particular 
mutations and genes. In particular, it is important to consider the 
phenotypic presentation and overlap of the individuals with the same 
presumptive underlying genetic lesion. In this regard, we note that 
21q22.13
DYRK1A
37650000 37700000 37750000 37800000
Cases
Controls
CNV deletions
Genes
CNV duplicationsa
b
De novo splice site mutation in autism patient
De novo truncating indel mutation in autism patient
Chr2
position
Cases
Controls
Chr21
position
Genes
148400000 148600000 148800000 149000000
2q22.3
2q23.1
ACVR2A
ORC4
MBD5
Figure 2 CNV and exome intersections define 
candidate genes. (a,b) Deletion (red) and 
duplication (blue) burden for developmental 
delay or ID cases and controls for two genes, 
DYRK1A (a) and MBD5 (b), as compared to 
sporadic LoF mutations on the basis of exome 
sequencing of 209 autism simplex trios. DYRK1A 
is a strong candidate gene for cognitive deficits 
associated with Down syndrome; LoF mutations 
are associated with minibrain phenotype in 
Drosophila65, autism-like behavior in mouse64 
and a deletion syndrome in humans27,63. MBD5 
has been implicated as the causal gene for 
the 2q23.1 deletion syndrome associated with 
epilepsy, autism and ID91,92.
a bFigure 3 Phenotypic similarity of two patients 
with identical PACS1 de novo mutations and two 
patients with similar ADNP mutations. (a) These 
two unrelated patients show identical de novo 
point mutations (c.607C>T; p.Arg203Trp) in 
PACS1 (RefSeq NM_018026.3)53. The striking 
similarity in phenotype includes low anterior 
hairline, highly arched eyebrows, synophrys, 
hypertelorism with downslanted palpebral 
fissures, long eyelashes, a bulbous nasal tip, a 
flat philtrum with a thin upper lip, downturned 
corners of the mouth and low-set ears. Reprinted 
from ref. 53, Copyright (2012), with permission from The American Society of Human Genetics. (b) These two unrelated patients both show LoF mutations 
in ADNP (c.2496_2499delTAAA; p.Asp832Lysfs*80 and c.2157C>G; p.Tyr719*)44 resulting in a new SWI-SNF–related autism syndrome. Patients present 
with clinical similarities, including a prominent forehead, a thin upper lip and a broad nasal bridge. Reprinted from ref. 44.
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CNVs collectively have an appreciable impact on human mental 
health, but their large size often precludes specifying the underlying 
genes involved in the disorder. The pathogenicity of many CNVs 
observed in the clinic is unknown because the typical variant is also 
extremely rare, requiring large surveys to achieve significance in 
case-control cohorts1–4. Large-scale analyses of clinical microarray 
data from children with developmental delay, intellectual disability 
and autism spectrum disorder (ASD) are now possible and have 
been used to catalog regions of human dosage imbalance. In most 
cases, multiple candidate genes still underlie the smallest region of 
overlap. In contrast, exome sequencing studies of parent-child trios 
provide the necessary specificity to discover de novo truncating 
mutations—that is, nonsense and frameshift indel mutations—with 
gene-level specificity5–14. Because of the extreme locus heteroge-
neity of such diseases, however, relatively few recurrences have 
been reported, as surveys of tens of thousands of exomes are still 
prohibitively expensive. As large-scale deletions and truncating 
mutations result in the same dosage imbalance for critical genes, 
we reasoned that systematically integrating both classes of muta-
tion would improve power in discovering genes associated with 
developmental delay. Here we have constructed one of the larg-
est CNV morbidity maps of individuals with intellectual disability, 
developmental delay and/or ASD, both as a clinical resource for 
pathogenic CNVs and also to identify genes potentially sensitive 
to dosage imbalance. We then integrated these data with published 
exome sequencing data and used next-generation sequencing 
methods to rapidly resequence candidate genes in individuals 
with unexplained developmental delay. Using this approach, we 
identified pathogenic mutations in new genes with both statistical 
significance and clinical relevance.
Refining analyses of copy number variation identifies 
specific genes associated with developmental delay
Bradley P Coe1, Kali Witherspoon1, Jill A Rosenfeld2, Bregje W M van Bon3,4, Anneke T Vulto-van Silfhout3, 
Paolo Bosco5, Kathryn L Friend4, Carl Baker1, Serafino Buono5, Lisenka E L M Vissers3,  
Janneke H Schuurs-Hoeijmakers3, Alex Hoischen3, Rolph Pfundt3, Nik Krumm1, Gemma L Carvill6, Deana Li7, 
David Amaral7, Natasha Brown8,9, Paul J Lockhart8,10, Ingrid E Scheffer11, Antonino Alberti5, Marie Shaw4,  
Rosa Pettinato5, Raymond Tervo12, Nicole de Leeuw3, Margot R F Reijnders3, Beth S Torchia2, Hilde Peeters13,14, 
Elizabeth Thompson4,15, Brian J O’Roak1,18, Marco Fichera5,18, Jayne Y Hehir-Kwa3, Jay Shendure1,  
Heather C Mefford6, Eric Haan4,15, Jozef Gécz4,16, Bert B A de Vries3, Corrado Romano5 & Evan E Eichler1,17
Copy number variants (CNVs) are associated with many neurocognitive disorders; however, these events are typically  
large, and the underlying causative genes are unclear. We created an expanded CNV morbidity map from 29,085 children  
with developmental delay in comparison to 19,584 healthy controls, identifying 70 significant CNVs. We resequenced 26 
candidate genes in 4,716 additional cases with developmental delay or autism and 2,193 controls. An integrated analysis of  
CNV and single-nucleotide variant (SNV) data pinpointed 10 genes enriched for putative loss of function. Follow-up of a subset  
of affected individuals identified new clinical subtypes of pediatric disease and the genes responsible for disease-associated 
CNVs. These genetic changes include haploinsufficiency of SETBP1 associated with intellectual disability and loss of expressive 
language and truncations of ZMYND11 in individuals with autism, aggression and complex neuropsychiatric features.  
This combined CNV and SNV approach facilitates the rapid discovery of new syndromes and genes involved in neuropsychiatric 
disease despite extensive genetic heterogeneity.
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to that expected with intersections by random chance (OR = 1.15, 
95% confidence interval (CI) = 0.8–1.6; P = 1, Fisher’s exact test). 
However, when we limited our analysis to the 21 genes with 2 or 
more truncating mutations in probands, we observed significant dele-
tion enrichment for 33.3% of the genes (7 of 21 genes; OR = 2.72; 
P = 0.034, Fisher’s exact test), supporting the notion that integrat-
ing CNV data and exome sequencing data increases power to detect 
disease-related genes. Using a statistical framework based on a hyper-
geometric distribution, we computed a joint probability of putative 
loss of function (Online Methods), combining the CNV data with 
the SNV data for the 6,500 individuals from the Exome Sequencing 
Project (ESP) (ESP6500 controls) and published de novo loss-of- 
function mutations in probands. This analysis highlighted 38 of the 
247 genes with nominally significant increases in loss-of-function 
events in cases in comparison to controls (19 with q value a 0.01), 
including 13 genes previously identified as disease causing (Online 
Mendelian Inheritance in Man, OMIM) (Table 2).
Targeted resequencing of candidate genes in ASD and 
intellectual disability
On the basis of the analyses above, we selected a set of 26 candidate 
genes with significant CNV enrichment, rare focal CNVs with de novo 
mutations from exome sequencing studies and top candidates from 
targeted resequencing in ASD and/or intellectual disability (Table 3). 
For three of these regions, we selected at least two adjacent genes map-
ping within the SRO; we also selected six genes (GRIN2B, ARID1B, 
MBD5, PTEN, SCN1A and KANSL1) known to be associated with 
ASD and/or intellectual disability as positive controls30–35. We used 
molecular inversion probe (MIP)-based capture36 to sequence the 26 
genes in 3,387 cases of intellectual disability and/or developmental 
Table 2 Intersection of CNV and exome data
Gene Isoform
Exome data Array CGH
Combined  
LoF P value
Combined  
LoF q valuee
1,879  
published  
cases LoF
1,879 published 
cases de novo 
LoF (ESP average 
read depth >20, 
Dustmasked)
6,500 ESP LoF 
(ESP average 
read depth >20, 
Dustmasked)
Signature  
deletions  
(n = 29,085)
Control  
deletions  
(n = 19,584)
ANK2a NM_020977.3b 1 1 0 5 0 0.0171 0.169
ARHGAP5 NM_001030055.1 1 1 0 7 0 0.0061 0.0833
BCL11A NM_022893.3 1 0 0 4 0 0.0286 0.244
CAPRIN1 NM_005898.4 1 1 0 4 0 0.0286 0.244
CARKD NM_001242881.1c 1 1 0 12 4 0.0363 0.28
CHD2a NM_001271.3 3 3 0 0 0 0.0113 0.127
CHD8a NM_001170629.1 3 3 0 2 0 0.00402 0.0703
CSDE1 NM_001130523.2 1 1 0 3 0 0.0479 0.311
CUL3a NM_003590.4 2 2 0 5 0 0.00383 0.0703
DLL1 NM_005618.3 1 0 0 32 1 2.17 × 10−7 2.68 × 10−5
DYRK1Aa NM_001396.3 2 2 0 11 0 1.74 × 10−4 8.60 × 10−3
FAM8A1 NM_016255.2 1 1 0 5 0 0.0171 0.169
FOXP1a NM_001244810.1 1 1 0 4 0 0.0286 0.244
GRIN2Ba NM_000834.3 3 3 0 2 0 0.00402 0.0703
GTPBP4 NM_012341.2 1 1 0 3 0 0.0479 0.311
LTN1 NM_015565.2 1 1 0 6 0 0.0102 0.12
MBD5a NM_018328.4 1 1 0 16 6 0.0343 0.273
MYT1L NM_015025.2 1 1 0 8 0 0.00365 0.0703
NAA15 NM_057175.3 2 2 0 5 3 0.0296 0.244
NCKAP1 NM_205842.1 2 2 0 7 0 0.00137 0.0564
NFIA NM_001134673.3 1 1 0 3 0 0.0479 0.311
NRXN1a NM_001135659.1 1 1 0 30 9 0.00427 0.0703
NTM NM_001144058.1 1 1 0 40 0 2.53 × 10−10 6.25 × 10−8
PCOLCE NM_002593.3 1 1 0 7 0 0.0061 0.0833
PHF2 NM_005392.3 1 1 0 4 0 0.0286 0.244
RAB2A NM_002865.2 1 1 0 3 0 0.0479 0.311
SCN1Aa NM_001165963.1 4 4 0 10 1 7.36 × 10−5 4.55 × 10−3
SCN2Aa NM_021007.2 6 5 0 10 0 7.34 × 10−7 6.04 × 10−5
SLC6A1 NM_003042.3 1 1 0 6 0 0.0102 0.12
SRM NM_003132.2 1 1 0 9 0 0.00218 0.0703
STXBP1a NM_003165.3 2 2 0 4 0 0.00641 0.0833
SUV420H1 NM_016028.4d 1 1 0 3 0 0.0479 0.31135
SYNGAP1a NM_006772.2 4 4 0 0 1 0.00252 0.0703
TBR1 NM_006593.2 2 2 0 7 1 0.00522 0.0806
UBN2 NM_173569.3 1 1 0 5 0 0.0171 0.169
WAC NM_016628.4 1 1 0 3 0 0.0479 0.31135
WDFY3 NM_014991.4 1 1 0 8 0 0.00365 0.0703
ZMYND11 NM_006624.5 1 1 0 8 0 0.00365 0.0703
LOF, loss of function.
aDisease gene in OMIM. bVariant 2; this is the major form of ankyrin in the adult brain. cVariant 2; this isoform and variants 3 and 4 are shorter than variant 1. dVariant 2; this isoform is shorter 
and has a distinct C terminus in comparison to isoform 1. ePlease see the Supplementary Note for discussion of the q values shown.
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delay and 1,329 cases of ASD, totaling 4,716 cases. Putative loss-of-
function SNVs and indels were validated by Sanger sequencing and 
assessed in parental DNA, when available, to determine inheritance. 
Genes with significant enrichment were identified by comparison 
with the MIP resequencing data for 2,193 unaffected siblings from 
the Simons Simplex Collection37 and ESP6500. We tested each gene 
for combined enrichment of loss-of-function variation across CNV 
and SNV data (Online Methods) and identified 16 genes (Table 3 and 
Supplementary Table 5) with a significant enrichment of disruptive 
mutations in cases. Additionally, to control for the differential effects 
of terminal truncating events, we applied a statistical model based 
on predicted protein lengths for genes with truncating or splice-site 
events in ESP6500 (Supplementary Fig. 5), as this approach was com-
plementary to the results from case-control 
comparison (Table 3).
Among the positive controls, our analy-
sis confirmed the pathogenicity of five genes 
using a nominal threshold of significance on 
the joint P values: ARID1B (five CNVs and 
nine truncating SNVs, one of which was 
confirmed to be de novo; P = 1.51 × 10−4, 
q = 6.54 × 10−4), GRIN2B (two CNVs—one focal CNV disrupting 
the distal end of GRIN2B—and four new truncating variants; P = 
0.00546, q = 0.0142) and MBD5 (P = 0.0429, q = 0.0744), as well 
as SCN1A (P = 0.0036, q = 0.0117), in comparison to the adjacent 
gene TTC21B (P = 1.00, q = 1.00). Integration of SNV and CNV 
data confirmed KANSL1 as the gene responsible for the 17q21.31 
deletion syndrome32 (P = 0.000418, q = 0.00155) in comparison 
to the adjacent gene MAPT (P = 0.36, q = 0.455) (Table 3 and 
Supplementary Table 5). Clinical follow-up for one KANSL1 case 
with a severe frameshift demonstrated striking phenotypic resem-
blance to microdeletion carriers, confirming this gene as the major 
contributor to the phenotype of 17q21.31 microdeletion (Koolen– 
de Vries) syndrome32,38.
Table 4 Brief phenotypic description of cases with SETBP1 loss-of-function variants
Case
Age at  
examination Sex Alteration Inheritance Cognitive
Hyperactive 
or ADHD
Social  
difficulties
Other  
behavioral  
difficulties
Speech 
delay
Motor  
delay
Facial  
dysmorphism
Seizures  
or EEG  
abnormalities
DNA03-00335 14 years M p.Ile822Tyrfs*13 De novo Normal IQ + + + +
DNA-008897 73 years M p.Leu411Glyfs*6 Profound ID + + + + +
Troina 1274 19 years M p.Trp532* De novo Severe ID + + + + −
Troina 1512 17 years M p.Ser1011* De novo Mild ID + (3y 8m) + + + + −
Troina 3097 34 years F p.Arg143Valfs*64 Severe ID + + + +
DNA11-21308Z 36 years F p.Arg625* Mild to  
moderate ID
+ + + + + +
DNA11-19324Z 9 years F p.Arg626* 2- to 2.5-year 
delay at  
9 years old
+ − + −
DNA08-08272 9 years M p.Gly15Argfs*47 Mild ID + + + + + +
Rauch et al. 13 years F p.Lys592* Mild ID + + + − +
9886269 5 years M Deletion De novo Global delay + + + + +
Marseglia et al. 15 years M Deletion De novo Mild ID + + + + + + +
Filges et al. pt. 1 7 years M Deletion De novo Moderate ID + + + +
Filges et al. pt. 2 4 years M Deletion De novo + + +
ID, intellectual disability;  EEG, electroencephalogram; M, male; F, female.
1
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1,597
SETSKI
p.Gly15Argfs*47
p.Arg143Valfs*64
p.Leu411Glyfs*6
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p.Ser1011*p.Lys592* p.Ile822Tyrfs*13
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LINC01478
RefSeq genes
SETBP1
MIR4319
SLC14A2
SLC14A1
SLC14A2
FLJ44087
Marseglia  et al.
18q12.3
Chr. 18
Scale
40,000,000 40,500,000
Chromosome bands localized by FISH mapping clones
41,000,000 41,500,000
hg181 Mb
SETBP1
6 years, 2 months
3 years, 8 months
34 years
17 years
19 years
SETBP1 p.Trp532*
SETBP1 p.Ser1011*
14 years
SETBP1 p.Ile822Tyrfs*13
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Figure 1 Truncating SETBP1 mutations and 
associated phenotypes. (a) CNV data define a focal 
CNV region around SETBP1. Combining a focal 
de novo deletion observed in our study (9886269) 
with CNVs from Filges et al.41 and Marseglia et al.42  
(red bars) highlights minimal common regions, 
including SETBP1 and LINC01478. (b) Targeted 
resequencing identified eight truncating variants 
in SETBP1 and none in controls. Integration of 
published exome data identified one additional 
case and no truncating events in controls.  
Ath, AT hook; SKI, SKI-homologous region;  
SET, SET-binding domain; Rpt, repeat. (c) Phenotypic 
assessment (summarized in Table 4) identified 
a recognizable phenotype, including IQ deficits 
ranging from mild to severe, impaired speech and 
distinctive facial features. See the Supplementary 
Note for additional photographs of affected 
individuals and clinical descriptions. We obtained 
informed consent to publish the photographs.
©
20
14
 N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
NATURE GENETICS ADVANCE ONLINE PUBLICATION 5
A RT I C L E S
delay and 1,329 cases of ASD, totaling 4,716 cases. Putative loss-of-
function SNVs and indels were validated by Sanger sequencing and 
assessed in parental DNA, when available, to determine inheritance. 
Genes with significant enrichment were identified by comparison 
with the MIP resequencing data for 2,193 unaffected siblings from 
the Simons Simplex Collection37 and ESP6500. We tested each gene 
for combined enrichment of loss-of-function variation across CNV 
and SNV data (Online Methods) and identified 16 genes (Table 3 and 
Supplementary Table 5) with a significant enrichment of disruptive 
mutations in cases. Additionally, to control for the differential effects 
of terminal runcating events, we appli d a statistical model based 
on predicted protein lengths for genes with truncating or splice-site 
events in ESP6500 (Supplementary Fig. 5), as this approach was com-
plementary to the results from case-control 
comparison (Table 3).
Among the positive controls, our analy-
sis confirmed the pathogenicity of five genes 
using a nominal threshold of significance on 
the joint P values: ARID1B (five CNVs and 
nine truncating SNVs, one of which was 
confirmed to be de novo; P = 1.51 × 10−4, 
q = 6.54 × 10−4), GRIN2B (two CNVs—one focal CNV disrupting 
the distal end of GRIN2B—and four new truncating variants; P = 
0.00546, q = 0.0142) and MBD5 (P = 0.0429, q = 0.0744), as well 
as SCN1A (P = 0.0036, q = 0.0117), in comparison to the adjacent 
gene TTC21B (P = 1.00, q = 1.00). Integration of SNV and CNV 
data confirmed KANSL1 as the gene responsible for the 17q21.31 
deletion syndrome32 (P = 0.000418, q = 0.00155) in comparison 
to the adjacent gene MAPT (P = 0.36, q = 0.455) (Table 3 and 
Supplementary Table 5). Clinical follow-up for one KANSL1 case 
with a severe frameshift demonstrated striking phenotypic resem-
blance to microdeletion carriers, confirming this gene as the major 
contributor to the phenotype of 17q21.31 microdeletion (Koolen– 
de Vries) syndrome32,38.
Table 4 Brief phenotypic description of cases with SETBP1 loss-of-function variants
Case
Age at  
examination Sex Alteration Inheritance Cognitive
Hyperactive 
or ADHD
Social  
difficulties
Other  
behavioral  
difficulties
Speech 
delay
Motor  
delay
Facial  
dysmorphism
Seizures  
or EEG  
abnormalities
DNA03-00335 14 years M p.Ile822Tyrfs*13 De novo Normal IQ + + + +
DNA-008897 73 years M p.Leu411Glyfs*6 Profound ID + + + + +
Troina 1274 19 years M p.Trp532* De novo Severe ID + + + + −
Troina 1512 17 years M p.Ser1011* De novo Mild ID + (3y 8m) + + + + −
Troina 3097 34 years F p.Arg143Valfs*64 Severe ID + + + +
DNA11-21308Z 36 years F p.Arg625* Mild to  
moderate ID
+ + + + + +
DNA11-19324Z 9 years F p.Arg626* 2- to 2.5-year 
delay at  
9 years old
+ − + −
DNA08-08272 9 years M p.Gly15Argfs*47 Mild ID + + + + + +
Rauch et al. 13 years F p.Lys592* Mild ID + + + − +
9886269 5 years M Deletion De novo Global delay + + + + +
Marseglia et al. 15 years M Deletion De novo Mild ID + + + + + + +
Filges et al. pt. 1 7 years M Deletion De novo Moderate ID + + + +
Filges et al. pt. 2 4 years M Deletion De novo + + +
ID, intellectual disability;  EEG, electroencephalogram; M, male; F, female.
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Figure 1 Truncating SETBP1 mutations and 
associated phen types. (a) CNV ata d fine a focal 
CNV region around SETBP1. Combining a focal 
de novo deletion observed in our study (9886269) 
with CNVs from Filges et al.41 and Marseglia et al.42  
(red bars) highlights minimal common regions, 
including SETBP1 and LINC01478. (b) Targeted 
resequencing identified eight truncating variants 
in SETBP1 and none in controls. Integration of 
published exome data identified one additional 
case and no truncating events in controls.  
Ath, AT hook; SKI, SKI-homologous region;  
SET, SET-binding domain; Rpt, repeat. (c) Phenotypic 
assessment (summarized in Table 4) identified 
a recognizable phenotype, including IQ deficits 
ranging from mild to severe, impaired speech and 
distinctive facial features. See the Supplementary 
Note for additional photographs of affected 
individuals and clinical descriptions. We obtained 
informed consent to publish the photographs.
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delay and 1,329 cases of ASD, totaling 4,716 cases. Putative loss-of-
function SNVs and indels were validated by San er sequencing and 
assessed in parental DNA, when available, to determine inheritance. 
Genes with significant enrichment were identifie  by comparison 
with the MIP resequencing data for 2,193 unaff cted siblings from 
th  Simons Simplex Collection37 and ESP6500. We tested each gen  
for combi ed e richment of loss-of-function a iation acro s CNV 
and SNV data (Online Methods) and identified 16 genes (Table 3 and 
Suppleme tary Table 5) with a significant enrichme t of disruptive 
mutations in cases. Additionally, to control for the differential effects 
of terminal truncating ev nts, w  applied a statistical model based 
on predicted protein l gths for genes with tr ati g o  splice-site 
events in ESP6500 (Supplementary Fig. 5), as this approach was com-
plementary to th  results from case-control 
comparison (Table 3).
Among the positive controls, our analy-
sis confirmed the pathogenicity of five genes 
using a nominal thresh ld of significance on 
the joint P values: ARID1B (five CNVs and 
nine truncating SNVs, one of which was 
confirmed to be de novo; P = 1.51 × 10−4, 
q = 6.54 × 10−4), GRIN2B (two CNVs—one focal CNV disrupting 
the distal end of GRIN2B—and f ur new truncating variants; P = 
0.00546, q = 0.0142) and MBD5 (P = 0.0429, q = 0.0744), as well 
as SCN1A (P = 0.0036, q = 0.0117), in comparison to the adjacent 
gene TTC21B (P = 1.00, q = 1.00). Integration of SNV and CNV 
data confirmed KANSL1 as the gene responsible for the 17q21.31 
deletion syndrom 32 (P = 0.000418, q = 0.00155) in omparison 
to the adjacent gene MAPT (P = 0.36, q = 0.455) (Table 3 and 
Supplementary Table 5). Clinical follow-up for one KANSL1 case 
with a severe frameshift demonstrated striki g phen typic resem-
blance to micr deletion carriers, confirming thi  ge e as the major 
contributor to the phenotype of 17q21.31 microdeletion (Koolen– 
de Vries) syndrome32,38.
Table 4 Brief phenotypic description of cases with SETBP1 loss-of-function variants
Case
Age at  
examination Sex Alteration Inheritance Cognitive
Hyperactive 
or ADHD
Social  
difficulties
Other  
behavioral  
difficulties
Speech 
delay
Motor  
delay
Facial  
dysmorphism
Seizures  
or EEG  
abnormalities
DNA03-00335 14 years M p.Ile822Tyrfs*13 De novo Normal IQ + + + +
DNA-008897 73 years M p.Leu411Glyfs*6 Profound ID + + + + +
Troina 1274 19 years M p.Trp532* De novo Severe ID + + + + −
Troina 1512 17 years M p.Ser1011* De novo Mild ID + (3y 8m) + + + + −
Troina 3097 34 years F p.Arg143Valfs*64 Severe ID + + + +
DNA11-21308Z 36 years F p.Arg625* Mild to  
moderate ID
+ + + + + +
DNA11-19324Z 9 years F p.Arg626* 2- to 2.5-year 
delay at  
9 years old
+ − + −
DNA08-08272 9 years M p.Gly15Argfs*47 Mild ID + + + + + +
Rauch et al. 13 years F p.Lys592* Mild ID + + + − +
9886269 5 years M Deletion De novo Global delay + + + + +
Marseglia et al. 15 years M Deletion De novo Mild ID + + + + + + +
Filges et al. pt. 1 7 years M Deletion De novo Moderate ID + + + +
Filges et al. pt. 2 4 years M Deletion De novo + + +
ID, intellectual disability;  EEG, electroencephalogram; M, male; F, female.
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Figure 1 Tru cating SETBP1 mutations and 
associated phenotypes. (a) CNV data define a focal 
CNV region around SETBP1. Combining a focal 
de novo deletion observed in our study (9886269) 
with CNVs from Filges et al.41 and Marseglia et al.42  
(red bars) highlights minimal common regions, 
including SETBP1 and LINC01478. (b) Targeted 
resequencing identified eigh  truncating variants 
i  SETBP1 and none in controls. Integration of 
published xome ata identifi d one additional 
case and no truncating events in controls.  
Ath, AT hook; SKI, SKI-homologous regi n;  
SET, SET-binding domain; Rpt, repeat. (c) Phenotypic 
assessment (summarize  i  Table 4) identified 
a recognizable phenotype, including IQ deficits 
ranging from mild to severe, impaired speech and 
distinctive faci l features. See th  Suppleme tary 
Note for additional photographs of affected 
individuals and clinical descriptions. We obtained 
informed consent to publish the photographs.
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An enrichment of loss-of-function mutations in cases was observed 
for ten additional genes (ADNP, DYRK1A, NRXN1, NRG3, SETBP1, 
ZMYND11, DNM3, CYFIP1, FOXP1 and SCN2A) (Table 4). In one 
case with a de novo DYRK1A splice-site mutation (see Troina1818 
in Supplementary Table 5), the affected individual presented with 
severe microcephaly, consistent with published autism-related 
de novo truncating mutations and CNVs from earlier studies36,39. 
Among the genes for which there was no enrichment in cases ver-
sus controls, two were notable: CHD1L and ACACA—candidates 
for the 1q21 deletion and 17q12 deletion syndromes, respectively40. 
In our resequencing study of CHD1L, for example, we identified 
14 likely truncating variants (Table 3) in comparison to 9 inde-
pendent truncating variants in controls, which indicates that rare 
truncating mutations of CHD1L are not uncommon (Table 3 and 
Supplementary Table 5). There was also no significant decrease in 
the predicted protein size in cases in comparison to controls (P = 0.94, 
log-rank test).
Phenotypic examination of cases with SETBP1 and ZMYND11 
truncations
Among the significant genes, we focused on SETBP1 and ZMYND11 
for further phenotypic characterization. We confirmed a focal de novo 
deletion and five cases with truncating mutations (three tested and 
confirmed to be de novo) in the SETBP1 gene (encoding SET-binding 
protein 1). Disruptive mutations were absent in controls, with 
the exception of a splice-site alteration predicted to lead to the loss 
of an in-frame exon encoding 18 amino acids. Notably, all truncat-
ing mutations in cases occurred in cohorts of intellectual disability, 
where we observed an enrichment of mutations (P = 0.0093, joint 
loss of function) and decreased predicted protein size (P = 0.011, 
log-rank test) (Fig. 1, Table 3 and Supplementary Tables 5 and 6). 
Integration of our variants from cases with 2 additional truncating 
variants found in a separate genetic screen for intellectual disability 
(n = 847) with the same MIPs, as well as published small deletions 
and de novo variants, highlighted a similar phenotype for the affected 
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c
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Figure 2 Truncating ZMYND11 mutations and associated phenotypes. (a) CNV data refine a focal CNV deletion region (red bars) containing two genes 
(ZMYND11 and DIP2C). (b) Targeted resequencing identified five truncating variants and one single-amino-acid deletion predicted to behave as loss-
of-function variants by removing a critical binding residue in the MYND domain (Gln587). Analysis of control resequencing and exome data identified 
no additional truncating events in ZMYND11 but highlighted two truncating mutations in DIP2C. PHD, plant homeodomain; Bromo, bromodomain; 
PWWP, conserved ProTrpTrpPro motif; NLS, nuclear localization sequence; MYND, zinc finger MYND type (myeloid, Nervy and DEAF-1); DMAP, DNA 
methyltransferase–associated protein; CaiC, crotonobetaine/carnitine-CoA ligase; AMP, AMP-dependent synthetase/ligase. (c) Phenotypic assessment 
(summarized in Table 5) showed a consistent phenotype characterized by mild intellectual disability accompanied by speech and motor delays, as 
well as complex neuropsychiatric behavioral and characteristic facial features. See the Supplementary Note for additional photographs of the affected 
individuals and clinical descriptions. We obtained informed consent to publish the photographs.
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individuals12,41,42. The majority of cases demonstrated IQ and lan-
guage deficits (completely absent or substantially impaired speech in 
92% (12/13) of the cases). Cases positive for mutation in SETBP1 also 
frequently exhibited impairment of fine motor skills (n = 8), hyper-
activity and/or ADHD (attention deficit and hyperactivity disorder) 
(n = 7) and autistic features and/or poor social skills (n = 4). We also 
observed a dysmorphism typified by a long face (n = 10), characteris-
tic eyebrows and, less frequently, low-set ears (n = 4) and café-au-lait 
spots (n = 4) (Fig. 1, Table 4 and Supplementary Table 6).
The smallest region of overlap for the 10p15.3 microdeletion 
predicted two possible candidate genes43: ZMYND11 and DIP2C  
(Fig. 2). We resequenced both candidates and detected five truncating 
variants in ZMYND11 (two confirmed to be de novo and one inherited 
from an affected father) and none in DIP2C. In contrast, concur-
rent examination of controls identified truncating mutations only for 
DIP2C (Fig. 2, Table 3 and Supplementary Table 5). Integration of 
CNV and truncating SNV data strongly supports ZMYND11 (devel-
opmental delay P = 2.81 × 10−5, joint loss of function) as opposed to 
DIP2C (developmental delay P = 0.48, joint loss of function) as the 
critical gene. Comparing the phenotypes of affected individuals with 
truncating SNVs in ZMYND11 (Fig. 2, Table 5 and Supplementary 
Table 7) showed a striking resemblance to the 10p15.3 microdele-
tion cases described previously43 and highlighted a consistent set 
of behavioral features, mild intellectual disability and subtle facial 
features, including hypertelorism (n = 6), ptosis (n = 3) and a wide 
mouth (n = 4). The most consistent features seen in all subjects 
were speech and motor delays, which were observed in all affected 
individuals for whom information was available, including in cases 
with CNVs43. Interestingly, a psychiatric phenotype was apparent in 
three of five affected individuals, including aggression in three of 
four males. Three cases were accessible for parental DNA testing, by 
which we determined that two variants were de novo and one was 
paternally inherited. The paternal carrier of the variant encoding 
p.Met187Ilefs*19 also had developmental delay, including walking 
at 3–4 years of age and learning problems, in addition to aggression 
in childhood with mood swings. We also detected a de novo in-frame 
deletion (encoding p.Gln587del) in the MYND domain (Gln587), 
which represents a critical residue in corepressor binding (including 
NCoR)44–46. Examination of this individual identified similarities 
with published 10p15.3 microdeletion syndrome cases (Fig. 2 and 
Supplementary Table 7), including characteristic facial dysmor-
phisms, global developmental delay and speech delay. Taking this 
evidence together, we propose that ZMYND11 is the critical gene 
associated with the 10p15.3 microdeletion syndrome.
DISCUSSION
In this study, we leverage the large sample size of cases avail-
able from CNV clinical microarrays and the precision of next-
generation sequencing to identify specific genes associated with 
 neurodevelopmental disease. The expanded CNV morbidity map 
offers clinical usefulness as a resource to assess the pathogenic rel-
evance of rare events, as well as a research tool to prioritize genes 
discovered from exome sequencing studies that are currently too 
underpowered to achieve statistical significance5–14,36. It is important 
to note that the large sample size (nearly 50,000 cases and controls) 
has begun to highlight regions that map outside of recurrent CNVs 
mediated by segmental duplications. The sample size is thus sufficient 
to survey the background level of CNVs, identifying critical regions 
outside of regions with elevated mutation rates (Table 2). In addition, 
the sample size has allowed the identification of various recurrent 
duplications (Supplementary Tables 2 and 3) that are neither neces-
sary nor sufficient to cause disease but are more likely to act as genetic 
modifiers or risk factors similar to the 15q11.2 microdeletion47. It is 
possible that copy number polymorphisms occurring at a frequency of 
>1% might also contribute as weaker risk factors, but such events are 
typically smaller and have not been sufficiently assayed by microar-
rays. We identify, for example, the 16p13.11 microduplication among 
68 cases in comparison to 27 controls, giving a likelihood ratio of 1.7 
(95% CI = 1.13–2.56). Exploring these high-impact risk factors will 
be important in understanding the genetic architecture of ASD and 
developmental delay and its relationship to that for other neuropsy-
chiatric features.
Under the assumption that different classes of genetic mutation 
(microdeletions and truncating SNVs and indels) will expose the 
same genic haploinsufficiency, we developed a joint probability sta-
tistic to identify 38 specific genes (Table 3) with a higher prior of 
disease involvement. Although we have not explored it here, a similar 
approach might be useful in assessing microduplications and hyper-
morphic missense mutations. Although it is clear that not all CNVs 
are monogenic and will be amenable to this integrated strategy, for-
ward resequencing of 23 candidate regions (including 6 controls) 
identified 11 genes where there is an excess of deletions and truncat-
ing mutations in cases in comparison to controls (Table 3). Targeted 
resequencing, in particular, allows the discrimination of adjacent 
genes within an SRO (that is, SCN1A versus TTC21B, KANSL1 versus 
MAPT or ZMYND11 versus DIP2C). A comparison of the frequency 
of truncating mutations in cases and controls also reduces the likeli-
hood that specific genes highlighted by case reports of atypical CNVs 
are pathogenic (for example, ACACA and CHD1L)40.
Follow-up and phenotypic evaluation in cases provide the most 
compelling evidence that we have identified genes that likely under-
lie CNV haploinsufficiency. Studies of cases with microdeletion and 
translocation originally narrowed a 1-Mb deletion region on chro-
mosome 18q12.3 to a 372-kb critical region spanning three genes 
(SETBP1, SLC14A2 and MIR4319)41,42. We identified five truncat-
ing mutations (three of three tested and confirmed to be de novo) in 
SETBP1 among cases with moderate to severe intellectual disability. 
The phenotypic similarity among microdeletion cases and cases with 
Table 5 Brief phenotypic description of cases with ZMYND11 loss-of-function variants
Case
Age at  
examination Sex Alteration Inheritance Cognitive Speech delay
Social  
difficulties
Behavioral 
problems
Facial  
dysmorphism
Adelaide20124 4 and 9 years F p.Gln587del De novo Global DD + + +
Adelaide3553 22 years M p.Asn152Thrfs*26 Global DD + +
DNA-017151 17 years F p.Thr70Asnfs*12 De novo Normal IQ + + + +
DNA04-02424 41 years M p.Gln326* Mild ID + + + +
DNA05-04370 M p.Glu416Serfs*5 Severe ID + + +
DNA-013587 25 years M p.Met187Ilefs*19 Inherited Global DD + + + +
Father of DNA-013587 M p.Met187Ilefs*19 Carrier DD +
DD, developmental delay; ID, intellectual disability; M, male; F, female.
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Abstract
To identify previously reported disease mutations that are compatible with
extraordinary longevity, we screened the coding regions of the genomes of 44
Ashkenazi Jewish centenarians. Individual genome sequences were generated
with 309 coverage on the Illumina HiSeq 2000 and single-nucleotide variants
were called with the genome analysis toolkit (GATK). We identified 130 coding
variants that were annotated as “pathogenic” or “likely pathogenic” based on
the ClinVar database and that are infrequent in the general population. These
variants were previously reported to cause a wide range of degenerative, neo-
plastic, and cardiac diseases with autosomal dominant, autosomal recessive, and
X-linked inheritance. Several of these variants are located in genes that harbor
actionable incidental findings, according to the recommendations of the Ameri-
can College of Medical Genetics. In addition, we found risk variants for late-
onset neurodegenerative diseases, such as the APOE e4 allele that was even
present in a homozygous state in one centenarian who did not develop Alzhei-
mer’s disease. Our data demonstrate that the incidental finding of certain
reported disease variants in an individual genome may not preclude an extraor-
dinarily long life. When the observed variants are encountered in the context of
clinical sequencing, it is thus important to exercise caution in justifying clinical
decisions.
Introduction
Human genetic studies have linked many variants to
human diseases or nondisease phenotypes. How to handle
the incidental finding of a disease variant is a topic of
current discussion (Green et al. 2013a; Klitzman et al.
2013). Incidental findings often occur, when genome
sequencing data are screened for disease-causing variants
that are recorded in databases such as Online Mendelian
Inheritance in Man (OMIM) (Hamosh et al. 2005) or,
more recently, ClinVar (Landrum et al. 2014) and the
Genome Wide Association Studies (GWAS) catalog
ª 2014 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
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MICROBIAL EVOLUTION
Global epistasis makes
adaptation predictable despite
sequence-level stochasticity
Sergey Kryazhimskiy,1,3*† Daniel P. Rice,1,3* Elizabeth R. Jerison,2,3 Michael M. Desai1,2,3†
Epistatic interactions between mutations can make evolutionary trajectories contingent
on the chance occurrence of initial mutations. We used experimental evolution in
Saccharomyces cerevisiae to quantify this contingency, finding differences in adaptability
among 64 closely related genotypes. Despite these differences, sequencing of 104 evolved
clones showed that initial genotype did not constrain future mutational trajectories.
Instead, reconstructed combinations of mutations revealed a pattern of diminishing-returns
epistasis: Beneficial mutations have consistently smaller effects in fitter backgrounds. Taken
together, these results show that beneficial mutations affecting a variety of biological
processes are globally coupled; they interact strongly, but only through their combined effect
on fitness. As a consequence, fitness evolution follows a predictable trajectory even though
sequence-level adaptation is stochastic.
E
pistatic interactions betweenmutations are
pervasive in microbial and viral systems
(1–6). In some cases, a single mutation can
open up previously unavailable opportuni-
ties for a population to colonize a new
metabolic niche (2) or survive in a previously
intolerable drug concentration (3). Such idio-
syncratic epistasis makes evolutionary trajecto-
ries dependent on the chance occurrence of
initial mutations that constrain or potentiate fu-
ture adaptation. This historical contingency can
render adaptation fundamentally unpredictable
(7). However, recent work has also provided evi-
dence for more systematic patterns of epistasis
(8–10), which can drive convergent phenotypic
evolution (11–13) or can lead to parallel adapta-
tion at the sequence level (14). These observa-
tions suggest that evolutionary outcomesmay be
statistically predictable ifmutations causing idio-
syncratic changes in adaptability are rare, and if
epistasis instead channels evolution into conver-
gent phenotypic or genotypic pathways.
To test how epistasis and historical contin-
gency affect the predictability of adaptation, we
conducted a hierarchical laboratory evolution
experiment in S. cerevisiae (fig. S1). In the first
phase of the experiment (“diversification”), we
created 432 independent lines from a single
haploid clone (the diversification ancestor, DivAnc)
isolated from an earlier long-term evolution ex-
periment (15).We evolved each line independently,
half at large and half at small population size, in
rich media in 96-well microplates for 240 genera-
tions (16).We then selected 64 clones (“founders”),
each from a different line, chosen to span a range
of fitness relative to the DivAnc (16) (table S1).
Founders differed from the DivAnc by 4.2 muta-
tions on average (16). In the second phase of the
experiment (“adaptation”), we founded 10 inde-
pendent replicate populations with each founder
and then allowed each of the resulting 640 lines
to adapt at large population size for 500 gen-
erations. This enabled us to compare variation
among lines descended from the same founder
(which reflects the inherent stochasticity of evo-
lution) to variation between lines descended from
different founders, thereby providing an assess-
ment of the extent to which genetic background
influences evolution.
The competitive fitness of each population
after 250 and 500 generations of the adaptation
phase increased on average by 3.3% and 6.6%,
respectively (Fig. 1A and table S2). However, not
all populations adapted at the same rate. Instead,
the initially large variation in fitness between
lines declined with time (Fig. 1A). We carried out
an analysis of variance (ANOVA) to partition ob-
served variance in fitness increase during the
adaptation phase into contributions from mea-
surement noise, inherent stochasticity of the evo-
lutionary process, and the identity of the founder
(16, 17). After 250 generations of adaptation, 49%
of the variance in fitness incrementwas attributed
to inherent evolutionary stochasticity, 17% to
measurement error, and 34% to founder iden-
tity; after 500 generations, 29% of the variance
in fitness increment was attributed to inherent
stochasticity, 21% tomeasurement error, and 50%
to founder identity (Fig. 1B and table S3). This
demonstrates that genetic background is a key
determinant of howrapidly apopulationwill adapt.
These differences in adaptability are not ran-
dom: Populations with lower initial fitness sys-
tematically adapt more rapidly than populations
with higher initial fitness, driving the overall pat-
tern of convergent evolution in fitness (Fig. 1C).
We further partitioned the variation in fitness
increment attributed to founder identity and found
that after 250 generations of adaptation, 31% of
this variation was explained by the fitness of the
founder, whereas 3% was determined by its spe-
cific genotype; for 500 generations, these percent-
ages rose to 46% and 4%, respectively (Fig. 1B
and table S3). Thus, the differences in adaptabil-
ity between founders are almost entirely predicted
by their differences in fitness and are indepen-
dent of the specific mutations underlying this
fitness. The initial fitness of the founder therefore
predicts the average rate of adaptation in its de-
scendant lines (Fig. 1D). Although the effects of
specific genotype on adaptability are rare or weak,
they are significant (fig. S2 and tables S3 and S4).
A negative correlation between fitness and
adaptability has also been observed in prokary-
otes (11, 12), and it is consistent with the common
observation in evolution experiments that the
rate of increase in fitness slows down over time
(13, 18). Combined with this earlier work, our
results suggest a general “rule of declining adap-
tability” that holds for prokaryotes and eukary-
otes adapting to rich andminimalmedia. Further,
our observations support a stronger version of
this rule: Genotypes with lower fitness are more
adaptable than those with higher fitness, and dis-
tinct genotypes with identical fitness are equally
adaptable (up to the rare or weak exceptions
noted above). This is consistentwith the argument
recently presented in (13).
The rule of declining adaptability could arise
for two non-exclusive reasons. First, there could
be only a few ways to increase in fitness. In this
model, high-fitness founders have lower adapta-
bility because they have already acquired all or
most of the possible strong-effect beneficial mu-
tations: They are “running out” of beneficial mu-
tations. In contrast, low-fitness founders adapt
more quickly because they have not yet acquired
these mutations. More generally, some groups of
mutations may have redundant functional ef-
fects (e.g., those that knock out a given pathway).
In this case, the number of nonredundant ways
to increase fitness would be much smaller than
the number of distinct beneficial mutations. We
refer to this general form of the running-out-of-
mutations hypothesis as the “modular epistasis”
model [inspired by (14)]: Each beneficial muta-
tion improves a single module, mutations within
each module are redundant, and high-fitness
founders adapt more slowly because they have
fewer remaining modules to improve, especially
among those modules that confer the largest fit-
ness gains (16).
Alternatively, mutations arising in higher-fitness
backgrounds may be less beneficial than those
arising in lower-fitness backgrounds; that is,
diminishing-returns epistasis may be pervasive
among adaptivemutations, as suggested by (8–10).
This epistasis could have two forms. If epistasis is
idiosyncratic, mutations may often have widely
different effects in different genetic backgrounds
(possibly including sign epistasis, where the sign
of the fitness effect depends on genetic back-
ground), but the average effect of a beneficial
mutation is smaller in fitter backgrounds. On the
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MICROBIAL EVOLUTION
Global epistasis makes
adaptation predictable despite
sequence-level stochasticity
Sergey Kryazhimskiy,1,3*† Daniel P. Rice,1,3* Elizabeth R. Jerison,2,3 Michael M. Desai1,2,3†
Epistatic interactions between mutations can make evolutionary trajectories contingent
on the chance occurrence of initial mutations. We used experimental evolution in
Saccharomyces c revi iae to quantify this contingency, finding differences in adaptability
among 64 closely related genotypes. Despite these differences, sequencing of 104 evolved
clones showed that i itial genotype did not constrain future mutational trajectories.
Instead, reconstructed combinations of mutations revealed a pattern of diminishing-returns
epistasis: Beneficial mutations have consistently smaller effects in fitter backgrounds. Taken
together, these results show that beneficial mutations affecting a variety of biological
processes are globally coupled; they interact strongly, but only through their combined effect
on fitness. As a consequenc , fitness evolution follows a predictable trajectory even though
sequence-level d ptation is stochastic.
E
pistatic interactions betweenmutations are
pervasive in microbial and viral systems
(1–6). In some cases, a single mutation can
open up previously unavailable opportuni-
ti for a pop lation to colonize a new
metabolic niche (2) or survive in previously
intolerable drug concentration (3). Such idio-
syncratic epistasis makes evolutionary trajecto-
ries dependent on the chance occurrence of
initial mutations that constrain or potentiate fu-
ture ada tation. This historical conti gency can
render adaptation fu dament lly unpredictable
(7). How v r, recent work has also provided evi-
dence for more systematic patterns of epistasis
(8–10), which can drive convergent phenotypic
evolution (11–13) or can lead to parallel adapta-
tion at the sequence level (14). These observa-
tions suggest that evolutionary outcomesmay be
statistically p edictable ifmutat ons causing idio-
syncratic changes in adaptability are rare, and if
epistasis instead channels evolution into conver-
gent phenotypic or genotypic pathways.
To test how epistasis and historical contin-
gency affect the predictability of adaptation, we
conducted a hierarchical laboratory evolution
experiment in S. cerevisiae (fig. S1). In the first
phase of the experiment (“diversification”), we
created 432 independent lines from a si gle
haploid clone (the diversification ancestor, DivAnc)
isolated from an earlier long-term evolution ex-
periment (15).We evo ved each line independently,
half at large an half at small po ul tion size, in
rich media in 96-well microplates for 240 g ra-
tions (16).We then selected 64 clones (“founders”),
each from a different line, chosen to span range
of fitness relative to the DivAnc (16) (table S1).
Founders differed from the DivAnc by 4.2 muta-
tions on average (16). In the second phase of the
experiment (“adaptation”), we founded 10 inde-
pendent replicate populations with each founder
and then allowed each of the resulting 640 lines
to adapt at large population size for 500 gen-
erations. This enabled us to compare variation
among lines descended from the same founder
(which reflects the inherent stochasticity of evo-
lution) to variation between lines descended from
different founders, thereby providing an assess-
ment of the extent to which genetic background
influences evolution.
The competitive fitness of each population
after 250 and 500 generations of the adaptation
phase increased on average by 3.3% and 6.6%,
respectively (Fig. 1A and table S2). However, not
all populations adapted at the same rate. Instead,
the initially large variation in fitness between
lines declined with time (Fig. 1A). We carried out
an analysis of variance (ANOVA) to partition ob-
served variance in fitness increase during the
adaptation phase into contributions from mea-
surement noise, inherent stochasticity of the evo-
lutionary process, and the identity of the founder
(16, 17). After 250 generations of adaptation, 49%
of the variance in fitness incrementwas attributed
to inherent evolutionary stochasticity, 17% to
measurem t error, and 34% to founder iden-
tity; after 500 generations, 29% of the variance
in fitness increment was attributed to inherent
toch st city, 21% tomeasurement error, and 50%
to founder identity (Fig. 1B and table S3). This
demonstrates that genetic background is a key
determinant of howrapidly apopulationwill adapt.
These differences in adaptability are not ran-
dom: Populations with lower initial fitness sys-
tematically adapt more rapidly than populations
with hig er initial fitness, driving the overall pat-
tern of convergent evolution in fitness (Fig. 1C).
We further artitioned the variation in fitness
increment attributed to founder identity and found
that after 250 generations of adaptation, 31% of
this variation was explained by the fitness of the
founder, whereas 3% was determined by its spe-
cific genotype; for 500 generations, these percent-
ages rose to 46% and 4%, respectively (Fig. 1B
and table S3). Thus, the differences in adaptabil-
ity between founders are almost entirely predicted
by their differences in fitness and are indepen-
dent of the specific mutations underlying this
fitness. The initial fitness of the founder therefore
predicts the average rate of adaptation in its de-
scendant lines (Fig. 1D). Although the effects of
specific genotype on adaptability are rare or weak,
they are significant (fig. S2 and tables S3 and S4).
A negative correlation between fitness and
adaptability has also been observed in prokary-
otes (11, 12), and it is consistent with the common
observation in evolution experiments that the
rate of increase in fitness slows down over time
(13, 18). Combined with this earlier work, our
results suggest a general “rule of declining adap-
tability” that holds for prokaryotes and eukary-
otes adapting to rich andminimalmedia. Further,
our observations support a stronger version of
this rule: Genotypes with lower fitness are more
adaptable than those with higher fitness, and dis-
tinct genotypes with identical fitness are equally
adaptable (up to the rare or weak exceptions
noted above). This is consistentwith the argument
recently presented in (13).
The rule of declining adaptability could arise
for two non-exclusive reasons. First, there could
be only a few ways to increase in fitness. In this
model, high-fitness founders have lower adapta-
bility because they have already acquired all or
most of the possible strong-effect beneficial mu-
tations: They are “running out” of beneficial mu-
tations. In contrast, low-fitness founders adapt
more quickly because they have not yet acquired
these mutations. More generally, some groups of
mutations may have redundant functional ef-
fects (e.g., those that knock out a given pathway).
In this case, the number of nonredundant ways
to increase fitness would be much smaller than
the number of distinct beneficial mutations. We
refer to this general form of the running-out-of-
mutations hypothesis as the “modular epistasis”
model [inspired by (14)]: Each beneficial muta-
tion improves a single module, mutations within
each module are redundant, and high-fitness
founders adapt more slowly because they have
fewer remaining modules to improve, especially
among those modules that confer the largest fit-
ness gains (16).
Alternatively, mutations arising in higher-fitness
backgrounds may be less beneficial than those
arising in lower-fitness backgrounds; that is,
diminishing-returns epistasis may be pervasive
among adaptivemutations, as suggested by (8–10).
This epistasis could have two forms. If epistasis is
idiosyncratic, mutations may often have widely
different effects in different genetic backgrounds
(possibly including sign epistasis, where the sign
of the fitness effect depends on genetic back-
ground), but the average effect of a beneficial
mutation is smaller in fitter backgrounds. On the
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Supplementary Figures
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Figure S1. Experimental design. We created many independent lines from a single clone
(DivAnc) which came from a previous evolution experiment in the same environment (15) and
evolved each of them for 240 generations (Diversification). We then selected a single “Founder”
clone from 64 of these lines (chosen to span a range of fitness) and evolved 10 independent
replicate populations descended from each Founder for 500 generations (Adaptation).
20
leads to a striking pattern of convergent evo-
lution, making fitness evolution relatively pre-
dictable. Despite this fitness-level convergence,
evolution remains highly stochastic at the geno-
type level, likely because many distinct muta-
tional paths can lead a population to any given
fitness.
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NONHUMAN GENETICS
Genomic basis for the convergent
evolution of electric organs
Jason R. Gallant,1,2* Lindsay L. Traeger,3,4* Jeremy D. Volkening,4,5 Howell Moffett,6,7
Po-Hao Chen,6,7,8 Carl D. Novina,6,7,8 George N. Phillips Jr.,9 Rene Anand,10
Gregg B. Wells,11 Matthew Pinch,12 Robert Güth,12 Graciela A. Unguez,12 James S. Albert,13
Harold H. Zakon,2,14,15†Manoj P. Samanta,16†Michael R. Sussman4,5†
Little is known about the genetic basis of convergent traits that originate repeatedly over
broad taxonomic scales. The myogenic electric organ has evolved six times in fishes to
produce electric fields used in communication, navigation, predation, or defense. We have
examined the genomic basis of the convergent anatomical and physiological origins of
these organs by assembling the genome of the electric eel (Electrophorus electricus)
and sequencing electric organ and skeletal muscle transcriptomes from three lineages
that have independently evolved electric organs. Our results indicate that, despite millions
of years of evolution and large differences in the morphology of electric organ cells,
independent lineages have leveraged similar transcription factors and developmental and
cellular pathways in the evolution of electric organs.
E
lectric fishes use electric organs (EOs) to
produce electricity for the purposes of com-
munication; navigation; and, in extreme cases,
predation and defense (1). EOs are a dis-
tinct vertebrate trait that has evolved at
least six times independently (Fig. 1A). The tax-
onomic diversity of fishes that generate elec-
tricity is so profound that Darwin specifically
cited them as an important example of con-
vergent evolution (2). EOs benefit as a model for
understanding general principles of the evolu-
tion of complex traits, as fish have evolved other
specialized noncontractile muscle-derived or-
gans (3). Furthermore, EOs provide a basis to
assess whether similar mechanisms underlie
the evolution of other specialized noncontrac-
tile muscle derivatives, such as the cardiac con-
duction system (4).
Electric organs are composed of cells called
electrocytes (Fig. 1B). All electrocytes have an
innervated surface enriched in cation-specific ion
channels and, on the opposite surface, an in-
vaginated plasma membrane enriched in sodium
pumps, and, in some species, ion channels as
well. The functional asymmetry of these cells,
and their “in-series” arrangement within each
organ, allows for the summation of voltages, much
like batteries stacked in series in a flashlight.
Although EOs originate developmentally from
myogenic precursors, they are notably larger than
muscle fibers (5). Further, they either lack the
contractile machinery clearly evident in electron
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Fig. 3. Diminishing-returns epistasis among spe-
cific mutations. The fitness effect of knocking
out genes gat2, whi2, and sfl1 declines with the
fitness of the background strain. The ho knockout
is a negative control. Error bars are SEM over bio-
logical replicates.
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•  “Yet	  despite	  their	  lack	  of	  apparent	  func)onal	  
rela)onship,	  these	  muta)ons	  are	  globally	  
coupled	  by	  diminishing-­‐returns	  epistasis;	  their	  
eﬀects	  are	  strongly	  mediated	  by	  background	  
ﬁtness	  but	  are	  otherwise	  essen)ally	  
independent	  of	  the	  speciﬁc	  iden)ty	  of	  
muta)ons	  present	  in	  the	  background.	  The	  
biological	  basis	  of	  this	  global	  coupling	  remains	  
unknown”.	  	  
Clinical Evaluation of a Multiple-Gene Sequencing Panel for
Hereditary Cancer Risk Assessment
Allison W. Kurian, Emily E. Hare, Meredith A. Mills, Kerry E. Kingham, Lisa McPherson, Alice S. Whittemore,
Valerie McGuire, Uri Ladabaum, Yuya Kobayashi, Stephen E. Lincoln, Michele Cargill, and James M. Ford
Processed as a Rapid Communication manuscript
Allison W. Kurian, Meredith A. Mills,
Kerry E. Kingham, Lisa McPherson,
Alice S. Whittemore, Valerie McGuire,
Uri Ladabaum, James M. Ford, Stan-
ford University School of Medicine,
Stanford; Emily E. Hare, Yuya
Kobayashi, Stephen E. Lincoln, Michele
Cargill, InVitae, San Francisco, CA.
Published online ahead of print at
www.jco.org on April 14, 2014.
Supported by the Breast Cancer
Research Foundation, a Stanford
University Cancer Institute Develop-
mental Research Award, the Jan
Weimer Junior Faculty Chair in Breast
Oncology at Stanford University,
National Institutes of Health Clinical and
Translational Science Award No. UL1
RR025744, and InVitae.
Presented in part at the American Soci-
ety of Clinical Oncology Breast Cancer
Symposium, San Francisco, CA,
September 7-9, 2013, and at the Ameri-
can Society of Human Genetics Annual
Meeting, Boston, MA, October 22-26,
2013.
Terms in blue are defined in the glos-
sary, found at the end of this article
and online at www.jco.org.
Authors’ disclosures of potential con-
flicts of interest and author contribu-
tions are found at the end of this
article.
Corresponding author: James M. Ford,
MD, Associate Professor of Medicine,
Pediatrics and Genetics, Division of
Oncology, Stanford University School of
Medicine, CCSR Building, Room 1115,
269 Campus Dr, Stanford CA, 94305;
e-mail: jmf@stanford.edu.
© 2014 by American Society of Clinical
Oncology
0732-183X/14/3299-1/$20.00
DOI: 10.1200/JCO.2013.53.6607
A B S T R A C T
Purpose
Multiple-gene sequencing is entering practice, but its clinical value is unknown. We evaluated the
performance of a customized germline-DNA sequencing panel for cancer-risk assessment in a
representative clinical sample.
Methods
Patients referred for clinical BRCA1/2 testing from 2002 to 2012 were invited to donate a research
blood sample. Samples were frozen at !80° C, and DNA was extracted from them after 1 to 10
years. The entire coding region, exon-intron boundaries, and all known pathogenic variants in other
regions were sequenced for 42 genes that had cancer risk associations. Potentially actionable
results were disclosed to participants.
Results
In total, 198 women participated in the study: 174 had breast cancer and 57 carried germline
BRCA1/2mutations. BRCA1/2 analysis was fully concordant with prior testing. Sixteen pathogenic
variants were identified in ATM, BLM, CDH1, CDKN2A, MUTYH, MLH1, NBN, PRSS1, and SLX4
among 141 women without BRCA1/2 mutations. Fourteen participants carried 15 pathogenic
variants, warranting a possible change in care; they were invited for targeted screening
recommendations, enabling early detection and removal of a tubular adenoma by colonoscopy.
Participants carried an average of 2.1 variants of uncertain significance among 42 genes.
Conclusion
Among women testing negative for BRCA1/2 mutations, multiple-gene sequencing identified 16
potentially pathogenic mutations in other genes (11.4%; 95% CI, 7.0% to 17.7%), of which 15
(10.6%; 95% CI, 6.5% to 16.9%) prompted consideration of a change in care, enabling early
detection of a precancerous colon polyp. Additional studies are required to quantify the penetrance
of identified mutations and determine clinical utility. However, these results suggest that
multiple-gene sequencing may benefit appropriately selected patients.
J Clin Oncol 32. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Clinical genetic testing for cancer-risk assessment
has become widespread over the last two decades,
with evidence-based testing guidelines for heredi-
tary breast and ovarian cancer (BRCA1 andBRCA2;
BRCA1/2), Lynch syndrome (MLH1, MSH2,
MSH6, PMS2, and EPCAM), familial adenomatous
polyposis (APC), hereditary diffuse gastric cancer
(CDH1), Li-Fraumeni syndrome (TP53), Cowden’s
syndrome (PTEN), and a few other conditions.1-4
Cancer genetic counseling and risk-reducing in-
terventions have accordingly been developed for
high penetrance, autosomal dominant conditions.
Most of these interventions, especially prophylactic
surgery, are excessive for carriers of mutations that
have uncertain pathogenicity.5-7 Recently, next-
generation technology has enabled massively paral-
lel sequencing at low cost, and panels of multiple
cancer-associated genes are newly available for clin-
ical use.8,9
Despite these advances in technology, a critical
knowledgedeficit remains about the clinical valueof
multiple-gene panels for cancer susceptibility. Ma-
jor questions include howmany andwhich genes to
sequence, whether results are sufficiently under-
stood to guide intervention, and how best to coun-
sel patients about variants of low or moderate
penetrance.8,10-12 We designed a customized germ-
line sequencing panel of 42 cancer-associated genes
and evaluated its information yield among women
referred for clinical evaluation of hereditary breast
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“There	  are	  ~12	  billion	  nucleo)des	  in	  every	  cell	  of	  the	  human	  body,	  and	  there	  are	  
~25-­‐100	  trillion	  cells	  in	  each	  human	  body.	  Given	  soma)c	  mosaicism,	  epigene)c	  
changes	  and	  environmental	  diﬀerences,	  no	  two	  human	  beings	  are	  the	  same,	  
par)cularly	  as	  there	  are	  only	  ~7	  billion	  people	  on	  the	  planet”.	  	  


In	  the	  year	  2014….	  
This:	  
Is	  orders	  of	  magnitudes	  easier	  than	  
this:	  
Clinical	  Validity	  with	  Worldwide	  
Human	  Gene)c	  Varia)on	  “database”?	  
Pa;entsLikeMe	  
100,000	  Bri;sh	  Genomes	  
Clinical	  Validity?	  
	  
This	  is	  SO	  complex	  that	  the	  only	  solid	  
way	  forward	  is	  with	  a	  “networking	  of	  
science”	  model,	  i.e.	  online	  database	  
with	  genotype	  and	  phenotype	  
longitudinally	  tracked	  for	  thousands	  of	  
volunteer	  families.	  
Pa;entsLikeMe	  
Lost	  in	  Transla)on	  
•  We	  need	  to	  focus	  on	  the	  extremes,	  i.e.	  severe	  illness,	  
not	  just	  the	  “average”	  person,	  i.e.	  a	  new	  focus	  on	  rare	  
variant	  diseases	  uncovers	  fundamentally	  important	  
biological	  processes.	  
•  Many	  exci)ng	  gene)c	  discoveries	  are	  being	  made	  and	  
published.	  
•  There	  is	  much	  fanfare	  and	  media	  coverage.	  
•  But,	  then	  the	  gene)c	  researchers	  move	  on	  to	  the	  next	  
disease,	  expec)ng	  someone	  else	  will	  engage	  with	  the	  
families	  and	  perform	  counseling,	  educa)on	  and	  carrier	  
screening.	  
•  This	  does	  not	  happen	  mostly	  (certainly	  not	  always).	  	  
•  Only	  0.5%	  of	  the	  38	  MILLION	  published	  papers	  are	  cited	  
more	  than	  200	  )mes,	  and	  HALF	  are	  never	  cited	  (from	  
Topol,	  Crea)ve	  Destruc)on	  of	  Medicine,	  2012).	  
Systemic	  Barriers	  
•  Some)mes	  just	  simple	  lack	  of	  communica)on	  
between	  researchers	  and	  the	  physicians	  and	  
gene)c	  counselors.	  
•  We	  only	  have	  1500	  medical	  gene)cists	  and	  2000	  
cer)ﬁed	  gene)c	  counselors	  for	  310	  million	  
people	  in	  America!	  	  
•  Insurance	  will	  ohen	  deny	  coverage	  of	  gene)c	  
tes)ng,	  par)cularly	  for	  novel	  muta)ons,	  so	  
gene)c	  tes)ng	  is	  much	  under-­‐u)lized	  rela)ve	  to	  
procedure-­‐based	  medicine.	  
Systemic	  Barriers	  cont….	  
•  Physicians	  and	  health	  care	  system	  woefully	  
uneducated	  regarding	  gene)cs.	  
•  Current	  sequencing	  (exomes	  and	  whole	  
genomes)	  being	  sequenced	  in	  random	  
laboratories	  with	  no	  clinical	  standards	  in	  place	  
(although	  people	  trying	  to	  change	  this).	  
The	  End	  of	  Main	  Talk:	  
VigneXes	  to	  follow,	  if	  )me	  allows.	  
VigneXe	  #1:	  Discovering	  a	  new	  
syndrome	  and	  its	  gene)c	  basis.	  
Ogden	  Syndrome	  
We	  found	  the	  SAME	  muta)on	  in	  two	  unrelated	  families,	  with	  a	  very	  similar	  
phenotype	  in	  both	  families,	  helping	  prove	  that	  this	  genotype	  contributes	  to	  the	  
phenotype	  observed.	  
First	  boy.	  Called	  “a	  liXle	  old	  man”	  by	  
the	  family.	  Died	  around	  ~1	  year	  of	  
age,	  from	  cardiac	  arrhythmias.	  
This	  is	  the	  ﬁrst	  boy	  in	  the	  late	  1970’s.	  
prominence	  of	  eyes,	  down-­‐sloping	  palpebral	  ﬁssures,	  thickened	  
eyelids,	  large	  ears,	  beaking	  of	  nose,	  ﬂared	  nares,	  hypoplas)c	  nasal	  
alae,	  short	  columella,	  protruding	  upper	  lip,	  micro-­‐retrognathia	  
	  
This	  is	  the	  “Proband”	  photograph	  presented	  at	  Case	  Conference.	  
II-1 III-2 
A	  
B	  
C	   D	  
II-­‐1	   II-­‐6	   III-­‐7	  III-­‐4	   III-­‐6	  
These	  are	  the	  Major	  Features	  of	  the	  Syndrome.	  
VigneXe	  #2:	  New	  Syndrome	  with	  
Mental	  Retarda)on,	  “Au)sm”,	  “ADHD”	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Likely	  X-­‐linked	  or	  Autosomal	  Recessive,	  with	  X-­‐linked	  being	  supported	  by	  extreme	  X-­‐
skewing	  in	  the	  mother	  	  
1.5	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.5	  years	  old 	  	  
3	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  years	  old
	  	  
Dysmorphic	  
Mental	  Retarda)on	  
“au)sm”	  
“ADHD”	  
Hearing	  diﬃcul)es	  
UFBR	  Family	  3	  
Workup	  Ongoing	  for	  past	  10	  years	  
•  Numerous	  gene)c	  tests	  nega)ve,	  including	  
nega)ve	  for	  Fragile	  X	  and	  MANY	  candidate	  
genes.	  
Sequenced	  whole	  genomes	  of	  Mother,	  Father	  
and	  Two	  Boys,	  using	  Complete	  Genomics	  
•  Sequenced	  “whole”	  genomes	  to	  obtain	  noncoding	  and	  
other	  non-­‐exonic	  regions.	  
•  No	  obvious	  pathogenic	  CNVs	  –	  microarrays	  normal.	  
•  ~6	  million	  variants	  total	  in	  the	  4	  people	  diﬀerent	  from	  
Hg19	  reference	  genome.	  
•  No	  homozygous	  autosomal	  recessive	  muta)ons	  found.	  
•  No	  Nonsense/Frameshih	  muta)ons	  in	  both	  boys.	  
•  2	  muta)ons	  present	  in	  mother	  and	  two	  boys,	  on	  X-­‐
chromosome,	  not	  in	  father,	  not	  in	  dbSNP135,	  not	  in	  
1000Genomes	  April	  2012	  release,	  and	  not	  in	  NHLBI	  
6500	  Exomes	  
	  


CADD$full
Disease&model Location Reference&allele Alternative&allele CADD&score Annotation&software Function
Autosomal$recessive chr1:210851705 TT T 27.5 ANNOVAR,$GEMINI,$SVS UTR3
Autosomal$recessive chr1:224772440 AATAATTTG TA 22.1 GEMINI intergenic
Autosomal$recessive chr2:60537356 TTTTATTT ATTATTA 22.3 GEMINI intergenic
Autosomal$recessive chr8:109098066 AT A 24.6 GEMINI intergenic
Autosomal$recessive chr15:66786022 ACAAA A 23.6 GEMINI intronic:SNAPC5
Autosomal$recessive chr16:49061346 TA T 25.3 ANNOVAR,$GEMINI intergenic
Autosomal$recessive chr16:49612367 GAC G 20.5 GEMINI,$SVS intronic:ZNF423
XQlinked chrX:70621541 T C 22.9 ANNOVAR,$GEMINI,$SVS TAF1:NM_138923:I1316T
Coding$full
Disease&model Location Reference&allele Alternative&allele Gene&name Annotation&software Function
DeQnovo chr1:53925373 G GCCGCCC DMRTB1 GEMINI,$SVS nonframeshift
Autosomal$recessive chr10:135438929 T G FRG2B ANNOVAR,$GEMINI,$SVS NM_001080998:I171L
Autosomal$recessive chr10:135438951 GGCCC AGCCT FRG2B GEMINI,$SVS nonframeshift
Autosomal$recessive chr10:135438967 C T FRG2B GEMINI,$SVS NM_001080998:R158Q
Autosomal$recessive chr15:85438314 C CTTG SLC28A1 GEMINI nonframeshift
XQlinked chrX:34961492 T C FAM47B GEMINI NM_152631:Y182H
XQlinked chrX:70621541 T C TAF1 ANNOVAR,$GEMINI,$SVS NM_138923:I1316T
X:70621541-­‐SNV	  	  Nonsyn	  SNV	  	  TAF1	  	  	  c.4010T>C	  	  	  p.Ile1337Thr	  
	  
2	  muta)ons	  present	  in	  mother	  and	  two	  boys,	  on	  
X-­‐chromosome,	  not	  in	  father,	  not	  in	  dbSNP135,	  
not	  in	  1000Genomes	  April	  2012	  release,	  and	  not	  
in	  NHLBI	  6500	  Exomes	  
	  
•  Nonsyn	  SNV	  	  	  ZNF41	  	  	  	  c.1191C>A	  	  p.Asp397Glu	  	  
	  	  
•  Nonsyn	  SNV	  	  	  TAF1	  	  	  	  	  	  	  c.4010T>C	  	  p.Ile1337Thr	  	  
	  
TAF1	  RNA	  polymerase	  II,	  TATA	  box	  binding	  protein	  
(TBP)-­‐associated	  factor,	  250kDa	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Mutations in the ZNF41 Gene Are Associated with Cognitive Deficits:
Identification of a New Candidate for X-Linked Mental Retardation
Sarah A. Shoichet,1 Kirsten Hoffmann,1 Corinna Menzel,1 Udo Trautmann,2 Bettina Moser,1
Maria Hoeltzenbein,1 Bernard Echenne,3 Michael Partington,4 Hans van Bokhoven,5
Claude Moraine,6 Jean-Pierre Fryns,7 Jamel Chelly,8 Hans-Dieter Rott,2 Hans-Hilger Ropers,1
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3Centre Hospitalier Universitaire de Montpellier, Hoˆpital Saint-Eloi, Montpellier, France, 4Hunter Genetics and University of Newcastle,
Waratah, Australia; 5Department of Human Genetics, University Medical Centre, Nijmegen, The Netherlands; 6Services
de Ge´ne´tique–INSERM U316, CHU Bretonneau, Tours, France; 7Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium;
and 8Institut Cochin de Ge´ne´tique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris
Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal break-
point. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
•  KRAB	  (Kruppel-­‐associated	  box)	  domain	  -­‐A	  box.	  
•  The	  KRAB	  domain	  is	  a	  transcrip)on	  repression	  module,	  found	  
in	  a	  subgroup	  of	  the	  zinc	  ﬁnger	  proteins	  (ZFPs)	  of	  the	  C2H2	  
family,	  KRAB-­‐ZFPs.	  KRAB-­‐ZFPs	  comprise	  the	  largest	  group	  of	  
transcrip)onal	  regulators	  in	  mammals,	  and	  are	  only	  found	  in	  
tetrapods.	  	  
•  The	  KRAB	  domain	  is	  a	  protein-­‐protein	  interac)on	  module	  
which	  represses	  transcrip)on	  through	  recrui)ng	  corepressors.	  
The	  KAP1/	  KRAB-­‐AFP	  complex	  in	  turn	  recruits	  the	  
heterochroma)n	  protein	  1	  (HP1)	  family,	  and	  other	  chroma)n	  
modula)ng	  proteins,	  leading	  to	  transcrip)onal	  repression	  
through	  heterochroma)n	  forma)on.	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Figure 4 A, Pedigree of family P13, with sequence corresponding to the prolinerleucinemutation (left to right): unrelated control individual,
mother (II:1), index patient (III:2), and brother of the index patient (III:1). For the potentially affected female cousin (individual III-4) (indicated
with an asterisk [*]), no clinical data are available. Affected nucleotides are indicated with black arrows. B, Pedigree for family P42, with
sequence chromatograms indicating the splice-site mutation in affected individuals (left to right): father (I:1), mother (I:2), index patient (II:1),
and mildly affected sister (II:2). Uppercase letters indicate coding sequence; affected nucleotides are indicated with black arrows.
a diagnosis of mild MR. He was born at term (by Ce-
sarean section), with a birth weight of 3,000 g (10th–25th
percentile) and a length of 51 cm (50th percentile). He
walked at age 12–13 mo and reached early milestones
within the normal time frame; however, he exhibited a
severe language delay. He first made two-word associa-
tions at age 3 years and was first speaking in simple
phrases at age 4 years 6 mo. At age 8 years, he was 135
cm tall (90th percentile) and had a head circumference
of 53 cm (75th percentile). He had no additional dys-
morphic or neurological symptoms, and results of
screening for fragile X were negative. At age 10 years 3
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Figure 6 Northern blot hybridization of ZNF41, by use of a probe corresponding to nucleotides 621–1099 of ZNF41 transcript variant
1. A, Adult tissues (left to right): heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. B, Fetal tissues (left to right): brain,
lung, liver, and kidney.C,Adult brain structures (left to right): amygdala, caudate nucleus, corpus callosum, hippocampus, whole brain, substantia
nigra, and thalamus. Black arrowheads highlight the presence of a novel 6-kb transcript. Actin (A and C) or GAPDH (B) served as controls
for RNA loading.
sible for sequence-specific DNA binding. ZNF41, absent
in our patient, is a member of the subfamily of Krueppel-
type zinc-finger proteins harboring a highly conservedN-
terminal domain known as the Krueppel-associated box
(KRAB). Although the specific functions of ZNF41 are
not fully understood, various related genes play an es-
tablished and important role in human development and
disease (Ladomery and Dellaire 2002). In another female
patient with severe MRX and a balanced translocation,
the disorder probably resulted from the disruption of a
related X-chromosomal zinc-finger gene (Lossi et al.
2002). The X-chromosome breakpoint was located just
upstream of the Krueppel-like factor 8 (KLF8 [MIM
300286]), also known as the “ZNF741 gene,” and it was
confirmed that KLF8 transcripts were absent in the pa-
tient cell line. The Wilms tumor suppressor gene WT1
(MIM 194070), which harbors four Krueppel-type zinc
fingers, has been implicated in several urogenital devel-
opmental disorders, including WAGR syndrome (MIM
194072), which is associated with MR (Call et al. 1990;
Rose et al. 1990; Gessler et al. 1992). Of particular rel-
evance, however, are the biochemical studies that high-
light the links between the highly conserved KRAB/ZFP
subfamily of zinc-finger proteins and chromatin remod-
eling. Many disorders, several of which are associated
with MR, have been linked to defects in processes that
govern chromatin structural modification (Hendrich and
Bickmore 2001), suggesting that chromatin structural
regulationmay play a specific and important role in path-
ways critical for mental function.
Repression of transcription by a KRAB/ZFP requires
binding of the corepressor KAP-1 (also known as
“TIF1b” and “KRIP-1” [MIM 601742]) (Friedman et
al. 1996; Kim et al. 1996; Moosmann et al. 1996; Peng
et al. 2000a, 2000b). KAP-1 is a molecular scaffold that
coordinates gene-specific silencing by recruiting both
heterochromatin-associated proteins (Ryan et al. 1999)
and by interacting with the novel histone H3 Lys9–
specific methyltransferase SETDB1 (MIM 604396)
(Schultz et al. 2002). It is interesting that, within the
primary sequence of SETDB1, Schultz et al. (2002) iden-
tified a methyl CpG–binding domain that is related to
the domain found in the methyl CpG binding protein
MeCP2, which is mutated both in patients with Rett
syndrome (MIM 312750) (Amir et al. 1999) and in
patients with MRX (Couvert et al. 2001; Yntema et al.
2002). Like ZNF41, MECP2 is ubiquitously expressed;
yet loss of functional protein results in a neurological
phenotype. Although the mechanism by whichMECP2
mutations cause MR is not clear, it is well established
that MeCP2 binds to methylated CpGs and represses
transcription (for review, see Ballestar and Wolffe
[2001]), and it has recently been shown that MeCP2
associates with an unidentified methyltransferase that
specifically methylates Lys9 of histone H3 (Fuks et al.
2003), as does the KAP-1/KRAB/ZFP binding partner
SETDB1.
Further characterization of the KRAB/KAP-1 repres-
sor module has indicated that, in addition to the KRAB
domain, a bipartite domain of the plant homeodomain
(PHD) finger and a bromodomain, located within the C-
terminal portion of KAP-1, are also required for effective
gene silencing (Schultz et al. 2002). It is interesting that
the point mutations in that study were modeled after
naturally occurring mutations in the PHD finger of the
human ATRX gene, which has been implicated in both
X-linked a-thalassemia/MR syndrome (MIM 301040)
(Gibbons et al. 1995) and Juberg-Marsidi syndrome
(MIM 309590), which is also associated with MR (Vil-
lard et al. 1996a). In light of the fact that the PHD
Proving	  Causality	  
•  Will	  need	  to	  ﬁnd	  a	  second,	  unrelated	  family	  with	  same	  exact	  mu a)on	  and	  
similar	  phenotype.	  
•  Can	  also	  p rform	  in	  vitro/in	  vivo	  studies	  an 	  struct ral	  mod ling,	  and	  make	  
knock-­‐in	  mice	  and/or	  test	  in	  zebraﬁsh,	  etc…	  for	  biological	  func)on.	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abstract
BACKGROUND: The combination of microcephaly, pyramidal signs, abnormal corpus callosum, and intellectual
disability presents a diagnostic challenge. We describe an autosomal recessive disorder characterized by micro-
cephaly, pyramidal signs, thin corpus callosum, and intellectual disability. METHODS: We previously mapped the
locus for this disorder to 8q23.2-q24.12; the candidate region included 22 genes. We performed Sanger sequencing
of 10 candidate genes; to ensure other genes in the candidate region do not harbor mutations, we sequenced the
exome of one affected individual. RESULTS: We identiﬁed two homozygous missense changes, p.Thr186Arg and
p.Pro416His in TAF2, which encodes a multisubunit cofactor for TFIID-dependent RNA polymerase IIemediated
transcription, in all affected individuals. CONCLUSIONS: We propose that the disorder is caused by the more
conserved mutation p.Thr186Arg, with the second sequence change identiﬁed, p.Pro416His, possibly further
negatively affecting the function of the protein. However, it is unclear which of the two changes, or maybe both,
represents the causative mutation. A single missense mutation in TAF2 in a family with microcephaly and intel-
lectual disability was described in a large-scale study reporting on the identiﬁcation of 50 novel genes. We suggest
that a mutation in TAF2 can cause this syndrome.
Keywords: Microcephaly syndrome, TAF2, corpus callosum, pyramidal, autosomal recessive
Pediatr Neurol 2013; 49: 411-416
! 2013 Elsevier Inc. All rights reserved.
Introduction
The combination of microcephaly, pyramidal signs,
abnormal corpus callosum, and intellectual disability in
pediatric patients presents a diagnostic challenge. We
recently described a previously unreported syndrome
characterized by a progressive postnatal decline in head
circumference to between !2 and !5.5 standard deviations
within a few months of birth accompanied by pyramidal
signs (spasticity, brisk tendon reﬂexes, and extensor plantar
reﬂex), thin corpus callosum, and intellectual disability.1
The differential diagnosis of this combination of clinical
and radiological features includes several disorders.
Although autosomal recessive primary microcephaly can
present with a normal head circumference at birth, devel-
opmental impairment is usually milder and brain magnetic
resonance imaging typically shows a simpliﬁed gyral
pattern.2 The disease caused by mutations in TRAPPC9 is a
form of autosomal recessive nonsyndromic intellectual
disability associated with variable postnatal microcephaly.3
Spasticity with a thin corpus callosum may be part of
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Structural and functi n l insight into TAF1–TAF7,
a subcompl x of transcription factor II D
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Transcription factor II D (TFIID) is a multiprotein complex that
nucleates formation of the basal transcription machinery. TATA
binding protein-associated factors 1 and 7 (TAF1 and TAF7), two
subunits of TFIID, are integral to the regulation of eukaryotic tran-
scription initiation and play key roles in preinitiation complex (PIC)
assembly. Current models suggest that TAF7 acts as a dissociable
inhibitor of TAF1 histone acetyltransferase activity and that this
event ensures appropriate assembly of the RNA polymerase II-
mediated PIC before transcriptional initiation. Here, we report the
3D structure of a complex of yeast TAF1 with TAF7 at 2.9 Å reso-
lution. The structure displays novel architecture and is character-
ized by a large predominantly hydrophobic heterodimer interface
and extensive c folding of TAF subunits. Ther are no obvious
similarities betwe n TAF1 and known histone acetyltrans-
ferases. Instead, the surface of the TAF1–TAF7 complex contains
two prominent conserved surface pockets, one of which binds
selectively to an inhibitory trimethylated histone H3 mark on
Lys2 in a manner that is also r gulated by phosphorylation at
the neighbo ing H3 serine. Our findings could point toward novel
roles for the TAF1–TAF7 complex in regulation of PIC assembly via
reading epigenetic histone marks.
initiation complex | protein structure | protein–protein interaction |
X-ray crystallography
The general transcription factor II D (TFIID) plays a centralrole in recognition of the core promoter element and medi-
ates accurate transcription initiation by RNA Polymerase (Pol)
II for a large class of genes. TFIID nucleates the formation of
the preinitiation complex (PIC) at the transcriptional start site by
recruiting other general transcription factors (TFII-A, -B, -E, -F,
and -H), along with RNA Pol II. TFIID is assembled in a step-
wise manner, with a symmetric TFIID core complex recruited
first, followed by further recruitment of additional TATA binding
protein (TBP)-associated factors (TAFs) to form the complete
asymmetric holo–TFIID complex (1). This megadalton-sized
multiprotein assembly, comprised of TBP and 13 evolutionary
conserved TAFs (2), is organized into a trilobed structure (3)
and undergoes striking rearrangements upon binding to TFIIA
and DNA (4). TAF subunits serve multiple functions within the
TFIID holocomplex. In addition to TBP, TAF1, TAF2, TAF6,
and TAF9 are also involved in recognition of DNA initiator and
promoter elements. Moreover, TFIID can behave as an epige-
netic effector, capable of recognizing posttranslational histone
modifications associated with activated transcription. Eukaryotic
TAF1 contains a double bromodomain that recognizes acety-
lated histones, and TAF3 contains a plant homeo domain (PHD)
that binds to histone H3 methylated at lysine 4 (5, 6). In addition
to roles in basal transcription, TFIID is also associated with dis-
eases. Overexpression of TAF1, which acts as a specific coac-
tivator of androgen receptor, is related to the progression of
human prostate cancer (7). Additionally, alterations of TAF gene
copy numbers and mutations are reported in high-grade serous
ovarian cancer (8).
TAF1, the largest subunit of TFIID, plays a particularly im-
portant role in TFIID complex activity (9, 10). Unlike other
TAFs, it spans two lobes (from C through A) within the trilobed
structure of TFIID, as indicated by EM and immunomapping
stu ies, with the TAF1 C terminus located in the A lobe (3, 11).
TAF1 is c mprised of multiple separabl domains that variously
harbor HAT and kinas activities, TAND domain th t binds
TBP, DNA bi ding functions, and the aforementioned double
bromodo ain that contacts acetylated histone tails (5, 9, 10).
Yeast TAF1 (yTAF1) ret ins the HAT, TAND, and C-terminal
DNA recognition domains (12), and ∼90% of yeast gene ex-
pression is TAF1 dependent (13). Current reports suggest that
TAF7 exerts transcriptional ch ckpoint control activit by be-
having as a dissociable inhibitor f TAF1 HAT activity; this
event serves to ensure correct PIC assembly for effective Pol
II-mediated transcription initiation and is essential for progres-
sion through the cell cycle (14, 15).
Although crystal structures of small fragments of the TAF1
double bromodomain (5) and TAND domain bound to TBP
(16) are available, the structure of the large putative TAF1
HAT domain and the basis of its molecular interaction with
TAF7 remain unknown. To gain insight into TAF1–TAF7
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Transcription factor II D (TFIID) is a multiprotein complex that is
essential for gene transcription. Together, TATA binding pro-
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the atomic structure of the yeast TAF1/7 heterodimer and
probe its function using biochemical techniques. Our structure
suggests that yeast TAF1 is not a HAT and instead reveals that
TAF1/7 displays the unexpected capacity to bind a specific re-
pressive histone mark. This raises the possibility that TFIID
binds repressive chromatin marks to control gene expression.
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Science.	  1976	  Apr	  9;192(4235):105-­‐11.	  
“scien)ﬁc	  advance	  requires	  far	  more	  work	  than	  that	  reported	  by	  the	  
discoverer	  or	  by	  those	  who	  wrote	  key	  ar)cles	  essen)al	  for	  his	  
discovery….	  scien)sts	  earlier	  and	  later	  than	  the	  discoverer	  have	  always	  
been	  essen)al	  to	  each	  discovery	  and	  its	  full	  development.”	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  Leeds,	  July	  2014	  
Lancelot	  Hogben	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Ronald	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1890-­‐1962	  
Quote	  from	  Leroy	  Hood,	  2012	  
•  "I	  argue	  that	  the	  data	  for	  every	  pa)ent	  should	  
belong	  to	  society	  and	  not	  the	  individual,"	  
Hood	  says.	  "It's	  society	  that	  has	  created	  the	  
tools	  to	  enable	  the	  data	  to	  help	  with	  the	  
individual's	  health	  and,	  even	  more	  important,	  
it's	  cri)cal	  that	  that	  data	  be	  available	  aher	  
anonymiza)on	  for	  people	  to	  analyze	  and	  mine	  
for	  the	  predic)ve	  medicine	  of	  the	  future.	  This	  
is	  what's	  going	  to	  revolu)onize	  medicine	  for	  
your	  children	  and	  your	  grandchildren."	  
•  Yes,	  BUT	  it	  should	  not	  skip	  the	  step	  of	  the	  
actual	  individual!	  Generate	  the	  data	  for	  the	  
individual	  and	  obtain	  consent	  to	  anonymize	  
and	  use	  that	  data	  for	  the	  future.	  
•  So	  many	  papers	  describe	  muta)ons	  that	  are	  
found,	  but	  very	  liXle	  discussion,	  if	  any,	  on	  
whether	  these	  results	  were	  given	  back	  to	  the	  
families.	  
Autonomy	  vs.	  Privacy	  vs.	  Bureaucracy	  
Privacy	  
Autonomy	  
Bureaucracy	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“If you sequence people’s exomes you’re going to find stuﬀ,” said Gholson Lyon, 
a physician and researcher previously at the University of Utah, now at Cold 
Spring Harbor Laboratory.
As part of his research, Dr. Lyon worked with a family in Ogden, Utah. Over 
two generations, four boys had died from an unknown disease with a distinct 
combination of symptoms—an aged appearance, facial abnormalities, and devel-
opmental delay. Dr. Lyon sought to identify the genetic cause of this disease, and 
collected blood samples from 12 family members who had signed consent forms. 
The family members understood these forms to mean that they would have access 
to their results.
Dr. Lyon conducted exon capture and sequencing of the X chromosome—a 
process that analyzes specific regions of the X chromosome and is a less expensive 
alternative to whole genome sequencing—to analyze the blood samples. Dr. 
Lyon and his colleagues identified a genetic mutation, and named the disease 
Ogden Syndrome after the family’s hometown.
After Dr. Lyon and his team identified the genetic basis of Ogden Syndrome, 
one of the family members contacted him. This young mother of one daughter 
had submitted a blood sample for Dr. Lyon’s research. She had not been preg-
nant at the time, but was now four months pregnant with her second child. 
She knew that she was carrying a boy and wanted to know if she was a carrier 
of the mutation. She wanted to be able to mentally and emotionally prepare 
herself and her family.
By reexamining his research data, Dr. Lyon was able to see that the expectant 
mother was a carrier of Ogden Syndrome. This meant that her son had a 50 
percent chance of being born with the disease. Dr. Lyon could not, however, 
legally share this important information with the family because he had conducted 
the original sequencing in a research laboratory that had not satisfied federally 
mandated standards designed to ensure the accuracy of clinical genetic results.
Instead, Dr. Lyon worked to have the mutation validated at a laboratory that 
satisfied those federal standards; this involved overcoming substantial bureau-
cratic hurdles and other obstacles that held up the process. During this time, 
Policy and Governance
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the baby boy was born and died of Ogden Syndrome at four months of age. 
While knowing the results would not have changed the outcome, Dr. Lyon feels 
he should have been able to do more for the family.
Dr. Lyon has become an outspoken advocate for conducting whole genome 
sequencing in laboratories that satisfy the federal standards so that researchers 
can return results to participants, if appropriate. Dr. Lyon wants clear guid-
ance for laboratories conducting genetic research and clear language in consent 
forms that clarifies the results that participants should expect to have returned 
from the researchers.
Realizing the promise of whole genome sequencing requires widespread 
public participation and individual willingness to share genomic data and 
relevant medical information. This requires public trust that any whole 
genome sequence data shared by individuals with researchers and clinicians 
will be adequately protected. Individuals must trust that eir whole genome 
sequence d ta will not be either i tentionally or i advert ntly disclosed or 
misused. Current U.S. g vernance and oversight f genetic and genomic 
data, however, do not fully protect i dividuals from the risks associated with 
sharing their whole genome sequence data and information. 
The Genetic Information Nondiscrimination Act of 2008 (GINA) is the 
leading federal protection of genetic information, but it oﬀers only prohibi-
tion of genetic discrimination in health insurance and employment. GINA 
does not regulate access, security, and disclosure of genetic or whole genome 
sequence information across all potential users, nor does it protect against 
discrimination in other contexts. U.S. state laws on genetic information 
vary greatly in their protections of individuals, and they also fail to provide 
uniform privacy protections. In an era in which whole genome sequence data 
are increasingly stored and shared using biorepositories and databases, there 
is little to no systematic oversight of these systems. 
Ethical Principles
Laws and regulations cannot do all of the work necessary to provide suﬃcient 
privacy protections for whole genome sequence data. Individuals who obtain 
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systems and infrastructure to facilitate health information exchange so that 
data can be easily aggregated and studied.213 Integrating whole genome 
sequence data into health records within the learning health system model 
can provide researchers with more data to perform genome-wide analyses, 
which in turn can advance clinical care. Several Institute of Medicine (IOM) 
working groups have supported these goals, outlining the desirability of 
establishing a universal health information technology system and learning 
environment that engages health care providers and patients. The IOM 
reports recommend that such a system include both genomic and clinical 
information, increased interoperability of medical records systems, and 
reduced barriers to data sharing.214 The President’s Council of Advisors 
on Science and Technology identified the lack of sharing electronic health 
records—with patients, with a patient’s health care providers at other 
organizations, with public health agencies, and with researchers—as a barrier 
to improved health care.215
Recommendation 4.1
Funders of whole genome sequencing research, relevant clinical entities, 
and the commercial sector should facilitate explicit exchange of information 
between genomic researchers and clinicians, while maintaining robust data 
protection safeguards, so that whole genome sequence and health data can be 
shared to advance genomic medicine.
Performing all whole genome sequencing in CLIA-approved laboratories 
would remove one of the barriers to data sharing. It would help ensure that 
whole genome sequencing generates high-quality data that clinicians and 
researchers can use to draw clinically relevant conclusions. It would also 
ensure that individuals who obtain their whole genome sequence data could 
share them more confidently in patient-driven research initiatives, producing 
more meaningful data. That said, current sequencing technologies and those 
in development are diverse and evolving, and standardization is a substantial 
challenge. Ongoing eﬀorts, such as those by the Standardization of Clinical 
Testing working group are critical to achieving standards for ensuring the 
reliability of whole genome sequencing results, and facilitating the exchange 
and use of these data.216
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Recent advances in sequencing technology are making possible the application of large-scale genomic anal-
yses to individualized care, both in wellness and disease. However, a number of obstacles remain before ge-
nomic sequencing can become a routine part of clinical practice. One of the more signiﬁcant and
underappreciated is the lack of consensus regarding the proper environment and regulatory structure
under which clinical genome sequencing and interpretation should be performed. The continued reliance
on pure research vs. pure clinical models leads to problems for both research participants and patients in
an era in which the lines between research and clinical practice are becoming increasingly blurred. Here,
we discuss some of the ethical, regulatory and practical considerations that are emerging in the ﬁeld of geno-
mic medicine. We also propose that many of the cost and safety issues we are facing can be mitigated through
expanded reliance on existing clinical regulatory frameworks and the implementation of distributive
work-sharing strategies designed to leverage the strengths of our genomics centers and clinical interpretive
teams.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
We are entering a fascinating and uncertain period of medical his-
tory, as today's DNA sequencing technology has the potential to help
each of us direct our care and predict our future based on knowledge
of our own individual inherited and acquired genetics. However,
from a global and local economic perspective, these are lean years,
and this adds a signiﬁcant degree of uncertainty to the immediate fu-
ture of this enterprise. It is therefore incumbent upon us to show that
the personalized medical application of large-scale genomic analysis
will not just be a luxury or a burdensome cost center, but that it
truly has the potential to save both lives and health care expenses
via data-driven management, early disease detection/screening and
more efﬁcacious pharmaceutical delivery. To this end, we need to de-
termine how to move forward towards expanded clinical use of this
technology in a manner both rapid and economical, while ensuring
the integrity of the process and the safety and well-being of patients
and research participants. This will require careful thought and con-
sideration regarding the proper environment and regulatory structure
surrounding genomics, as well as the development of consensus re-
gardingwhat exactly constitutes a genetic test in the age of large-scale
genomics and informatics.
2. Paving the way for the broad implementation of clinical
genomic medicine
A report published in 2011 by the National Research Council for
the National Academy of Sciences elegantly described the major divi-
sions between the clinical and research worlds, including in regards
to large-scale genomic analyses, such as whole genome (WGS) se-
quencing. The report went on to offer suggestions for how to help
merge these two worlds, including articulating the need for a “Knowl-
edge Network” and “New Taxonomy”, with the recommendation that
pilot studies along such lines should be conducted (Anon., 2011).
However, the report did not address a critical issue related to genetic
testing, namely the rules that should govern genomic research and
clinical care as we move into the coming era of individualized medi-
cine. The United States federal government mandates that any labora-
tory performing tests on human specimens “for the purpose of
providing information for the diagnosis, prevention, or treatment of
any disease”must satisfy the conditions set forth in the Clinical Labo-
ratory Improvement Amendments (CLIA) of 1988 (Group®, 2012).
Applied & Translational Genomics xxx (2013) xxx–xxx
Abbreviations: CLIA, Clinical Laboratory Improvements Amendments; NGS, Next
generation sequencing; WGS, whole-genome sequencing.
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entirely performed on Illumina equipment using one of a few library
preparation methods, with 100 base paired-end sequencing performed
in the major research sequencing centers to an average depth of 70–
100× to achieve >80% of the target region covered by 20 or more
reads. Others havemade suggestions for standardizing exome sequenc-
ing (Klein et al., 2012), and we believe it is high-time to establish such
standards, at least for exomes being sequenced from live human beings,
so that results can be returned to participants.
However, while sequencing is relatively standardizable, it is true
that many of the downstream processes are not, as bioinformatics
analyses and interpretive schemes can be extremely variable. While
the desired informatics and interpretive analysis for healthy individ-
uals might focus on alleles relevant for future disease risk, carrier sta-
tus and pharmacogenomics, genomic analyses for rare diseases might
instead focus on de novo, homozygous or X-linked disease variants,
possibly in the context of a parent–child trio or preferably in the con-
text of even larger families, including grandparents. Certain ﬁndings
seen in one patient may escape detection in another patient simply
due to differences in the basic strategy of analysis or the phenotype
of the individuals. With respect to population studies, the analytical
variation can be tremendous, with focuses ranging from ethnicity-
speciﬁc variation to variation associated with complex disease, basic
human phenotypes and evolutionary processes. The number of differ-
ent performable analyses is limited only by the imagination.While the
informed consent process for each individual study would be required
to include a discussion of the analysis details, the process can be con-
fusing for participants and easily leave them at the end unclearwheth-
er or not particular ﬁndings were investigated and frustrated by an
inability to access the data. This being the case, it would be beneﬁcial
to move towards a systemwhereby a straightforward clinical analysis
of data from research projects could be subsequently performed at a
later time, within a proper regulatory framework.
This downstream variation in informatics and interpretation raises
an important question: from the clinical standpoint, what exactly con-
stitutes a genetic laboratory test? Is it simply the analytics (the se-
quencing), or is it a combination of analytics and interpretation, or is
it the entire process from sample receipt through to the generation
and return of a report? Here, the legal deﬁnition is really quite
clear, as CLIA speciﬁcally states that a medical laboratory test is an all-
encompassing process (Anon., 2013a). The introduction to CLIA subpart
K states that “each laboratory that performsnonwaived testingmust es-
tablish and maintain written policies and procedures that implement
and monitor quality systems for all phases of the total testing process
(that is, preanalytic, analytic, and postanalytic) as well as general labo-
ratory systems” (see Table 1 for a summary of the analytic systems).
It is noteworthy that test interpretation and reporting are speciﬁ-
cally covered by the CLIA statutes and included as part of the regulated
test process. This is important because, as the community has discov-
ered, the actual sequencing has become increasingly straightforward,
whereas the true difﬁculties and pitfalls lie in the informatics, inter-
pretation and reporting. Any meaningful regulatory framework for
NGS-based diagnostics must include oversight of informatics path-
ways and interpretive criteria, as there are simply too many ways to
do informatics incorrectly, with resultant possibilities for harm to pa-
tients and participants.
This issue is beginning to get the attention of the agencies respon-
sible for overseeing clinical laboratories, now that a large number of
clinical laboratories have begun developing a variety of tests on NGS
instruments. The College of American Pathologists (CAP) has recently
released a new checklist for molecular pathology laboratories that
includes both general laboratory and test development guidelines
covering NGS wet lab practices, bioinformatics processing and data
storage and transfer practices. Additionally, the New York State De-
partment of Health Clinical Laboratory Evaluation Program (CLEP)
has issued detailed guidelines for the development and validation of
NGS cancer genomics assays (Anon., 2013b). New York is one of
two CLIA-exempt states as a result of its own state licensure regula-
tions being deemed “equal to, or more stringent than” CLIA by CMS
per CLIA subpart E, thus clinical laboratories in New York receive
their CLIA license through th tate following s ccessful state certiﬁ-
cation. The CLEP NGS oncology guidelines are quite thorough, includ-
ing requirements for quality scores, control procedures, acceptabl
numbers of sp cimens for valid tion studies and guideli es for
stablishi g read dep , accuracy, sensitivity, tc., focusing on actual
performance rather than the details of bioinformatics pipelines. Over-
all, the regulatory framework for NGS on the pure clinical side is com-
ing together, with certain aspects such as reporting criteria hopefully
being sorted out in the near future.
However, if a clinical NGS test is deﬁned by both the sequencing
and downstream informatics, and the informatics possibilities for a
standar equence are essentially limitless, how could CLIA supervi-
sion be applied to combined research and clinical genomics operations
without placi g an extreme regu atory burden on the sequencing
laboratory? Would every analysis type need to be certiﬁed, or would
a time-consuming standardized analysis be required even if it were
not needed for each p rticular peration?
6. The distributive model: an analytical-interpretive split
across genomics
Any ideal solution would allow sequencing centers to focus on
their strengths and to leverage their economies of scale, without re-
quiring them to devote their time to unnecessary informatics and in-
terpretation. How can that be achieved in keeping with the spirit of
proper CLIA oversight? As a solution, we would propose an analytic-
interpretive split (or a so-called “distributivemodel”) across both clin-
ical and research genomics. This split model simply means that one
laboratory performs analytics and then a second laboratory performs
the interpretation and reporting. Thus, together, the two laboratories
perform all the functions that make up a laboratory test. This should
be a straightforward arrangement, but while some precedent and
guidance policies exist, the regulatory structure that would govern
such a system is still evolving, as we will discuss.
The beneﬁts of enacting such a split model could be substantial,
and we believe they could be gained without signiﬁcantly burdening
our sequencing centers with undue excess costs. Under this type of
system, the basic sample processing and sequencing operation could
be standardized across clinical patients and the majority of new geno-
mics research participants. The practical effect of this split would be
to turn an exome or genome sequence into a discrete deliverable unit
that could be used for multiple downstream purposes by multiple
downstream labs. For each patient or participant, the same validated
sequencing would be performed, and that raw data, if individually
Table 1
Processes involved in a CLIA-certiﬁed genetic test.
Preanalytic system
1) Test request and specimen collection criteria
2) Specimen submission, handling and referral procedures
3) Preanalytic systems assessment
Analytic system
1) A detailed step-by-step procedure m nual
2) Test systems, equipment, instrum nts, reagents, mat rials and
supplies
3) Establishment and veriﬁcation of performance speciﬁcations
4) Maintenance and function checks
5) Calibration and calibration veriﬁcation procedures
6) Control procedures, test records, and corrective actions
7) Analytic systems assessment
Post-analytic system
1) Test report, including (among other things):
a) interpretation
b) reference ranges and normal values
2) Post-analytic systems assessment
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“This	  laboratory	  test	  was	  developed,	  and	  its	  performance	  characteris;cs	  
were	  determined	  by	  the	  Illumina	  Clinical	  Services	  Laboratory	  (CLIA-­‐cer;ﬁed,	  
CAP-­‐accredited).	  Consistent	  with	  laboratory-­‐developed	  tests,	  it	  has	  not	  been	  
cleared	  or	  approved	  by	  the	  U.S.	  Food	  and	  Drug	  Administra;on.	  If	  you	  have	  
any	  ques;ons	  or	  concerns	  about	  what	  you	  might	  learn	  through	  your	  genome	  
sequence	  informa;on,	  you	  should	  contact	  your	  doctor	  or	  a	  gene;c	  
counselor.	  Please	  note	  that	  Illumina	  does	  not	  accept	  orders	  for	  Individual	  
Genome	  Sequencing	  services	  from	  Florida	  and	  New	  York.”	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‘‘In reality, discoveries are due to people at the edge of the
formalised groups of researchers’’
Pierre Laszlo
Fifty years ago, I was the co-author1 of the first paper that
showed the presence of an additional chromosome (Lejeune
et al. 1959) in the syndrome identified by Langdon Down
in 1866 and commonly known as ‘‘mongolism’’ in France at
the time. This, the first autosomal chromosome aberration
recognised in the cells of the human species, was named
trisomy 21. I thought it would be of historical interest to bring
my own personal testimony as an actor in that discovery.
A historical background
Going back to 1958 involves rediscovering the context and
the firmly held beliefs of that period. Although it had been
accepted for decades that human beings possessed 48 chro-
mosomes, Tjio and Levan (1956) demonstrated in 1956 that
there were in fact only 46. This did not affect many people,
apart from a few geneticists, and for a long time 48 was still
the figure taught in schools. This stage, which seemed sim-
ple, was followed by other more important stages that
brought us closer to finding the origins of life; however, this
did not create such a stir in the media as the launch of the first
artificial satellite Sputnik (meaning ‘‘fellow traveller’’ in
Russian) a few months later, which drew us closer to finding
the origins of the universe. Science advances on different
levels, depending on the disciplines.
It had been necessary to wait 30 years before the genetic
laws of peas, as observed by Johan Mendel or ‘Brother
Gregor’ of the Augustinian Monastery of Brno, was recog-
nised by biologists. Soon after this, Nettie Stevens revealed
the existence of sex chromosomes in a certain species of
beetle (Gilgenkrantz 2008). In about 1910, Morgan’s work
on Drosophila, the providential fruit fly with its amazingly
fast reproduction rate and giant chromosomes, laid the first
foundations of cytogenetics (Morgan et al. 1925). Had it not
been for the attitudes of Alexis Carrel (1912 Nobel Prize
winner) during the Occupation (Gilgenkrantz and Rivera
2003), his cell culture experiments would have been widely
used. However, a long sequence of errors and failures dis-
couraged the researchers. And it was not until 1949, and then
only on cat neuronal cells, that Barr and Bertram (1949)
discovered the existence of a body only in the female
nucleus; this in fact proved to be a general phenomenon that
indicated the presence of two X-chromosomes. The cyto-
logical explanation for this (lyonisation) fell to Lyon (1961).
Simple swabs of the mucous membrane in the mouth then
allowed inter-sexual states to be diagnosed.
This article by Marthe Gautier was translated from the French by
Cardiff University Centre for Lifelong Learning and Peter S. Harper.
The commentary is by Peter Harper. Originally published in
Me´decine Sciences [Gautier M (2009) Cinquantenaire de la trisomie
21. Retour sur une de´couverte. Med Sci (Paris) 25(3): 311–315], this
article now reappears in English by kind permission of the publisher,
E´ditions EDK.
M. Gautier
6 Rue de Douai, 75009 Paris, France
e-mail: marthe.gautier@free.fr
P. S. Harper (&)
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Cardiff University, Heath Park, Cardiff CF14 4XN, UK
e-mail: HarperPS@cardiff.ac.uk
1 By a slip of the pen that I dare not interpret, my name was wrongly
entered as ‘‘Marie Gauthier’’. The error was corrected in subsequent
publications.
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It would have been a personal triumph for 
Marthe Gautier, an 88-ye r-old pediatric 
cardiologist and scientist living in Paris. On 
31 January, during  meeting in Bordeaux, 
Gautier was to r ceive a medal for her role in 
the discovery of the cause of Down syndrome 
in the late 1950s. In a speech, she planned to 
tell an audience of younger Fr ch ge eticists 
her story about the discovery—and how she 
felt the credit she deserv d went to a ale col-
league, Jérôme Lejeune. 
But Gautier’s talk was canceled just hours 
in advance, and she received the medal a d y 
later in a small, private ceremony. The French 
Federation of Human Genetics (FFGH), 
which organized the meeting, decided to 
scrap the event after two bailiffs showed up 
with a court order granting them permission 
to tape Gautier’s speech. They were sent by the 
Jérôme Lejeune Foundation, which wanted 
to have a record of the talk. The foundation, 
which supp rts research and car  for patients 
with genetic intellectual disabilities and 
campaigns against abortion, said it had 
reason to believe Gautier would “tarnish” the 
memory of Lejeune, who died in 1994.
A brilliant cytogeneticist with a storied 
career, Lejeune has become widely known 
as the scientist who discovered that Down 
syndrome is caused by an extra copy of 
chromosome 21. H  receiv d many awards, 
including one from former U.S. President John 
F. Kennedy. But in recent years, Gautier has 
claimed that she did most of the experimental 
work for the discov ry. In the French 
newspaper Le Monde, Alain Bernheim, the 
pre ident of the French Society of Human 
Genetics, last week compared her ca e to that 
of Rosalind Franklin, whose contribution to 
the discovery of the double helix structure of 
DNA i  the early 1950s was long overlooked.
In an e-mail to Science, 
Gautier referred to an 
interview published on the 
Web for her version of events 
more than half a century ago. 
In it, she explained that she 
worked on Down syndrome 
in the pediatric unit led 
by Raymond Turpin at the 
Armand-Trousseau Hospital 
in Paris, which she joined in 
1956 after a year at Harvard 
Medical School in Boston. 
Hum n cytogenetics was 
just coming of age. In 1956, a Swedish team 
showed that humans have 46 chromosomes in 
every cell, not 48, as was widely beli ved. In 
the United States, Gautier had learned to grow 
heart cell cultures, so she proposed to set up 
an advanced cell culture lab and study Down 
syndrome. She says she received her first 
patient sample in May 1958; examing slides, 
she soon not ced an extra chromosome, but 
she was unable to identify it or take pictures 
with her low-power microscope. In June 1958, 
she “naively” accepted an offer from Lejeune, 
who Gautier says was studying Down 
syndrome using other techniques, to take her 
slides and get them photographed. 
Gautier claims she was “shocked” 
when, after more than 6 months of silence, 
she learned that the discovery was about to 
be published in the journal of the French 
Academy of Sciences, with Lejeune as the 
fi rst author and Turpin the last; Gautier was 
in the middle, her last name misspelled 
as Gauthier. Gautier doesn’t dispute that 
Lejeune identifi ed the 47th chromosome as 
an extra copy of chromosome 21, but she 
maintains that she was the fi rst to notice the 
abnormal count.
While ackowledging that Gautier played a 
role, the Jérôme Lejeune Foundation claims 
that Lejeune himself made the discovery. “In 
July 1958, during a study of chromosomes 
of a so-called ‘mongoloid’ child, [Lejeune] 
discovered the existence of an extra 
chromosome on the 21st pair,” according to 
the foundation’s website. The foundation has 
denied that Lejeune appropriated Gautier’s 
discovery; in a press statement, it says a letter 
Turpin sent in October 1958 suggests Gautier 
still hadn’t seen the 47 chromosomes.  
Things came to a head at the meeting in 
Bordeaux. After calling off Gautier’s talk and 
the award ceremony, FFGH issued a statement 
saying it would have been “unacceptable” to 
hold the ceremony under the threat of a legal 
suit. But the federation also 
said it “bitterly regretted” the 
cancellation and condemned 
the use of legal power to 
put pressure on a scientifi c 
meeting. 
Simone Gilgenkrantz, a 
professor emeritus of human 
genetics at the University 
of Lorraine in France and 
a friend of Gautier’s, says 
the presentation, which she 
has seen, was “completely 
innocuous.” Gautier writes 
in an e-mail to Science that she accepted the 
decision and that she felt unprepared to deal 
with what she calls “an aggression.” “To talk 
under the pressure of justice is not tolerable 
for me or anyone else,” she writes.
Ideology is fueling some of the rancor. 
Lejeune, a staunch Catholic, was horrified 
by the advent of prenatal diagnostics, which 
made it possible to screen fetuses for Down 
syndrome and other abnormalities, and 
abort those afflicted. He set out to find a 
After More Than 50 Years, a Dispute 
Ov r Down Sy drome Discov ry
H I STO RY  O F  S C I E N C E
14 FEBRUARY 2014    VOL 343    SCIENCE    www.sciencemag.org  
Claiming credit. Marthe Gautier’s talk at a recent 
genetics meeting in Bordeaux was canceled.
First author. Jérôme Lejeune, who 
passed away in 1994.
Published by AAAS
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It would have been a personal triumph for 
Marthe Gautier, an 88-year-old pediatric 
cardiologist and scientist living in Paris. On 
31 January, during a meeting in Bordeaux, 
Gautier was to receive a medal for her role in 
the discovery of the cause of Down syndrome 
in the late 1950s. In a speech, she planned to 
tell an audience of younger French geneticists 
her story about the discovery—and how she 
felt the credit she deserved went to a male col-
league, Jérôme Lejeune. 
But Gautier’s talk was canceled just hours 
in advance, and she received the medal a day 
later in a small, private ceremony. The French 
Federation of Human Gene ics (FFGH), 
which organized the meeting, decided to 
scrap th  event after two bailiffs showed up 
with a court order granting them permission 
to tape G utier’s speech. They were sent by the 
Jérôme Lejeune Foun ation, w ich wanted 
to have a record of the talk. The foundation, 
which supports research and care for patients 
with genetic intellectual disabilities and 
campaigns against abortion, said it had 
reason to believe Gautier would “tarnish” the 
memory of Lejeune, who died in 1994.
A brilliant cytogeneticist with a storie  
career, Lejeune has become widely known 
as the scientist who discovered that Down 
syndrome is caused by an extra copy of 
chromoso e 21. He received many awards, 
including one from former U.S. President John 
F. Kennedy. But in recent years, Gautier has 
claimed that she did most of the experimental 
work for the discovery. In the French 
newspaper Le Monde, Alain Bernheim, the 
president of the French Society of Human 
Genetics, last week compared her case to that 
of Rosalind Franklin, whose contribution to 
the discovery of the double helix structure of 
DNA in the early 1950s was long overlooked.
In an e-mail to Science, 
Gautier referred to an 
interview published on the 
Web for her version of events 
more than half a century ago. 
In it, she explained that she 
worked on Down syndrome 
in the pediatric unit led 
by Raymond Turpin at the 
Armand-Trousseau Hospital 
in Paris, whic  she joined in 
1956 after a year at Harvard 
Medical School in Boston. 
Human cytogenetics was 
just coming of age. In 1956, a Swedish team 
showed that humans have 46 chro osomes in 
every cell, not 48, as was widely believed. In 
the United States, Gautier had learned to grow 
heart cell cultures, so she proposed to set up 
an advanced cell culture lab and study Down 
syndrome. She says she received her first 
patient sample in May 1958; examing slide , 
she soon noticed an ext a chromosome, but 
she was unable to identify it or take pictures 
with her low-power microscope. In June 1958, 
she “naively” accepted an offer from Lejeune, 
who Gautier says was studying Down 
syndrome using other techniques, to take her 
slides and get them photographed. 
Gautier claims she was “shocked” 
when, after more than 6 months of silence, 
she learned that the discovery was about to 
be published in the journal of the French 
Academy of Sciences, with Lejeune as the 
fi rst author and Turpin the last; Gautier was 
in the middle, her last name misspelled 
as Gauthier. Gautier doesn’t dispute that 
Lejeune identifi ed the 47th chromosome as 
an extra copy of chromosome 21, but she 
maintains that she was the fi rst to notice the 
abnormal count.
While ackowledging that Gautier played a 
role, the Jérôme Lejeune Foundation claims 
that Lejeune himself made the discovery. “In 
July 1958, during a study of chromosomes 
of a so-called ‘mongoloid’ child, [Lejeune] 
discovered the existence of an extra 
chromosome on the 21st pair,” according to 
the foundation’s website. The foundation has 
denied that Lejeune appropriated Gautier’s 
discovery; in a press statement, it says a letter 
Turpin sent in October 1958 suggests Gautier 
still hadn’t seen the 47 chromosomes.  
Things came to a head at the meeting in 
Bordeaux. After calling off Gautier’s talk and 
the award ceremony, FFGH issued a statement 
saying it would have been “unacceptable” to 
hold the ceremony under the threat of a legal 
suit. But the federation also 
said it “bitterly regretted” the 
cancellation and condemned 
the use of legal ower to 
put pressure on a scientifi c 
meeting. 
Simone Gilgenkrantz, a 
professor emeritus of human 
genetics at the University 
of Lorraine in France and 
a friend of Gautier’s, says 
the presentation, which she 
has seen, was “completely 
innocuous.” Gautier writes 
in an e-mail to Science that she accepted the 
decision and that she felt unprepared to deal 
with what she calls “an aggression.” “To talk 
under the pressure of justice is not tolerable 
for me or anyone else,” she writes.
Ideology is fueling some of the rancor. 
Lejeune, a staunch Catholic, was horrified 
by the advent of prenatal diagnostics, which 
made it possible to screen fetuses for Down 
syndrome and other abnormalities, and 
abort those afflicted. He set out to find a 
After More Than 50 Years, a Dispute 
Over Down Syndrome Discovery
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Claiming credit. Marthe Gautier’s talk at a recent 
genetics meeting in Bordeaux was canceled.
First auth r. Jérôme Lejeune, who 
passed away in 1994.
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